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The phenomenon of cell type-specific DNA methylation has received much attention 
in recent years and a number of DNA methylation differences have been described 
between cells of the immune system. Of particular interest when studying DNA 
methylation are CpG islands (CGIs) which are distinct from the rest of the genome 
due to their elevated CpG content, generally unmethylated state and promoter 
association. In the instances when they become methylated this is associated with 
gene repression although it is unclear the extent to which differential methylation 
corresponds to differential gene expression. I have used an immune system model to 
assess the role of CGI methylation and the role of the methylation reader MBD2 in 
regulation of gene expression. 
 
A relatively small number of DNA methylation differences were seen between 
immune cell types with the most developmentally related cells showing the fewest 
methylation differences. Interestingly, the vast majority of CGI-associated cell-
specific methylation occurred at intragenic CGIs located, not at transcription start 
sites, but in the gene body. Increased intragenic CGI methylation tended to associate 
with gene repression, although the precise reason for this remains unclear. Most 
differentially methylated CGIs were depleted for the active chromatin mark 
H3K4me3 regardless of their methylation state but some of these were associated 
with the silencing mark H3K27me3 when unmethylated. These findings suggest that 
intragenic CGIs are a distinct class of genomic element particularly susceptible to 
cell type-specific methylation. I also looked at the effect of removing the methyl-
CpG binding domain protein MBD2 from immune system cells. Immune cells from 
Mbd2-/- mice showed a number of previously uncharacterised phenotypes as well as 
a number of differences in gene expression compared to wild-type animals. Most of 
these genes increased their expression in the absence of MBD2 consistent with 
MBD2’s role as a transcriptional repressor and Mbd2-/- Th1 cells showed increases 
in histone H3 acetylation compared to wild-type Th1 cells. This work provides an 
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Chapter 1 Introduction 
 
The protein-coding capacity of mammalian genomes does not, at first glance, fit with 
organismal complexity. The human genome has approximately 22,000 protein-
coding genes whilst the genome of the simple invertebrate Caenorhabditis elegans 
contains approximately 20,000 (source http://www.ensembl.org). However, less than 
5% of the 3 billion base pair human genome codes for protein (Lander et al., 2001). 
The remainder includes a large amount of repetitive sequence as well as regulatory 
sequences, such as transcription factor binding sites and enhancers, and non-coding 
RNA genes, which contribute to complex patterns of gene expression in the 
organism. As well as the genetic information carried by the DNA sequence itself, 
additional complexity resides in chemical modification of DNA in the form of 
cytosine methylation and in the way DNA is packaged into chromatin. Such 
information stored outside the primary DNA sequence is commonly referred to as 
“epigenetic” although more rigorous definitions require epigenetic phenomena to be 
heritable through cell division (Russo et al., 1996). Heritability, whilst holding true 
for DNA methylation and the polycomb-trithorax system, does not apply to all 
chromatin states. Epigenetic phenomena contribute to developmental and tissue-
specific gene expression which allows specification of the hundreds of distinct cell 
types that make up the human body. Cells of the immune system, which are the focus 
of this work, have the property of responding rapidly to infection yet can also 
develop into memory cells to fight future infections. Immune cells are frequently 
differentiating and specialising so it is not surprising that epigenetic mechanisms 
have been found to be important in their regulation. This thesis investigates the role 





1.1 DNA methylation 
The cytosine base of DNA can be chemically modified by addition of a methyl-group 
to the carbon-5 position of its pyrimidine ring (Figure 1.1.1A). This bestows an 
additional layer of information on the DNA sequence as DNA methylation patterns 
can be maintained through cell division. Vertebrate genomes are extensively 
methylated (Ehrlich, 1982), perhaps reflective of their genomic complexity, and 
DNA methylation is essential for life (Li et al., 1992; Okano et al., 1999). 
Methylation does not affect the coding potential of DNA but when it occurs at 
promoters it is associated with transcriptional repression (Laurent et al., 2010; Lister 
et al., 2009; Stein et al., 1982; Vardimon et al., 1982). The best-characterised roles of 
DNA methylation in mammals are in X chromosome inactivation, where CpG island 
promoters gain methylation, and in imprinting, where methylation directs 
monoallelic gene expression. 
 
1.1.1 Vertebrate genomes are globally methylated 
Vertebrates have cytosine methylation throughout their genomes while invertebrates 
have less DNA methylation. Drosophila melanogaster and Caenorhabditis elegans 
have very low levels of cytosine methylation (Hodgkin, 1994; Lyko et al., 2000) 
whilst some invertebrates such as Ciona intestinalis have a mosaic methylation 
pattern consisting of large domains of methylated or unmethylated DNA (Suzuki et 
al., 2007; Tweedie et al., 1997). In organisms such as C. intestinalis methylation 
seems to be enriched in constitutively expressed “housekeeping genes” which is in 
contrast to vertebrate genes where methylation is present regardless of activity. The 
origin of vertebrates coincides with this transition from partial to global cytosine 
methylation with even the most primitive vertebrates (lamprey and hagfish) showing 
global DNA methylation (Tweedie et al., 1997). An attractive proposal is that global 
DNA methylation arose to facilitate appropriate gene regulation and dampen 




1.1.2 Methylation occurs in the context of CpG dinucleotides 
The vast majority of cytosine methylation occurs in the context of CpG 
dinucleotides. As this site is symmetrical, methylation occurs on both strands of the 
DNA and can be copied during DNA replication making it a heritable mark (Figure 
1.1.1B). Whilst being heritable, DNA methylation patterns can change, for example 
during development and differentiation (Meissner et al., 2008; Mohn et al., 2008; 
Morgan et al., 2005) suggesting that CpG methylation can be regulated to influence 
expression of different genes in different cellular contexts. Mammalian cytosine 
methylation in contexts other than CpG has been documented, predominantly in 
embryonic stem (ES) cells. This does not, however, have the heritable properties of 
CpG methylation (Laurent et al., 2010; Lister et al., 2009; Ramsahoye et al., 2000).  
 
In vertebrates approximately 70% of CpG sites are methylated (Ehrlich et al., 1982). 
This global pattern of CpG methylation has led to a partitioning of the genome into 
two distinct fractions with respect to CpG content and methylation status. Methyl-
CpG is mutagenic as methyl-cytosine (mC) spontaneously deaminates to thymine (T) 
(Figure 1.1.1A) resulting in a T.G mismatch. Although there is cellular machinery to 
repair this (Hendrich et al., 1999b; Millar et al., 2002; Wiebauer and Jiricny, 1990), 
repair is inefficient, and over evolutionary time CpGs have been lost in the genome. 
Human bulk genomic DNA contains approximately one-fifth the number of CpGs 
than would be expected from its G+C content (Bird, 1980). A small fraction of the 
genome (~1%) is maintained in an unmethylated state and therefore shows elevated 
CpG and G+C content compared to the bulk (Bird et al., 1985). These functionally 
important regions are termed CpG islands (CGIs), often associate with gene 

















1.1.3 Cytosine is methylated by the DNA methyltransferase 
enzymes 
The DNA methyltransferase enzymes (Dnmts) are responsible for establishing and 
maintaining the DNA methylation pattern. They act by transferring methyl-groups 
from S-adenosyl methionine (SAM) to cytosine. The maintenance methyltransferase 
Dnmt1 re-establishes the CpG methylation state after DNA replication and the de 
novo methyltransferases Dnmt3a and 3b act on previously unmethylated CpGs 
[Dnmts are reviewed in (Hermann et al., 2004)]. The function of another Dnmt 
family member, Dnmt2, appears to be in methylating tRNA rather than DNA (Goll et 
al., 2006). 
 
Dnmt1 restores the symmetrical pattern of CpG methylation following DNA 
replication. When DNA is replicated during cell division the newly synthesised DNA 
is initially unmethylated while the template strand remains methylated, a state known 
as hemi-methylation. Dnmt1 associates with the replication machinery to methylate 
Figure 1.1.1 Cytosine methylation 
A) Cytosine can be methylated at the carbon-5 position to form 5-methylcytosine which can deaminate 
to thymine. 




the daughter DNA strand and is therefore necessary to propagate the DNA 
methylation state through cell division. Knock out of the Dnmt1 gene in mouse is 
embryonically lethal demonstrating the essential role of DNA methylation in 
development (Li et al., 1992). 
 
Dnmt3a and Dnmt3b catalyse the de novo methylation of CpGs and, like Dnmt 1, are 
essential for mouse development. Dnmt3a and 3b have partially overlapping roles in 
de novo methylation as a Dnmt3a/3b double knockout mouse has a more severe 
phenotype than either single deletion (Okano et al., 1999).  Dnmt3a and 3b are highly 
expressed in early embryonic development where, after erasure of the parental 
methylation pattern, they act to re-establish methylation (Morgan et al., 2005). 
Promiscuous activity of Dnmt3a and 3b due to this high expression level is also 
thought to be responsible for the non-CpG methylation found in ES cells (Laurent et 
al., 2010; Lister et al., 2009; Ramsahoye et al., 2000). Dnmt3a and 3b do have 
specialised functions and differ in their mechanism of action (Gowher and Jeltsch, 
2002). Dnmt3b alone methylates the pericentromeric repeats while there have been 
suggestions that Dnmt3a is involved in targeting methylation to discrete genomic loci 
(Hermann et al., 2004). Dnmt3a also seems to have a more essential role in 
imprinting (Kaneda et al., 2004).  
 
Dnmt3L is a member of the Dnmt3 family that lacks a catalytic domain. It has been 
identified as an interacting partner for Dnmt3a and Dnmt3b and is essential for 
imprinting (Hata et al., 2002). Dnmt3L enhances the catalytic activity of the de novo 
methyltransferases (Gowher et al., 2005; Suetake et al., 2004) and is also required for 
mouse spermatogenesis (Webster et al., 2005). 
 
1.1.4 DNA demethylation and 5-hydoxymethylcytosine 
DNA methylation can be removed either by passive or active demethylation. Passive 
demethylation results from the failure of Dnmt1 to re-establish the methylation 
pattern after replication. This leads to loss of the DNA methylation pattern through 
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successive rounds of cell division. Active demethylation involves removal of 
methylation by an enzyme without the need for DNA replication. There is evidence 
for active demethylation of the paternal genome in the pre-implantation embryo 
(Mayer et al., 2000; Oswald et al., 2000). Demethylation of a region in the 
interleukin-2 (Il2) promoter after T cell activation but prior to DNA replication has 
also been shown (Bruniquel and Schwartz, 2003) and a similar phenomenon has been 
observed at the Th2 locus control region, although here demethylation kinetics are 
slower (Kim et al., 2007). The identity of the DNA demethylation activity has, 
however, remained elusive. The methyl-binding domain protein, MBD2, was 
reported to act as a demethylase (Bhattacharya et al., 1999) but this has been widely 
disputed as paternal demethylation occurs normally in embryos deficient for MBD2 
and a number of studies have failed to find evidence for demethylase activity in vitro 
(Hendrich et al., 2001; Ng et al., 1999; Santos et al., 2002). The most likely 
mechanism of demethylation is thought to be modification of methylated cytosine 
(for example by deamination to T or conversion to a novel base) followed by 
removal by a base excision repair mechanism and replacement with unmethylated 
cytosine as has been shown in zebrafish and plants (Gong et al., 2002; Penterman et 
al., 2007; Rai et al., 2008). A cytidine deaminase (AID) has been found to be 
required for DNA demethylation during reprogramming of human fibroblasts into 
induced pluripotent stem (iPS) cells (Bhutani et al., 2009).  
 
Recently a potential intermediate in DNA demethylation, 5-hydroxymethylcytosine 
(hmC), was identified (Kriaucionis and Heintz, 2009; Tahiliani et al., 2009). mC is 
converted to hmC by the CxxC protein TET1 and this modified base is detectable in 
mouse ES cells and purkinje cells of the brain. hmC could represent a distinct 
modification state of DNA with its own specialized functions thus adding further 
complexity to epigenetic regulation in mammals. An alternative is that hmC could be 
an intermediate in DNA demethylation and be preferentially excised from DNA and 
replaced by unmodified cytosine. Support for this comes from the observation that 
TET1 is essential for maintaining the Nanog promoter in an unmethylated state in ES 
cells (Ito et al., 2010) 
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1.1.5 Role of DNA methylation 
 
DNA methylation is repressive at promoters and CGIs 
The methylation of promoters has been shown to result in gene repression (Siegfried 
et al., 1999; Stein et al., 1982; Vardimon et al., 1982). Genome-wide methylation 
studies also support an association between promoter methylation and transcriptional 
inactivity, but this is strongest for CGI promoters (Mohn et al., 2008). Promoter 
DNA methylation is traditionally thought to repress transcription in one of two ways: 
1) Directly through inhibition of protein binding to methyl-cytosine (Figure 1.1.2A) 
or 2) Indirectly via proteins that specifically bind to methylated DNA and recruit 









The model whereby methylation represses transcription by disrupting protein binding 
was initially proposed for transcription factors. Indeed, methylation-dependent 
inhibition of binding has been demonstrated for the ETS, MLTF, E2F, CREB and 
ATF/c-Jun activators (Campanero et al., 2000; Gaston and Fried, 1995; Iguchi-Ariga 
and Schaffner, 1989; Jones and Chen, 2006; Watt and Molloy, 1988) but binding of 
other transcription factors, such as Sp1, is not disrupted by methylation (Harrington 
et al., 1988). Further support for the direct inhibition model comes from the 
Figure 1.1.2 Mechanisms of DNA methylation-mediated transcriptional repression 
A) DNA methylation (black lollipops) can directly prevent binding of transcription factors (TF) and other 
proteins to the promoter preventing transcription. 




observation that DNA methylation is depleted at active enhancers and at protein 
interaction sites (Lister et al., 2009). In addition, promoter DNA methylation may be 
refractory to binding of RNA Polymerase II (Pol II) itself. Support that this is the 
case for CGI-associated promoters comes from genome-wide studies profiling DNA 
methylation and Pol II binding showing that methylated promoters are not occupied 
by Pol II (Mohn et al., 2008). Therefore the binding of proteins, other than 
transcriptional activators, is likely to depend on the methylation status of cytosine. 
One example of this is the binding of the chromatin insulator CTCF which can 
separate promoters from the effect of distal enhancer elements. CTCF binding is 
inhibited by DNA methylation and this inhibition of CTCF binding can activate 
transcription as is the case at the imprinted Igf2/H19 locus (discussed in section 
1.5.5) (Bell and Felsenfeld, 2000; Bell et al., 1999).  
 
Transcriptional repression can also be accomplished by proteins with specific affinity 
for methylated DNA. Members of the methyl-CpG binding domain (MBD) family of 
proteins are involved in methylation-dependent transcriptional repression (Hendrich 
and Bird, 1998; Nan et al., 1997) and act through recruitment of chromatin 
modifying activities (see sections 1.2 and 1.3). For example, methyl-CpG binding 
domain protein 2 (MBD2) is part of the NuRD chromatin remodelling complex 
which contains nucleosome remodelling and histone deacetylase activity (Ng et al., 
1999). The unrelated Kaiso proteins can also bind methylated DNA and repress 
transcription (Filion et al., 2006; Prokhortchouk et al., 2001). 
 
Gene body methylation occurs at active genes 
Much attention in recent years has focused on the role of intragenic or gene body 
methylation following reports that it is associated with actively transcribed genes in 
Arabidopsis (Zhang et al., 2006; Zilberman et al., 2007). In keeping with this, 
invertebrates such as C. intestinalis show gene body methylation associating with the 
most highly expressed housekeeping genes (Suzuki et al., 2007) .The 
transcriptionally active X chromosome in humans was found to show monoallelic 
gene body methylation that was absent from the inactive X chromosome (Hellman 
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and Chess, 2007). It has been suggested that this may contribute to dosage 
compensation through up-regulation of X-linked genes in order to balance the gene 
dosage with that of the autosomes (Payer and Lee, 2008). A number of recent studies 
in human have shown a more general correlation between DNA methylation in gene 
bodies and gene expression, with highly expressed genes tending to have more 
intragenic methylation (Ball et al., 2009; Deng et al., 2009; Rauch et al., 2009). 
Comprehensive analyses of methylation using whole genome bisulfite sequencing 
have also investigated the relationship between gene body methylation and 
transcriptional activity. Lister et al. (2009) found that in stem cells there was no 
correlation between the level of gene body methylation and gene expression but did 
observe a correlation for foetal fibroblasts where the most highly expressed genes 
had the highest level of methylation. Laurent and colleagues also showed that gene 
body methylation was positively correlated with gene expression but this effect was 
very small (Laurent et al., 2010). One mechanism by which gene body methylation is 
proposed to contribute to efficient transcription is through repression of spurious 
transcription initiating within the gene body. Alternative hypotheses are that gene 
body methylation is reinforced by transcriptional elongation or is targeted by RNA 
produced by antisense transcription [these possibilities are discussed in (Suzuki and 
Bird, 2008)]. A sharp change in methylation levels at exon-intron boundaries has 
been observed suggesting a role for DNA methylation in splicing or a role for the 
splicing machinery in directing methylation (Laurent et al., 2010). 
 
Role of DNA methylation in the bulk genome 
Outwith its role at genes, what is the function of genome-wide methylation? It has 
been proposed that DNA methylation could be related to the high incidence of 
repeats in the mammalian genome. Many of these repeats derive from transposable 
elements and are methylated and repressed although levels of methylation are often 
lower than those found in gene bodies (Laurent et al., 2010). In Dnmt1-deficient 
mice, transcription of IAP transposable elements is massively induced and human 
LINE and SINE promoters are also de-repressed when DNA methylation is depleted 
(Liu et al., 1994; Walsh et al., 1998; Woodcock et al., 1997). One theory is that 
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methylation of transposable elements is involved in “genome defence” and prevents 
unconstrained transposition which would be damaging to the genome (Yoder et al., 
1997). However, there is no evidence that depleting methylation leads to increased 
transposition (Wilson et al., 2007). Another hypothesis is that methylation of these 
repeats is involved in suppressing transcription from cryptic promoter elements as 
this could interfere with normal gene expression (Bird and Tweedie, 1995). Indeed, 
one of the most common repeat classes in the genome, the Alu elements, are usually 
transpositionally inert but contain numerous promoter sequences (Bird, 2002).  
 
Evidence suggests that DNA methylation is necessary to maintain genomic integrity. 
Cancer cells show global hypomethylation and this is associated with genome 
instability and chromosomal abnormalities (Jones and Baylin, 2007). In the inherited 
syndrome ICF (immunodeficiency, centromeric heterochromatin and facial 
anomalies) Dnmt3b mutation leads to hypomethylation of pericentromeric repeats 
and chromosome segregation defects in lymphoblastoid cells (Ehrlich, 2003). In 
normal cells DNA methylation is enriched at sub-telomeric regions of chromosomes 
and is important for regulating telomere length and recombination (Gonzalo et al., 
2006; Lister et al., 2009; Steinert et al., 2004). 
 
1.2 DNA is packaged into chromatin 
In the eukaryotic nucleus DNA is packaged into a structure called chromatin. Its core 
subunit is the nucleosome which consists of approximately 150bp of DNA wrapped 
around an octamer of the four core histone proteins (H2A, H2B, H3 and H4) (Luger 
et al., 1997). Nucleosomes are separated by linker DNA that interacts with histone 
H1. Histone H1 can facilitate compaction of nucleosomes into higher order 
chromatin structures, such as the 30nm chromatin fibre (Happel and Doenecke, 2009; 
Tremethick, 2007) with the ultimate level of organisation being the chromosome 
(Figure 1.2.1). The remodelling of chromatin, through the covalent modification of 
histones or the action of ATP-dependent complexes, allows modulation of DNA 
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1.2.1 Chromatin can be altered by covalent modification of 
histones 
Histones can be post-translationally modified. This occurs most extensively on the 
histone tails which are more accessible to modifying enzymes. Histone modifications 
include: acetylation (ac), mono-, di- or tri-methylation (me1, me2, me3), 
phosphorylation, ubiquitination and sumoylation. Acetylation and methylation of 
lysine residues (K) in the histone tails, in particular, have been the focus of much 
research. Histone modifications are often classified as “activating” or “repressive” 
depending on whether they are associated with transcriptional activity or 
transcriptional silencing. The most well-defined of these is the association of histone 
acetylation with gene activity. Histone modifications have been profiled extensively 
in mammalian genomes using chromatin immunoprecipitation (ChIP) combined with 
Figure 1.2.1 Packaging of DNA into chromatin 
DNA is wrapped around a histone octamer to form the nucleosome and strings of nucleosomes can be 
packaged into a 30nm chromatin fibre, the structure of which is disputed. Chromatin fibres are further 
organised to form the chromosome. Within the chromosome chromatin can adopt an open transcriptionally 
permissive conformation or exist as a tightly packed condensed structure. Modulation of each level of 
chromatin structure can help regulate gene expression. 
Diagram adapted from (Felsenfeld and Groudine, 2003). 
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either microarrays (ChIP-chip) or high-throughput sequencing (ChIP-seq) and related 
to transcriptional status. Modifications associated with transcriptional activity 
identified by these studies include H3K4me2, H3K4me3, and H3/H4ac, which occur 
at gene promoters, and H3K36me3, which is found in the gene body of actively 
transcribed genes. The H3K9me3 and H3K27me3 marks, amongst others, are 
associated with transcriptional silencing (Barski et al., 2007; Bernstein et al., 2005; 
Mikkelsen et al., 2007; Roh et al., 2005; Wang et al., 2008). A schematic illustrating 





















The ability of histone modifications to be activating or repressive with respect to 
transcription can be modulated by direct influence of the histone modification on 
nucleosome structure or by proteins that recognize modified histones themselves. In 
the case of histone acetylation, the acetyl-group neutralizes positively charged 
lysines at histone tails leading to a conformational change that renders nucleosomal 
Figure 1.2.2 Histone modifications and transcriptional activity 
A) Modifications of histone tails that have been associated with gene activity. B) Histone modifications 
associated with gene silencing. Top: nucleosome bearing me (green) or ac (blue) marks on lysine (K) 
residues. Bottom: location of histone modification relative to the gene promoter (arrow). 
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DNA more accessible to the transcriptional machinery (Hong et al., 1993; Lee et al., 
1993). H3K9me3 recruits Heterochromatin Protein 1 (HP1) and H3K27me3 can 
recruit Polycomb Repressive Complex 1 (PRC1) both of which lead to formation of a 
repressive chromatin environment (Bannister et al., 2001; Cao and Zhang, 2004; 
Lachner et al., 2001; Simon and Kingston, 2009). H3K4me3 has been shown to 
interact with the NuRF chromatin remodelling complex amongst others (Li et al., 
2006; Ruthenburg et al., 2007; Wysocka et al., 2006) and in vitro recruitment of the 
core transcription factor TFIID by H3K4me3 has also been reported (Vermeulen et 
al., 2007), both of which may help to promote transcription.  
 
It has been proposed that a “histone code” could predict transcriptional activity on 
the basis of post-translational modification of histones (Jenuwein and Allis, 2001; 
Strahl and Allis, 2000). Several studies have identified bivalent chromatin domains 
marked by overlapping regions of the activating mark H3K4me3 and the repressive 
mark H3K27me3 (Barski et al., 2007; Bernstein et al., 2006; Roh et al., 2006). Such 
findings demonstrate that chromatin regulation is more complex than simple “on” or 
“off” marks and may involve many layers of complexity. Many genes have been 
shown to be “poised” for activation bearing active chromatin modifications even 
when the gene is silent (Barski et al., 2009; Guenther et al., 2007; Roh et al., 2006) 
and, consistent with this, the so-called active mark H3K4me3 is present at nearly all 
CGI promoters regardless of gene activity (Illingworth et al., 2010; Mikkelsen et al., 
2007). This evidence weakens the hypothesis that histone modifications alone are 
sufficient to predict transcriptional activity. It is important to bear in mind that the 
appropriate transcription factors must be present to activate transcription, even if the 
chromatin environment is permissive for gene expression. 
 
1.2.2 Histone modifications can be actively removed  
Although an enzyme which actively demethylates DNA has remained elusive there 
are several activities that deacetylate and demethylate histones. Histone deacetylases 
(HDACs) are recruited to DNA via direct interaction with transcriptional repressors 
or as part of multi-subunit complexes such as the NuRD (nucleosome-remodelling 
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and histone deacetylase) complex. The deacetylation of histones correlates with gene 
repression and, in general, HDACs can be viewed as having repressive activity 
(HDACs are reviewed in (Haberland et al., 2009). More recently, enzymes which 
actively demethylate histones have been identified. These enzymes are specialised to 
remove specific methylation marks and, so far, demethylases that act on 
H3K9me1/2/3, H3K36me1/2/3, H3K4me1/2/3 and H3K27me2/3 have been 
discovered. The vast majority of these belong to the Jumonji-C (JmjC) domain-
containing family of proteins [reviewed in (Agger et al., 2008; Klose and Zhang, 
2007)]. Significantly a H3K36 demethylase has recently been shown to associate 
with unmethylated CGIs, highlighting the link between histone modification and the 
DNA methylation state (Blackledge et al., 2010).  
 
1.2.3 ATP-dependent chromatin remodelling activities 
The packaging of DNA into nucleosomes can occlude access of the transcriptional 
machinery and other proteins to the DNA sequence. Therefore transcriptional activity 
can be regulated by altering the histone-DNA contacts, potentially changing the 
position of nucleosomes and the chromatin architecture at specific loci. There are 
several families of chromatin remodelling complexes that physically disrupt 
nucleosome interactions through the use of ATP hydrolysis. They can be divided into 
four main classes of complex; SWI/SNF (Switch/Sucrose non-fermentable), CHD 
(chromodomain and helicase domain), ISWI (imitation SWI) and INO80. 
Significantly, these complexes contain domains that recognise specific histone 
modification states and have been shown to be important for differentiation and 
development. For example, the SWI/SNF family members brahma (BRM) and 
brahma-like 1 (BRG-1) contain a bromodomain that recognises acetylated histones, 
while CHD family members possess chromodomains which bind to methylated 




1.2.4 The polycomb and trithorax proteins form an epigenetic 
system based on chromatin modification 
One of the first epigenetic systems to be identified was the Polycomb 
(PcG)/Trithorax (TrxG) system which maintains expression patterns of 
developmental Hox genes in Drosophila even after removal of initial transcription 
factors. This system is conserved in vertebrates where it also has a role in regulating 
Hox gene expression as well as roles in stem cell identity (Pietersen and van 
Lohuizen, 2008), lineage specification (Schwartz and Pirrotta, 2007), imprinting (Wu 
and Bernstein, 2008) and X chromosome inactivation (Payer and Lee, 2008). PcG 
proteins promote transcriptional repression through two multimeric complexes – 
Polycomb Repressive Complex 2 (PRC2) which di- and tri-methylates H3K27 and 
Polycomb Repressive Complex 1 (PRC1) which can be recruited by H3K27me3, 
ubiquitylates histone H2A and is thought to mediate gene repression by blocking 
transcriptional elongation. TrxG proteins maintain transcriptional activity and can 
have H3K4 trimethylase activity (MLL1-3) as well as the ability to remodel 
chromatin (SWI/SNF and NuRF complexes) [reviewed in (Schuettengruber et al., 
2007; Simon and Kingston, 2009)]. The TrxG protein UTX (Ultratrithorax) has 
recently been shown to be an H3K27me2/3 demethylase, demonstrating how TrxG 
proteins can directly antagonize polycomb silencing (Agger et al., 2007). There have 
been reports that PcG proteins can be recruited by ncRNAs (Rinn et al., 2007; Zhao 
et al., 2008) further demonstrating the complexity of mammalian gene regulation. 
 
There have been several studies focusing on the interaction between the polycomb 
and DNA methylation systems. It has been claimed that in cancer cells polycomb-
mediated H3K27me3 marks genes for aberrant methylation (Schlesinger et al., 
2007). Physical interaction between polycomb components and the Dnmts have been 
reported (Reynolds et al., 2006; Vire et al., 2006) although this has not been 
substantiated by in vivo findings. In normal gene expression, DNA methylation and 
polycomb (as assessed by presence of H3K27me3) are mutually exclusive silencing 
mechanisms (Fouse et al., 2008; Mohn et al., 2008) and studies have also shown this 
to be the case in cancer (Coolen et al., 2010; Kondo et al., 2008). However, the two 
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systems do show interdependence. Many polycomb targets in ES cells acquire DNA 
methylation during neuronal differentiation (Mohn et al., 2008) and there are several 
studies showing that CGI promoters becoming aberrantly methylated in cancer tend 
to be marked by H3K27me3 in ES cells (Keshet et al., 2006; Ohm et al., 2007; 
Widschwendter et al., 2007) (Illingworth et al., 2010)). In X inactivation H3K27me3 
precedes methylation of CGIs suggesting that H3K27me3 may be able to “instruct” 
DNA methylation (Payer and Lee, 2008). 
 
1.2.5 Functional interplay between DNA methylation, histone 
modification and ATP-dependent chromatin remodelling 
DNA methylation state, histone modification and the action of ATP-dependent 
chromatin remodellers all co-operate to regulate gene expression. As mentioned 
previously, particular histone modifications can be recognised by different classes of 
chromatin remodelling complexes. DNA methylation also has a function in 
regulating the chromatin state. DNA methylation state correlates with specific 
histone modification states, for example, unmethylated CGIs are marked by 
H3K4me3 (Illingworth et al., 2010; Mikkelsen et al., 2007) whilst in ES cells distinct 
sets of promoters are marked by H3K27me3 and DNA methylation (Fouse et al., 
2008). Furthermore, DNA methylation or its absence can directly recruit chromatin 
and histone modifying activities. There is new evidence suggesting that 
unmethylated CGIs recruit the H3K4me3 methyltransferase complex SETD1 via 
CxxC finger protein 1 (CFP1) (Thomson et al., 2010) and as well as the H3K36 
demethylase KDM2A (Blackledge et al., 2010). A protein that binds specifically to 
methylated DNA, MBD2, is part of the NuRD complex which possesses histone 
deacetylase and chromatin remodelling activity (Feng and Zhang, 2001; Ng et al., 
1999) as well as recently reported histone demethylase activity (Wang et al., 2009).  
 
The enzymes responsible for DNA methylation, the Dnmts, are also associated with 
chromatin modifying activities. There have been a number of reports describing 
Dnmt interaction with HDACs (Fuks et al., 2000; Robertson et al., 2000; Rountree et 
al., 2000) and histone methyltransferases (Epsztejn-Litman et al., 2008; Esteve et al., 
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2006; Fuks et al., 2003; Lehnertz et al., 2003; Vire et al., 2006). Interaction between 
Dnmts and the chromatin remodeller hSNF2H has also been observed (Geiman et al., 
2004; Robertson et al., 2004) as has an interaction with a related protein, LSH 
(Myant and Stancheva, 2008). Knock out of LSH in mice leads to genomic 
hypomethylation and premature death (Dennis et al., 2001) and one possibility is that 
chromatin remodelling is necessary in order for the Dnmts to gain access to DNA.  
 
1.3 The MBD proteins 
 
1.3.1 The MBD proteins specifically bind to methylated DNA 
One way in which the DNA methylation pattern can be interpreted is through the 
binding of factors with specific affinity for methylated DNA which can, in turn, 
affect the chromatin state. The first specific methyl-CpG binding protein, MeCP 
(later renamed MeCP1) was isolated based on its ability to bind probes containing 
multiple methylated CpGs in bandshift assays. MeCP1 complexes were detected in a 
range of tissues but were not formed when probes were unmethylated (Meehan et al., 
1989). The MeCP1 complex was shown to exert a repressive effect on transcription 
(Boyes and Bird, 1991, 1992) and was later identified as being the MBD2/NuRD 
complex (Feng and Zhang, 2001; Ng et al., 1999). A second methyl-binding activity, 
MeCP2, was subsequently identified and was also shown to repress transcription 
(Lewis et al., 1992; Meehan et al., 1992). Deletion analysis was used to characterise 
the domain from MeCP2 required for binding to methylated DNA and this was 
termed the methyl-CpG binding domain (MBD) (Nan et al., 1993). A search for 
proteins containing an MBD homologous to that of MeCP2 led to the identification 
of the MBD family of proteins (Cross et al., 1997; Hendrich and Bird, 1998). The 
MBD proteins consist of MeCP2, MBD1, MBD2, MBD3 and MBD4 (Figure 1.3.1). 
MeCP2, MBD1 and MBD2 specifically bind methylated DNA and repress 
transcription. The effect of knocking out these proteins in mouse is a lot less severe 
than the effect of disrupting DNA methylation arguing that DNA methylation exerts 
its effects independently of MBD proteins in many cases. MBD3 is a transcriptional 
 
 35 
repressor but has no methyl-specific binding while MBD4 is involved in DNA repair. 
In addition, an unrelated family of Kaiso-like proteins also have binding specificity 
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1.3.2 MeCP2 
MeCP2 represses transcription in a methylation-dependent manner and this 
repression is mediated by its transcriptional repression domain (TRD) in reporter 
assays (Nan et al., 1997). MeCP2 has been reported to exert its repressive effect by 
interacting with the Sin3a HDAC co-repressor complex (Nan et al., 1998) although 
this association must be transient as MeCP2 usually exists as a monomer (Klose and 
Bird, 2004). In vitro studies have shown that, in addition to a binding requirement for 
methyl-CpG, the MeCP2 MBD prefers to bind DNA sequences containing a run of 
A/T residues (Klose et al., 2005).  
 
Figure 1.3.1 The MBD proteins 
The MBD proteins were identified on the basis of their MBD domain (blue). MeCP2, MBD1 and MBD2 
contain a transcriptional repression domain (TRD; pink) that interacts with chromatin modifying activities. 
MBD1 contains three CxxC domains, the third of which is functional. MBD2 exists in a long isoform, MBD2a 
which contains a run of glycine arginine residues (GR) and a short isoform, MBD2b. MBD3 has 75% 
homology to MBD2b and contains a coiled-coil domain (C-C) similar to MBD2 but has a unique glutamatic 
acid repeat (E) at the C-terminus. MBD4 has a glycosylase domain at its C-terminus which is involved in 
DNA repair. All amino acid lengths are given for the mouse MBD proteins. 
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MeCP2 is particularly abundant in the brain, specifically neurons, and mutations in 
MeCP2 are responsible for the neurological disorder Rett syndrome (Amir et al., 
1999). Rett syndrome is an autism spectrum disorder characterised by a period of 
normal development followed by regression in terms of speech, motor function and 
acquired skills around 6-18 months of age. Knock out of the MeCP2 gene in mice 
recapitulates many features of the Rett syndrome phenotype and results in the 
premature death of null animals (Chen et al., 2001; Guy et al., 2001). Significantly, 
this phenotype can be reversed by reintroduction of a functional copy of MeCP2 
even after the onset of symptoms (Guy et al., 2007). The majority of Rett mutations 
occur in the MBD of MeCP2 highlighting the importance of its methyl-CpG binding 
function. The structure of the MeCP2 MBD bound to methylated DNA has recently 
been solved showing how many of these mutations interfere with binding (Ho et al., 
2008). 
 
Despite the severity of the Rett phenotype, changes in gene expression in the MeCP2 
null mouse brain are rather subtle (Nuber et al., 2005; Tudor et al., 2002). This, along 
with the abundance of MeCP2 in neurons, has led to the proposal that MeCP2 has a 
global role in regulating neuronal chromatin rather than one as a classical 
transcriptional repressor controlling expression of a defined set of genes. A recent 
study showed that in neurons, there is one molecule of MeCP2 for every two 
nucleosomes and that MeCP2 binds throughout the genome tracking methyl-CpG 
density. A global increase in the levels of histone acetylation and histone H1 in 
neurons lacking MeCP2 was observed, consistent with a role for MeCP2 in 
regulating the chromatin state (Skene et al., 2010). There have also been suggestions 
that MeCP2 can act as a transcriptional activator (Chahrour et al., 2008) and that it 
functions in alternative splicing (Young et al., 2005). 
 
1.3.3 MBD1 
MBD1 was the first MBD to be identified on the basis of homology to MeCP2 and 
was initially believed to be the methyl-binding activity of MeCP1 (Cross et al., 
1997). This 70kDa protein has an MBD and a TRD as well as two or three CxxC 
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domains depending on alternative splicing. One of these CxxC domains, CxxC3, is 
functional and facilitates binding of MBD1 to unmethylated CpGs. In DNA 
methylation-deficient cells localisation of MBD2 and MeCP2 to CpG-rich major 
satellite sequence is lost due to lack of methylation. However, MBD1 remains 
correctly localised in these cells and this localisation is dependent on its CxxC3 
domain (Hendrich and Bird, 1998; Jorgensen et al., 2004). A recent study has shown 
that the MBD of MBD1 prefers to bind methylated CpGs in a TGCGCA or TCGCA 
context while the CxxC3 domain requires a single unmethylated CpG for binding. 
Several MBD1 target genes were identified and binding to these targets was shown 
to be dependent on the MBD but not on the CxxC3 domain suggesting that, in vivo, 
MBD1 acts primarily as a methyl-binding protein (Clouaire et al., 2010). 
 
MBD1 can act as a transcriptional repressor on methylated and unmethylated 
templates (Fujita et al., 1999; Jorgensen et al., 2004) and this repression seems to 
involve histone deacetylation (Ng et al., 2000) but, contrast to MeCP2 and MBD2, 
MBD1 does not directly recruit HDACs (Fujita et al., 2003). MBD1 can mediate 
transcriptional repression via the H3K9 methyltransferase Suvar39h1 and HP1α and 
this seems to be partially dependent on interactions between Suvar39h1 and HDACs 
(Fujita et al., 2003). MBD1 has also been reported to form a complex with another 
H3K9 methyltransferase SETDB1 and interact with chromatin assembly factor 
(CAF-1) and the DNA replication machinery during S phase. This could represent a 
mechanism by which histone and DNA methylation could be propagated together 
through cell division (Sarraf and Stancheva, 2004).  
 
MBD1 is expressed in many tissues and has high expression in brain, but is not 
detectable in ES cells (Hendrich and Bird, 1998). Disruption of the Mbd1 gene in 
mouse results in a mild phenotype. Animals develop normally but show decreased 
neurogenesis, impaired learning and autism-like behavioural characteristics (Allan et 
al., 2008; Zhao et al., 2003). Similar to MeCP2, disruption of MBD1 does not result 
in many changes in gene expression detectable by microarray analysis. Expression 
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microarrays on Mbd1-/- hippocampus showed the only transcripts with increased 
expression were from IAP endogenous retroviruses (Zhao et al., 2003). 
 
1.3.4 MBD3 
MBD3 shows strong homology to MBD2b and the two are thought to have evolved 
from duplication of an ancestral Mbd2/3 gene (Hendrich et al., 1999a). However, due 
to an amino acid substitution in the MBD, MBD3 does not have the ability to bind 
methylated DNA (Fraga et al., 2003; Hendrich and Bird, 1998; Saito and Ishikawa, 
2002). Like MBD2, MBD3 is a component of the NuRD chromatin remodelling 
complex (Zhang et al., 1999) although MBD2 and MBD3 form separate NuRD 
complexes (Le Guezennec et al., 2006). Consistent with this, MBD2 and MBD3 have 
non-redundant functions. Mbd2-/- mice are viable and fertile whereas Mbd3-/- 
embryos die before implantation indicating that MBD3 is essential for normal 
development, (Hendrich et al., 2001). This lethality is thought to be due to a failure 
to repress pluripotency markers and undergo proper differentiation. Mbd3-/- ES cells 
fail to form a functional NuRD complex and cannot differentiate or down-regulate 
Oct4 (Kaji et al., 2006). Similarly, in vivo, lack of MBD3 results in a failure of the 
inner cell mass (ICM) of the blastocyst to develop further after implantation (Kaji et 
al., 2007). 
 
1.3.5  MBD4 
Although MBD4 has specific binding affinity for methylated DNA it does not act as 
a transcriptional repressor but rather functions in DNA mismatch repair (Hendrich 
and Bird, 1998; Hendrich et al., 1999b). As discussed, mC is mutagenic because it 
can be deaminated to a thymine residue (T) resulting in a methyl-CpG (mCpG) 
dinucleotide which is paired with a TpG dinucleotide. MBD4 can specifically 
recognise these sites and excise the mismatched nucleotide using its glycosylase 
domain which has homology to bacterial repair proteins (Hendrich et al., 1999b). In 
Mbd4-/- mice, CpG to TpG transitions are enhanced 3-fold supporting a function for 
MBD4 in limiting the mutability of mCpG. In addition, tumour prone ApcMin mice 
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show increased tumour formation when MBD4 is deleted due to C to T mutations in 
the Apc gene (Millar et al., 2002). 
 
1.3.6 MBD2 
MBD2 has binding specificity for methylated DNA and stably associates with the 
NuRD co-repressor complex (Feng and Zhang, 2001; Le Guezennec et al., 2006; Ng 
et al., 1999). Despite a relatively mild phenotype in the absence of MBD2 (Hendrich 
et al., 2001), significant gene deregulation has been observed in all systems 
examined in the Mbd2-/- mouse (Barr et al., 2007; Berger et al., 2007; Hutchins et 
al., 2002). This points to a role for MBD2 as a methylation-dependent transcriptional 
repressor. One example of gene deregulation in Mbd2-/- mice occurs in the immune 
system and it is tempting to speculate that many more phenotypes may be observed 
upon careful probing of immune system function. A main focus of this thesis is to 
explore the role of MBD2 in gene expression using the immune system as a model. 
 
MBD2 is widely expressed and exists in two isoforms 
MBD2 is expressed in all tissues with the notable exception of ES cells where MBD3 
exerts an important role instead. MBD2 exists in 2 isoforms; a full-length isoform, 
MBD2a, and a shorter isoform, MBD2b, thought to result from use of an alternative 
translation start site (Hendrich and Bird, 1998). The functional significance of these 
two isoforms is still unclear. The most significant difference is that MBD2a contains 
a run of glycine-arginine (GR) repeats that can be subject to arginine methylation. 
This has been reported to impair MBD2’s function as a transcriptional repressor (Le 
Guezennec et al., 2006; Tan and Nakielny, 2006). MBD2 does not saturate the 
genome as MeCP2 does. Estimates suggest that there are approximately 4 x 105 
molecules of MBD2 per cell which is much less than the number of potential binding 
sites (there are approximately 2 x 107 mCpGs in the haploid genome). This suggests 
that MBD2 must have specific targets in the genome. (R Ekiert, unpublished results). 
 
MBD2 is part of the NuRD complex 
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MBD2 is part of the NuRD chromatin remodelling and HDAC complex and this was 
found to represent the MeCP1 methyl-binding activity previously described (Feng 
and Zhang, 2001; Ng et al., 1999; Zhang et al., 1999). The NuRD complex contains 
the SWI/SNF chromatin remodelling protein Mi-2α/β, HDAC 1 and HDAC2, along 
with other factors including the MTA (metastasis-associated) proteins (different 
members of which may be involved in functional specialisation of NuRD 
complexes), p66α/β and the histone binding proteins RbAp48 and RbAp46 (Bowen 
et al., 2004; Brackertz et al., 2006; Xue et al., 1998; Zhang et al., 1998). MBD2 
always associates with the NuRD complex (Feng and Zhang, 2001; Le Guezennec et 
al., 2006) but the NuRD complex can exist without MBD2 as the related protein, 
MBD3, can also interact with NuRD components. MBD2/NuRD preferentially 
remodels and deacetylates methylated nucleosomes in vitro. Consistent with this, 
MBD2/NuRD has been shown to repress transcription in reporter assays in a 
methylation-dependent manner which requires nucleosome remodelling and, to some 
extent, deacetylation (Feng and Zhang, 2001; Ng et al., 1999).  
 
In addition to members of the NuRD complex a number of interactors have been 
reported for MBD2 which include the arginine methylase PRMT5, the zinc-finger 
protein MIZF, a novel protein MBD2in and focal adhesion kinase (FAK) (Lembo et 
al., 2003; Luo et al., 2009; Sekimata et al., 2001; Tan and Nakielny, 2006). A report 
claiming that MBD2b is a DNA demethylase (Bhattacharya et al., 1999) has not been 
substantiated by other studies (Hendrich et al., 2001; Ng et al., 1999; Santos et al., 
2002). 
 
Mbd2-/- mice are viable and fertile  
Knockout of the Mbd2 gene in mice has a relatively mild phenotype and mice are 
viable and fertile. Mbd2-/- mice exhibit a maternal behaviour defect but imprinting 
and repression of retroviral elements tested is normal. Mbd2-/- cells from these mice 
fail to fully repress methylated reporter constructs and this can be rescued by 




Strikingly, absence of MBD2 results in resistance to tumours in a mouse model of 
intestinal cancer. When Mbd2-/- mice are crossed onto a tumour-prone ApcMin 
background they show reduced tumour burden and increased life-span (Sansom et 
al., 2003). This suggests that MBD2 is necessary for development or maintenance of 
tumours in these mice. This could be due to a role for MBD2 regulating a repressor 
of the Wnt signalling pathway which is constitutively active in these tumours (Phesse 
et al., 2008) or due to increased immune surveillance of cancer cells in the absence of 
MBD2.  
 
Removal of MBD2 results in gene expression changes 
Although Mbd2-/- mice are viable and fertile the three systems that our lab has 
studied in detail in this mouse show significant gene de-regulation; interleukin-4 (IL-
4) and interferon-γ (IFN-γ) are aberrantly expressed during T helper cell 
differentiation leading to a compromised immune response, genes coding for 
pancreatic enzymes are mis-expressed in the colon and a fraction of Xist is de-
repressed on the active X chromosome (Barr et al., 2007; Berger et al., 2007; 
Hutchins et al., 2005; Hutchins et al., 2002). In addition, MBD2 is required for 
silencing of particular tumour-suppressor genes in human colorectal carcinoma cells 
and other cancer cell lines (Auriol et al., 2005; Bakker et al., 2002; Lin and Nelson, 
2003; Martin et al., 2008; Pulukuri and Rao, 2006). Other reported targets for MBD2 
include the gene for the pluripotency factor Oct4, the telomerase reverse 
transcriptase gene hTERT and the estrogen responsive gene pS2/TFF1 (Chatagnon et 
al., 2010; Chatagnon et al., 2009; Gu et al., 2006). This suggests that it is worth 
comprehensively examining systems in the Mbd2 null mouse to look for gene 
expression changes.  
 
It is worth noting that many of these MBD2 targets were confirmed to be methylated 
and, for a number of these, disruption of DNA methylation has been shown to relieve 
gene repression. In several cases, removal of MBD2 increased histone acetylation of 
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target genes or rendered them more sensitive to inhibition of HDACs (Barr et al., 
2007; Berger et al., 2007; Hutchins et al., 2002). 
 
MBD2 is important for immune system function 
MBD2 has been implicated in a number of aspects of immune system function. 
Reported examples include in vitro T helper cell differentiation, response to infection 
in vivo and memory T cell development (Hutchins et al., 2005; Hutchins et al., 2002; 
Kersh, 2006).  
 
T helper (CD4) cells of the immune system, upon stimulation with certain antigens, 
can differentiate into Th1 or Th2 effector cells and this can be recapitulated in a cell 
culture system. These cells are characterised by different repertoires of cytokine 
expression; Th1 cells express cytokine IFN-γ while Th2 cells express IL-4 and this is 
accompanied by DNA methylation changes at the relevant gene loci. When Mbd2-/- 
T helper cells are differentiated in vitro, IFN-γ and IL-4 expression, and 
consequently cell identity, is perturbed. Th1 cells from Mbd2-/- mice aberrantly 
express IL-4 while Th2 cells mis-express IFN-γ. MBD2 was found to bind two 
regions of the Il4 locus in Th1 cells where presumably it contributes to gene 
silencing (Hutchins et al., 2002). Th1 cells mediate the immune response to 
intracellular bacteria and viruses while Th2 cells coordinate the response to 
extracellular parasites. When infected with a Th2-inducing intestinal worm, Mbd2-/- 
mice show an impaired Th2 response compared to wild-type animals but show 
enhanced resistance to Th1-inducing Leishmania. These phenotypes are reportedly 
due to excess IFN-γ production (Hutchins et al., 2005). 
 
Memory T cells are produced during an infection and help protect the organism if the 
same pathogen is encountered again. During viral infection, cytotoxic CD8 T cells 
are produced in order to fight infection and some of these differentiate into memory 
CD8 cells. Infection of Mbd2-/- mice with lymphocytic choriomeningitis virus 
showed a reduction in the numbers of CD8 memory T cells produced compared to 
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wild-type animals. In addition, the CD8 memory cells that were formed were found 
to be defective in protecting against re-infection (Kersh, 2006) further highlighting a 
role for MBD2 in the immune system. 
 
1.4 The CxxC proteins 
Much as the MBDs link methylated CpG to the chromatin state, the CxxC domain 
proteins have been implicated in linking non-methylated CpG to chromatin 
modification.  
 
1.4.1 The CxxC proteins bind unmethylated CpGs and are 
involved in epigenetic regulation 
The CxxC domain proteins are characterised by the presence of a cysteine-rich zinc 
finger domain (CxxC amino acid motif) that has specific affinity for non-methylated 
CpGs (Voo et al., 2000). CxxC proteins have been implicated in linking non-
methylated CpGs to specific chromatin states and also in catalysing and recognising 
DNA methylation. The CxxC domain family of proteins consists of CFP1, MLL 1 
and 2, KDM2A, Dnmt1, TET1 and MBD1 as well as several proteins with 
uncharacterised function. Several CxxC proteins are involved in histone methylation; 
CFP1 is part of the SETD1 H3K4 methyltransferase complex (Lee and Skalnik, 
2005), the trithorax group proteins MLL 1 and 2 are also H3K4 methyltransferases 
(Birke et al., 2002) whereas KDM2A has H3K36 demethylase activity (Tsukada et 
al., 2006). Some enzymes involved in the chemical modification of DNA also 
possess CxxC domains, for example Dnmt1 the maintenance DNA 
methyltransferase, and TET1 which catalyses conversion of mC to hmC, a potential 
DNA demethylation intermediate (Pradhan et al., 2008; Tahiliani et al., 2009) 
(Dnmt1 and TET1 are discussed in section 1.1). The methyl-binding protein MBD1 
which was identified on the basis of its MBD domain (Cross et al., 1997) also has a 
CxxC domain with specific affinity for unmethylated DNA (Jorgensen et al., 2004) 



























1.4.2 CFP1 and KDM2A have a role at CGIs 
Recently the CxxC proteins CFP1 and KDM2A have been shown to direct chromatin 
structure at unmethylated CGIs. CFP1 (CxxC finger protein 1; also known as CGBP 
or CxxC1) contains two plant homeodomains (PHD) along with its CxxC domain 
and a set interaction domain (Voo et al., 2000). CFP1 interacts with the SETD1 
methyltransferase complex (Lee and Skalnik, 2005) and is an orthologue of the 
protein SPP1 a component of the only H3K4 histone methyltransferase complex in 
yeast, SET1 (Miller et al., 2001). Deletion of Cfp1 results in early embryonic 
lethality consistent with an essential role for the protein (Carlone and Skalnik, 2001) 
while Cfp1 null ES cells show increased apoptosis and failure to differentiate 
(Carlone et al., 2005). Based on its ability to bind to unmethylated CpGs, Thomson 
and colleagues investigated whether CFP1 was found at CGIs and discovered that it 
could direct H3K4me3 to unmethylated CGIs (Thomson et al., 2010).  
Figure 1.4.1 The CxxC domain proteins 
Members of this protein family contain a CxxC domain (yellow) capable of binding unmethylated CpG. MLL1 
and 2 contain a SET domain (red) which catalyses H3K4 methylation while CFP1 associates with a complex 
that has H3K4 methylation activity. CFP1, MLL1 and 2 and KDM2A contain chromatin binding PHD fingers.  
KDM2A contains the JmjC domain characteristic of this family of histone demethylases and Dnmt1 contains 
a C-terminal catalytic domain. TET1 possesses cysteine-rich (Cys-rich) and double stranded beta-helix 
(DSBH) domains that are responsible for its catalytic activity. MBD1 has an MBD domain and two non-





KDM2A (Lysine specific demethylase 2a) was characterised a number of years ago 
based on its ability to demethylate H3K36me2 (Tsukada et al., 2006). Recently a 
study by Blackledge and colleagues (2010) demonstrated specific affinity of 
KDM2A’s CxxC domain for unmethylated CpG and showed that KDM2A 
specifically binds the vast majority of CGIs. Knockdown of KDM2A led to an 
increase in H3K36me2 specifically over CGIs (Blackledge et al., 2010). The CxxC 
domain has also been utilised to biochemically purify CGIs, a technique known as 
“CxxC affinity purification” (CAP) which uses the CxxC3 domain of MBD1 
(Illingworth et al., 2008). The relationship between CxxC proteins and CGIs will be 
discussed further in section 1.5.  
 
1.5 CpG islands 
The genome is punctuated by CpG-rich unmethylated CGIs that frequently associate 
with gene promoters. CGIs are permissive to transcription except in the rare cases 
when they become silenced by DNA methylation. Methylation of CGIs is well-
documented in X inactivation, imprinting and cancer but also occurs in normal 
development.  
Bulk genome CGI 
 
 
Figure 1.5.1 CGIs represent a distinct fraction of the genome 
The genome can be divided into two fractions with respect to DNA methylation and CpG content. The bulk 
genome is CpG deficient and methylated (~70% of CpGs) while CGIs are generally unmethylated with little 
CpG suppression. CGIs often associate with gene promoters. Filled circles = methylated CpG, empty circles 
= unmethylated CpG. The arrow indicates a TSS and the direction of transcription. 
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1.5.1 Characterisation of CGIs 
CGIs represent a distinct and functionally important fraction of the genome. They 
show elevated G+C content and little CpG depletion due to the fact that, unlike the 
bulk genome, CGIs are usually unmethylated. Methylation is mutagenic and leads to 
CpG deficiency, therefore maintaining an unmethylated state prevents loss of CpG 
(section 1.1.2). CGIs were first identified by digestion of genomic DNA with the 
methyl-sensitive restriction enzyme HpaII (recognition site CCGG) which left bulk 
genomic DNA intact whilst liberating small fragments of CpG-rich unmethylated 
DNA initially known as HpaII tiny fragments (Bird et al., 1985). Based on initial 
characterisation of these fragments CGIs were defined as being regions longer than 
200bp, with a G+C content of 50% and a CpG observed/expected ratio (CpGo/e)i of 
at least 0.6 (Gardiner-Garden and Frommer, 1987; Larsen et al., 1992). These criteria 
are often used to bioinformatically predict the location of CGIs but can be sensitive 
to the presence of CpG-rich repeats such as Alu elements. More stringent criteria for 
prediction of CGIs were employed by Takai and Jones which, whilst eliminating 
repetitive Alu elements, are also likely to exclude some genuine CGIs (Takai and 
Jones, 2002). Initial analysis of the human genome sequence identified over 50,000 
CGIs of which, just over half were unique. Building repeat-masking into CGI 
prediction algorithms can help eliminate contaminating repeats from CGI sets. 
However, all prediction algorithms fail to take into account methylation status when 
predicting CGIs and, by necessity they employ arbitrary thresholds, alteration of 
which dramatically changes the number of CGIs predicted (Illingworth et al., 2008; 
Illingworth and Bird, 2009). 
 
Biological identification of CGIs is preferable to prediction algorithms especially as 
it takes methylation status into account. This has been accomplished using a CxxC 
domain that specifically binds unmethylated CpG-rich sequences to isolate CGIs 
from genomic DNA. The technique has been termed “CxxC affinity purification” 
(CAP) after the protein domain used. An initial study purifying CGIs from human 
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blood combined with traditional Sanger sequencing identified approximately 17,000 
CGIs (Illingworth et al., 2008). This number does not represent the full complement 
of CGIs in the genome because of a high rate of sequence failure due to the GC-rich 
nature of the sequence and because any CGIs that are fully methylated in blood were 
excluded as they are not bound by the CxxC domain. Germline CGIs are 
hypomethylated (Weber et al., 2007) making tissues such as sperm more suitable for 
comprehensive identification of CGIs.  
 
Recently the CGI complement of human and mouse has been comprehensively 
characterised using CAP combined with high throughput sequencing technology 
(CAP-seq) (Illingworth et al., 2010). A panel of tissues including sperm was used so 
practically all CGIs should be included. CGI numbers in human and mouse were 
very similar, at 25,495 and 23,021 respectively, despite the fact that algorithms 
predict a reduction in mouse CGI numbers (Waterston et al., 2002), further 
emphasising the importance of using biological purification to identify CGIs. 
 
1.5.2 CGIs are associated with promoter function 
CGIs are traditionally associated with the promoters of housekeeping genes and 
because of their promoter association localise to gene-rich regions of the genome 
(Lander et al., 2001). Approximately 60% of human genes have a CGI promoter 
including all housekeeping genes as well as approximately 40% of genes with tissue-
specific expression patterns (Larsen et al., 1992). Approximately half of CGIs 
associate with a known TSS with the remainder occurring within gene bodies 
(intragenic) or between genes (intergenic) in approximately equal proportions 
(Illingworth et al., 2010; Illingworth et al., 2008). Many of these “orphan” CGIs 
show evidence for promoter function and it is hypothesised that all CGIs act as 
promoters at some stage in development (Illingworth et al., 2010; Macleod et al., 
1998; Maunakea et al., 2010). Indeed, the presence of orphan CGIs has often led to 
                                                                                                                                          
i CpG o/e is the actual number of CpG sites present in a sequence compared to the number expected 
from its G+C content. 
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the identification of novel transcripts and alternative gene promoters (Gardiner-
Garden and Frommer, 1994; Macleod et al., 1998; Maunakea et al., 2010; Rauch et 
al., 2009). Most studies examining chromatin modification and DNA methylation of 
CGIs focus only on promoter CGIs so a lot remains to be uncovered about the role 
and properties of CGIs occurring outwith annotated TSSs. 
 
1.5.3 CGIs form transcriptionally permissive chromatin 
environments 
Consistent with their promoter function CGIs form a chromatin environment 
permissive for transcription (Tazi and Bird, 1990). Genome-wide studies have shown 
promoter CGIs to be frequently associated with the active chromatin mark H3K4me3 
regardless of transcriptional activity (Mikkelsen et al., 2007). This also holds true for 
intra- and intergenic islands although the association is weaker (Illingworth et al., 
2010; Maunakea et al., 2010). The H3K4me3 mark is directed to CGIs via the CxxC 
domain protein CFP1 (CxxC finger protein 1) (Thomson et al., 2010), a component 
of the H3K4 methyltransferase complex SETD1 (Lee and Skalnik, 2005). CFP1 
marks the vast majority of CGIs and knockdown of CFP1 leads to depletion of 
H3K4me3 from CGIs. Insertion of an artificial CGI into the genome recruits CFP1 
and creates a novel peak of H3K4me3 in the absence of Pol II (Thomson et al., 
2010). It is likely, however, that at many CGIs the presence of Pol II contributes to 
H3K4 tri-methylation as the core transcription complex itself can recruit H3K4 
methyltransferases (Ruthenburg et al., 2007). 
 
Another CxxC protein, KDM2A an H3K36me2 demethylase (Tsukada et al., 2006), 
also influences chromatin structure at CGIs. Recently a study by Blackledge et al 
(2010) showed that KDM2A specifically binds over 90% of CGIs which are depleted 
for H3K36me2 compared to non-CGI promoters and the bulk genome. The 
requirement for H3K36me2 depletion at CGIs is, as yet, unclear but H3K36me2 has 
been reported to inhibit transcription initiation through HDAC recruitment in both 
yeast and human so this could be related to the promoter function of CGIs (Li et al., 
2009; Strahl et al., 2002; Youdell et al., 2008).  
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In addition to being marked by H3K4me3 and depleted for H3K36me2, CGIs have a 
low density of nucleosomes and transcription from CGI promoters can initiate 
without a requirement for chromatin remodelling complexes (Ramirez-Carrozzi et 
al., 2009). This evidence suggests that the function of CGIs may be to provide 
environments permissive for transcription initiation within the complex mammalian 
genome. Most of the genome is not transcribed yet contains abundant transcription 
factor binding sites. Therefore chromatin structure and DNA methylation state must 
be important in directing transcription factors to their appropriate targets. To this end 
CGIs can be thought of as beacons directing transcription in the genome (Bird, 1995; 
Illingworth and Bird, 2009).  
 
1.5.4 Origin of CpG islands 
CGIs are distinct from the rest of the genome. One major question is how, in the face 
of genome-wide methylation, CGIs are protected from methylation and thus 
prevented from becoming CpG deficient. This may be directly related to their 
function as promoters. Deletion or mutation of SP1 transcription factor binding sites 
in the promoter of the mouse Aprt gene was shown to lead to methylation of the Aprt 
CGI suggesting that transcription keeps it free of methylation (Brandeis et al., 1994; 
Macleod et al., 1994). One way in which this could be achieved is if the presence of 
the transcriptional machinery at a CGI inhibits recruitment of Dnmts. However, CGIs 
tend to be larger than the area occupied by the basal transcription machinery. 
Transcriptionally active CGIs often act as origins of replication and an alternative 
hypothesis is that initiation of replication could help prevent Dnmt action, thus 
maintaining CGIs (Antequera, 2003; Delgado et al., 1998). At CGI promoters, 
transcription initiation occurs broadly over hundreds of base pairs (Carninci et al., 
2006) and, in addition, divergent initiation occurring in both orientations has been 
described at CGI promoters (Core et al., 2008). The combination of these phenomena 
could help to increase the methylation-free footprint maintained by transcription 
 
If transcription from a CGI is necessary to keep it free of methylation all CGIs would 
need to be transcribed during early development when genome-wide waves of 
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methylation occur. Genome-wide de novo methylation occurs at the blastocyst stage 
of the embryo and later in the developing germ cells (Morgan et al., 2005). An early 
example supporting this hypothesis is that of the tissue-specific gene α-globin which 
is transcribed in the embryo and possesses a CGI while the related β-globin gene is 
silent and lacks a CGI (Daniels et al., 1997). Several other tissue-specific genes 
possessing CGIs have also been found to be expressed in early development (Daniels 
et al., 1995; Gardiner-Garden and Frommer, 1994).  More compelling evidence 
comes form a study showing that 93% of a panel of genes expressed in the early 
embryo have a promoter CGI (Ponger et al., 2001).  Embryonic stem cells have, 
more recently, been shown to be transcriptionally hyperactive with tissue-specific 
genes seen to be expressed at low levels (Efroni et al., 2008). If this is reflective of 
the situation in the early embryo such promiscuous transcription could help keep 
CGIs free of methylation. A recent genome-wide study showed that 90% of CGI-
associated genes were expressed in early embryo or testis and that 83% of annotated 
promoter CGIs functioned as origins of replication in ES cells (Sequeira-Mendes et 
al., 2009). This adds support to the notion that transcription, perhaps with the aid of 
replication initiation, acts to keep CGIs free of methylation.  
 
Large-scale promoter analysis using a method such as cap analysis of gene 
expression (CAGE) or global run-on sequencing (GRO-Seq) (Core et al., 2008; 
Faulkner et al., 2009) in the early embryo and in developing germ cells would allow 
promoter activity to be mapped so that it could be compared to the location of CGIs 
and, in particular, non-TSS-associated CGIs, in the genome. A major limitation, 
however, is likely to be the limiting amounts of material available from developing 
germ cells.  
 
CGIs are generally free of methylation in all cell types even when they are not 
expressed, despite the fact that de novo methylation can occur outside of early 
development (Meissner et al., 2008; Mohn et al., 2008). How then, are CGIs kept 
methylation free during other developmental stages with more restrictive expression 
patterns? One hypothesis is that de novo DNA methylation has to be targeted to 
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specific sequences in these contexts and does not promiscuously affect CGIs. This 
could be accomplished by recruitment of Dnmts to areas marked by repressive 
histone modifications as occurs in X inactivation where H3K27 tri-methylation 
precedes CGI methylation [reviewed in (Payer and Lee, 2008) and (Okamoto and 
Heard, 2009)].  
 
Another possibility is that the presence of CFP1 and H3K4me3 renders CGIs 
refractory to methylation. This suggestion initially came from evidence showing that 
binding of Dnmt3L, the partner protein of the de novo Dnmts is inhibited by H3K4 
tri-methylation (Ooi et al., 2007). A more recent report demonstrated that Dnmt3a 
complexes methylate chromatin modified by H3K4me3 less efficiently than 
unmodified H3 or H3K9me3 (Zhang et al., 2010). However, Thomson and 
colleagues (2010) see acquisition of methylation at an artificially inserted CGI 
despite the presence of CFP1 and H3K4me3. 
 
1.5.5 CGI methylation 
It was previously assumed that all CGIs were unmethylated except in special cases, 
such as X inactivation and imprinting, and aberrant situations such as cancer. Many 
studies have now shown that a small percentage of CGIs become methylated during 
normal development and that there are tissue-specific patterns of CGI methylation. 
CGI methylation is clearly associated with gene silencing although whether it 
initiates transcriptional silencing or “locks-down” already repressed genes is less 
certain. 
 
CGI methylation occurs in X inactivation 
Dosage compensation in female mammals occurs by inactivating of one of the X 
chromosomes through formation of a repressive chromatin environment. This is 
directed by the non-coding RNA (ncRNA) Xist which coats the future inactive X. 
Xist coating is followed by establishment of a repressive chromatin state involving 
polycomb recruitment and subsequent H3K27 tri-methylation of the X chromosome. 
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A later event is the acquisition of DNA methylation at X-linked CGIs. This is 
accomplished by the action of Dnmt3a and 3b and occurs after gene silencing [X 
inactivation is reviewed in (Payer and Lee, 2008) and (Okamoto and Heard, 2009)]. 
On the active X chromosome the CGI of the Xist gene becomes methylated ensuring 
that Xist is not transcribed and the chromosome is not subject to spurious 
inactivation. Depletion of methylation, via mutation of Dnmt1 or treatment with the 
chemical 5-azacytidine (5-azaC), leads to reactivation of X-linked genes 
(Csankovszki et al., 2001). The order of events in X inactivation suggests that CGI 
methylation is targeted to areas of already silent chromatin and is not the initiating 
event in transcriptional shut-down.  
 
Control of imprinting involves CGI methylation 
Imprinted genes are monoallelically expressed and this is determined by parental 
origin of the allele. Imprinting is controlled by imprinting control regions and often 
involves differential methylation of CGIs within these regions. CGI methylation can 
control imprinting in a number of ways. The CGI can be a promoter for a long 
ncRNA that induces silencing of the imprinted gene. One well-characterised example 
is that of the maternally expressed cluster of genes Igf2r/Slc22a2/Slc22a3. 
Expression of this cluster is inhibited by a paternally imprinted ncRNA called Air 
which might act by targeting repressive histone modifications to the locus.  The Air 
CGI is methylated on the maternal allele which prevents Air expression and thus 
allows Igf2r/Slc22a2/Slc22a3 to be transcribed (Nagano et al., 2008; Sleutels et al., 
2002). Differentially methylated CGIs can also act as binding sites for proteins with 
insulator function such as CTCF. Binding of CTCF to the CGI can prevent the action 
of enhancers on the imprinted gene. In these cases methylation interferes with 
insulator function by preventing CTCF binding, thereby promoting gene expression. 
A CGI in the imprinted Igf2/H19 locus acts as an insulator controlling expression of 
Igf2 in a methylation-dependent manner. In addition, many differentially methylated 
CGIs are found at gene promoters where methylation can directly inhibit expression 
of the methylated allele [a more comprehensive discussion of imprinting can be 
found in (Edwards and Ferguson-Smith, 2007)]. 
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Abnormal CGI methylation is a hallmark of cancer 
Aberrant acquisition of CGI methylation in cancer has been the focus of much 
research. The CGIs of several tumour suppressor genes have been shown to acquire 
cancer-specific methylation and many genes involved in familial forms of cancer 
undergo methylation-associated silencing in sporadic cancers (Jones and Baylin, 
2002). This is associated with gene silencing and is thought to contribute to 
uncontrolled proliferation and thus tumour development. Methylation in tumours has 
been found to affect specific groups of CGIs and this has been proposed to be a 
distinct phenotype known as the CGI methylator phenotype (Toyota et al., 1999). 
Genome-wide studies have confirmed that a small proportion of CGIs acquire 
methylation in cancer (Illingworth et al., 2010; Ruike et al., 2010; Weber et al., 
2005). Tumour-specific CGI methylation is now known to affect genes with a variety 
of functions and not just tumour-suppressors (Keshet et al., 2006), although for some 
of these repression does not seem to be dependent on methylation (Costello et al., 
2000). Whether cancer CGI methylation mirrors normal developmental methylation 
or chromatin state has received much recent attention. Acquisition of methylation in 
cancer has been found to preferentially occur at genes marked by H3K27me3 in ES 
cells (Ohm et al., 2007; Widschwendter et al., 2007). A recent report identified 
methylation occurring at the edges of CGIs in cancer and this was found to be the 
same as normal tissue-specific methylation (Irizarry et al., 2009). However, a 
subsequent study examining bone fide CGI methylation found the pattern of cancer-
specific methylation to be distinct to that of normal CGI methylation (Illingworth et 
al., 2010). Paradoxically, increased CGI methylation in cancer is accompanied by a 
genome-wide decrease in methylation associated with genome instability (Jones and 
Baylin, 2007). 
 
CGI methylation occurs during normal development 
There has been a plethora of studies in recent years profiling CGI methylation in 
normal tissues and it is now clear that CGI methylation occurs during development 
outwith X inactivation and imprinting. An initial study profiling methylation of three 
human chromosomes identified approximately 10% of CGIs as being extensively 
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methylated (Eckhardt et al., 2006). Weber and colleagues (2007) later surveyed 
methylation at the majority of promoters in human sperm and fibroblast cells. Sperm 
CGI promoters were found to be hypomethylated, confirming previous reports. They 
found that approximately 3% of strong CGI promoters were methylated in somatic 
cells compared to sperm but more methylation was seen at a class of weak CGI 
promoter (21% methylated). A significant proportion of CGIs that acquired 
methylation in fibroblasts (17%) were associated with germline-specific genes  
(Weber et al., 2007). Illingworth et al found 6-8% of CGIs to be methylated in any 
one human tissue and showed that CGIs outwith annotated gene promoters 
preferentially acquire methylation (Illingworth et al., 2008). In vitro differentiation 
systems have been used to track the extent of methylation changes during 
development. A gain in CGI methylation occurs during differentiation of ES cells to 
neurons, with the majority occurring at the early stages of differentiation and being 
maintained in all somatic tissues (Mohn et al., 2008)ii. There have been numerous 
other reports describing CGI methylation in normal tissues [for example (Meissner et 
al., 2008; Schilling and Rehli, 2007; Shen et al., 2007)]. Such methylation studies 
have shown that a small percentage of CGIs become methylated in somatic tissues 
and that there are CGI methylation differences between cell types, although these 
occur less frequently (Meissner et al., 2008).  
 
CGIs that can acquire methylation tend to be less CpG-dense than CGIs refractory to 
methylation (Eckhardt et al., 2006; Illingworth et al., 2010; Meissner et al., 2008; 
Weber et al., 2007). A likely explanation for this is the mutagenic effect of 
methylation which depletes CpGs from the genome. Alternatively, CpG-density 
could correlate with CFP1 occupancy and therefore the H3K4me3 level which may 
protect against methylation. Indeed, Illingworth and colleagues (2010) have shown 
H3K4me3 to decrease with CpG density. 
 
                                                 
ii Whilst sperm CGIs are devoid of methylation (except at paternally imprinted CGIs) a very small 




Cell type-specific CGI methylation and its relationship to gene expression 
A major question remaining involves the significance of somatic CGI methylation 
and its relationship to gene expression. CGI methylation is clearly associated with 
transcriptional silencing but does differential methylation correspond to differential 
gene expression? A study using restriction landmark genomic scanning (RLGS) to 
identify tissue-specific CGI methylation found that for several genes, differential 
CGI methylation, corresponded to differential gene expression (Song et al., 2005) 
and this was also the case in a study by Schilling and Rehli (2007). However, 
Eckhardt and colleagues observed that a large proportion of CGIs specifically 
unmethylated in sperm but methylated in somatic cells did not show germline-
specific expression of the associated gene (Eckhardt et al., 2006) and Illingworth et 
al did not find any obvious correlation between differential CGI methylation and 
gene expression (Illingworth et al., 2008).  
Another factor making the relationship between differential CGI methylation and 
gene expression less clear is the existence of large numbers of non-promoter-
associated CGIs. These intra- and intergenic CGIs represent the majority of 
methylated CGIs (Illingworth et al., 2010; Illingworth et al., 2008; Maunakea et al., 
2010; Rauch et al., 2009) and two recent studies have identified many of these as 
being novel promoters (Illingworth et al., 2010; Maunakea et al., 2010). Could CGIs 
within gene bodies be promoters for ncRNAs that regulate expression of the 
associated gene? Or might they represent an alternative TSS for that gene as 
suggested by Maunakea et al. (2010)? Alternatively, can methylation of an intragenic 
CGI affect transcription of the associated gene by another mechanism? 
 
1.5.6 CGI methylation – cause or consequence? 
Whether CGI methylation is an initiating event in gene silencing, a maintenance 
mechanism or a mere consequence of a transcriptionally repressed state remains 
unclear. CGI methylation is often preceded by gene silencing and repressive histone 
modifications, for example in X inactivation, arguing that DNA methylation is 
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targeted to already silent chromatin (Csankovszki et al., 2001). Mohn and colleagues 
(2008) found that more than half of CGIs that acquired methylation upon 
differentiation were already silent in ES cells prior to de novo methylation. Many of 
these were marked by H3K27me3 in ES cells but lost H3K27me3 and acquired DNA 
methylation upon differentiation. Studies showing gene reactivation as a result of 
depleting methylation argue that CGI methylation is essential for maintaining gene 
silencing (De Smet et al., 1999; Li et al., 1993; Sado et al., 2000). Most evidence 
seems to argue for targeting of CGI methylation to silent genes where it acts to 
maintain gene silencing in a heritable manner. It is also possible that CGI 
methylation can be a stochastic event occurring in the absence of transcriptional 
activity. This is supported by the occurrence of differential CGI methylation in 
tissues where the associated gene is constitutively repressed (Illingworth et al., 2008; 
Schilling and Rehli, 2007). However, a role for CGI methylation in initiation of gene 
silencing cannot be ruled out. Silencing of the trophectoderm-specific Rhox genes in 
the embryo proper has been shown to be highly dependent on de novo methylation 
mediated by Dnmt3a and 3b (Oda et al., 2006). 
 
1.6 Epigenetics and the immune system 
Immune system cells represent a distinct developmental lineage all derived from a 
common progenitor. Mature immune cells can further differentiate into specialised 
effector cells designed to deal with particular pathogens and some of these become 
memory cells which are poised to respond to re-infection. These factors make the 
immune system an appealing model in which to study epigenetic mechanisms. 
Epigenetic modification at the key cytokine loci, Ifng and Il4 has been extensively 
documented during T cell differentiation and, in addition, recent genome-wide 
studies have helped to shed light on the role of histone modifications in regulating T 




1.6.1 The Ifng and Il4 loci undergo epigenetic changes during T 
helper cell differentiation  
The first evidence for involvement of epigenetic mechanisms in T helper cell 
differentiation came from the observation that several rounds of cell division are 
required in order to achieve signature cytokine expression during this process. Naïve 
CD4 T cells can differentiate into Th1 cells expressing IFN-γ and repressing IL-4 or 
Th2 cells expressing IL-4 and silencing IFN-γ. Treatment of differentiating cells with 
agents that promote histone acetylation or prevent DNA methylation allowed earlier 
and increased expression of these cytokine genes in their appropriate lineages (Bird 
et al., 1998). Since then, histone acetylation (Avni et al., 2002; Baguet and Bix, 
2004; Fields et al., 2002; Fields et al., 2004; Grogan et al., 2003; Morinobu et al., 
2004) and DNA methylation (Jones and Chen, 2006; Kim et al., 2007; Lee, 2002; 
Makar and Wilson, 2004; Santangelo et al., 2002; Schoenborn et al., 2007; Winders 
et al., 2004; Yano et al., 2003) changes at the Ifng and Il4/Il5/Il13 loci have been 
profiled extensively during T cell differentiation as well as the appearance of DNase 
I hypersensitive sites, an indicator of open chromatin conformation (Agarwal and 
Rao, 1998; Fields et al., 2004; Santangelo et al., 2002; Schoenborn et al., 2007; 
Takemoto et al., 2000) and, more recently, histone methylation marks (Chang, 2007; 
Schoenborn et al., 2007; Wei et al., 2009). In general, the Ifng locus shows increased 
histone acetylation and reduced DNA methylation in Th1 cells while the Il4/Il5/Il13 
locus acquires acetylation and looses DNA methylation in Th2 cells consistent with 
gene activity. These epigenetic changes occur not only at gene promoters but also at 
conserved regulatory elements throughout the cytokine gene loci and are dependent 
on lineage-specific transcription factors and signalling events. Appropriate cytokine 
expression during T cell differentiation has been found to depend not only on DNA 
methylation but on MBD2, a reader of this mark [(Hutchins et al., 2002) and section 
1.3.6]. 
 
In many studies, DNA methylation changes at the Ifng and Il4/Il5/Il13 loci have been 
shown to require cell division indicating a gradual accumulation of methylation (Bird 
et al., 1998; Lee, 2002). Specific CpG sites, however, have been shown to undergo 
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rapid methylation changes. A CpG site in the Ifng promoter is rapidly methylated 
during Th2 differentiation and this interferes with transcription factor binding (Jones 
and Chen, 2006) while a CpG dinucleotide in the Il4/Il5/Il13 locus control region 
undergoes active demethylation under Th2 conditions (Kim et al., 2007) . Upon T 
cell activation a site in the Il2 promoter shows active demethylation concomitant 
with recruitment of the activator Oct-1 to this site (Bruniquel and Schwartz, 2003; 
Murayama et al., 2006). However, none of these genes is associated with a CGI. 
 
1.6.2 Dnmts are required in immune system cells 
Insights into the role of DNA methylation in the immune system have been gained 
from analysis of the phenotypes of immune-specific Dnmt knockouts. A T cell-
specific knockout (CD4 and CD8 cells) of the maintenance methyltransferase Dnmt1 
showed reduced proliferation of naïve CD4 cells upon stimulation but increased 
expression of Il2, Il4 and Ifng consistent with a role for DNA methylation in 
regulating appropriate expression of these genes (Lee et al., 2001). Dnmt1 and 
Dnmt3b were found to be recruited to regulatory regions of the Il4 locus in resting 
thymocytes (Makar et al., 2003) and, intriguingly, these regions are reported to be 
bound by MBD2 in Th1 cells (Hutchins et al., 2002). Removal of Dnmt1 specifically 
in cytotoxic CD8 T cells leads to reduced immunity to viral infections due to a 
massive proliferation defect as well as impaired differentiation into effector and 
memory cells (Chappell et al., 2006). 
 
Dnmt3a has recently been shown to be upregulated following T cell activation and 
demonstrated to be necessary for establishment of DNA methylation at the Ifng locus 
to ensure silencing under Th2 conditions. When Dnmt3a-/- T cells were stimulated 
and cultured over time, they simultaneously expressed Ifng and Il4 and, consistent 
with this, the genes were demethylated. Intriguingly, these cells also co-expressed 
Tbx21 and Gata3 suggesting that these genes might also be regulated by methylation 




The effect of depleting Dnmt1 earlier in development of the hematopoietic lineage 
has recently been described (Broske et al., 2009). Immune cells develop from a 
hematopoietic stem cell (HSC) which gives rise to either; a myeloid progenitor cell 
that is the precursor of monocytes, granulocytes and dendritic cells or a lymphoid 
progenitor from which B and T cells are formed. Conditional knockout of Dnmt1 
resulted in complete loss of HSCs and progenitor cells. Reducing Dnmt1 levels using 
a hypomorphic allele impaired HSC self-renewal and, in addition, HSCs were unable 
to suppress key myeloid genes. These mice could not make lymphoid progenitors 
due to a failure to silence the myeloid differentiation programme and as a 
consequence had drastically reduced numbers of B and T cells. In contrast, reducing 
DNA methylation after commitment to the B cell lineage had no effect on the 
number of mature B cells produced. This indicates that DNA methylation may be 
more important in specifying progenitor cell identity rather than maintaining the 
identity of differentiated cells and suggests that methylation patterns may be set up 
early in hematopoiesis. 
 
1.6.3 Global changes in histone modification during T cell 
activation and differentiation 
The genome-wide distribution of various histone modifications has been profiled in 
human and mouse T cells both with a view to understanding the role of histone 
modification in gene regulation generally and to elucidating T cell-specific roles. 
Some of the first studies profiling histone acetylation and methylation genome-wide 
by ChIP-Seq were carried out in resting human CD4 T cells. These drew general 
conclusions such as the association of specific histone methylation and acetylation 
marks with the promoters of active genes and also characterised bivalent promoters 
marked by both H3K27me3 and H3K4me3 in these cells (Barski et al., 2007; Wang 
et al., 2008). A subsequent study compared the pattern of histone modifications in 
resting CD4 cells to that of activated CD4 cells (i.e. those stimulated to respond to 
infection) and related this to gene expression. Genes that were induced upon 
activation were found to be poised for expression in resting cells and bore active 
chromatin modifications and together with Pol II at their promoters even though the 
genes were silent (Barski et al., 2009). Another study examining T cell stimulation 
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also found that the chromatin state was often set prior to gene activation (Smith et al., 
2009). This suggests that few epigenetic changes occur rapidly upon T cell activation 
and that a pre-existing chromatin state defines the ability of T cells to respond to 
stimuli in the short-term.  
 
However, longer-term differentiation into effector T cells is associated with some 
epigenetic changes. A study profiling the histone modifications H3K4me3 and 
H3K27me3 in naïve, Th1, Th2 and two recently discovered T cell types, Th17 and 
Treg cells, identified a small number of genes that change their histone modification 
state upon differentiation. This demonstrates that genes apart from Il4 and Ifng 
undergo epigenetic changes during T cell differentiation. Interestingly, the genes 
encoding two key regulators of T helper cell fate, Tbx21 (the gene for T-bet, a key 
Th1 transcription factor) and Gata3 (the key Th2 transcription factor) were found to 
be bivalent in cells when they were silent (Wei et al., 2009).  
 
1.6.4 DNA methylation changes in immune system cells 
In addition to the well-documented DNA methylation changes that take place at the 
Ifng and Il4 loci during T cell differentiation other genes have been reported to show 
methylation differences in immune system cells. Tregs show lineage-specific DNA 
demethylation at the gene for their master regulator Foxp3 (Floess et al., 2007; Kim 
and Leonard, 2007; Lal et al., 2009; Polansky et al., 2008). The gene encoding IL18-
Rα which is expressed in Th1 but not Th2 cells is differentially methylated in the two 
cell types and this involves a mechanism dependent on lineage-specific transcription 
factors (Yu et al., 2007).  
 
DNA methylation of key immune system genes has also been investigated in 
contexts outwith T cell differentiation. For example, the B cell-specific gene Cd19 
shows demethylation of an upstream enhancer in all immune cell progenitors 
regardless of gene expression. At the Cd19 promoter, however, the level of 
methylation inversely correlates with gene expression. Demethylation coincides with 
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gene expression in early B cell stages and is further enhanced during B cell 
differentiation (Walter et al., 2008). The DNA methylation state of 13 immune-
specific genes has been profiled in human naïve and memory CD4 T cells, CD8 T 
cells and B cells as well as in hematopoietic progenitors. Regions of the Spi1, Gata3, 
Tcf-7, Etv5, c-maf and Tbx21 promoters showed methylation differences between 
cell types. At the majority of these genes, methylation differed between naïve and 
memory cells of the same cell type (e.g. naïve and memory CD4 T cells) rather than 
between different cell types such as B and T cells (Ivascu et al., 2007). A study using 
targeted microarrays identified regions differentially methylated between Treg cells 
and conventional CD4 T cells and extended this analysis to include other immune 
cell types including B cells, monocytes, hematopoietic progenitor cells as well as the 
Jurkat T cell line. Most of the reported methylation differences occurred distal to 
gene promoters (Schmidl et al., 2009). 
 
These observations make it appealing to look globally for DNA methylation changes 
between immune system cells, although only a few of the examples described occur 
at CGIs. Two studies have characterised the “methylome” in CD4 T cells but have 
not compared between cell types or investigated methylation with regards to immune 
system function (Hughes et al., 2010; Smith et al., 2009). Studies in T cells 
describing DNA methylation and histone modifications such as H3K4me3, which is 
intimately associated with CGIs, do not differentiate between CGI and non-CGI 
promoters (Barski et al., 2009; Hughes et al., 2010; Smith et al., 2009). This may 
complicate some of the correlations between epigenetic modification and gene 
expression observed. Therefore it is worthwhile examining the methylation status of 
features with a clear function such as CGIs with respect to their behaviour in 
different immune cell lineages. 
 
1.7 PhD Objectives 
The aim of this PhD is to use an immune system model to assess the role of CGI 
methylation and the role of the methylation reader MBD2 in the regulation of gene 
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expression. CGI methylation will be profiled globally and compared to gene 
expression as well as H3K4me3 distribution in different cells of the hematopoietic 
lineage. After CGI methylation in wild-type cells is assessed, cells lacking MBD2 
will be investigated, as depletion of MBD2 has been shown to give immune system 
phenotypes. Gene expression changes in Mbd2-/- immune cells will be examined and 
related to histone acetylation and DNA methylation. It is hoped this study will 
provide insights into the role of CGI methylation and MBD2 generally as well as 
assessing their importance in immune cells. 
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Chapter 2 Materials and Methods 
The main reagents and experimental methods used will be outlined in this chapter. 
Some standard molecular biology reagents and protocols will not be described and 
details of these can be found in standard text books such as “Molecular Cloning: A 
laboratory manual” (Sambrook and Russell, 2001). All experiments were carried out 
at room temperature (R/T) unless otherwise stated. 
 
2.1 Experimental methods 
 
2.1.1 Immune cell purification and FACS staining 
 
Immune cell isolation and purification 
Immune cells were isolated from the spleens of C57/BL6 mice unless otherwise 
stated. Spleens were physically disrupted and cells were passed through a cell 
strainer (70µm; BD Falcon) into Hanks media and pelleted by centrifugation at 300g 
for 4min at 4°C. For isolation of splenic dendritic cells, spleens were chopped into 
small pieces and incubated in Hanks supplemented with DNase at 37°C for 15min 
with agitation prior to disruption in order to facilitate recovery. Red blood cells were 
lysed using Red Blood Cell Lysing Buffer (Sigma) according to manufacturers’ 
instructions. Splenocytes were then counted using a haemocytometer combined with 
trypan blue staining to check cell viability and the cells purified using magnetic cell 
sorting (MACS, Miltenyi Biotec) or fluorescence activated cell sorting (FACS). 
 
CD4 T cells were purified using the MACS system (Miltenyi Biotec). Hanks media 
was used as a buffer throughout. For all MACS purifications, buffers and reagents 
were kept at 4°C. Splenocytes were diluted in the appropriate volume of buffer (90µl 
beads per 107 cells) and incubated with magnetic CD4 microbeads (10µl beads per 
107 cells) at 4°C for 15min. Cells were then washed and CD4+ cells selected using 
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LS cell separation columns (Miltenyi Biotec) according to manufacturers’ in 
instructions. To isolate naïve CD4 T cells, CD4+ cells recovered by MACS were 
stained for the cell surface markers CD44 and CD62L. Naïve cells expressing low 
levels of CD44 and high levels of CD62L (Swain et al., 1991) were sorted by FACS. 
Dendritic cells were also isolated using the MACS system and MACS buffer was 
used for all purification steps. First, plasmacytoid dendritic cells which are lymphoid 
in origin were depleted using α-PDCA microbeads (400µl buffer and 100µl beads per 
108 cells) and LD columns according to manufacturers’ instructions. Then dendritic 
cells were blocked for 5min with 10µg/ml α-FcR, selected using CD11c microbeads 
(400µl buffer and 100µl beads per 108 cells) and purified by two passes over an LS 
column. Selection of CD11c+ cells and depletion of PDCA+ cells was confirmed by 
FACS analysis. To isolate B cells, splenocytes were stained for the B cell marker 
CD19 and cells positive for this marker were sorted by FACS. 
 
T cell differentiation 
T cell differentiation was carried out using CD4+ cells purified by MACS as 
described above. For Th1 and Th2 differentiation α-CD3 and α-CD28 (1.6µg of 
each/well in 250µl PBS) were bound to 24-well tissue-culture plates for 1-2 hours 
prior to plating cells and any excess removed by washing each well three times with 
PBS. Cells were seeded in “T cell media” at a density of 1.5x106 cells/well (Mbd2-/- 
cells were seeded at 2x106 cells/well to compensate for a reduced rate of 
proliferation) along with recombinant murine IL-2 (20ng/ml; Peprotech) and 
cytokines and antibodies to skew towards Th1 [IL-12 (5ng/ml; R&D) and α-IL-4 
(5µg/ml; BD Pharmingen)] or Th2 [IL-4 (10ng/ml; Peprotech) and α-IL-12 (5µg/ml; 
BioLegend)] cell fate in a final volume of 1ml. Cells were cultured at 37°C, 5% CO2  
and split approximately every two days replenishing cytokines and antibodies but 
without re-stimulating with α-CD3/α-CD28. Th1 and Th2 cells were cultured for 7 
days and then stimulated with PMA at 50ng/ml and ionomycin at 500ng/ml for 4 
hours prior to further analysis. For cells that were to be analysed by intracellular 
FACS staining a 1:2000 dilution of GolgiStop (BD Pharmingen) was added 2 hours 
prior to harvesting to help retain cytokines in the cell. 
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For in vitro generation of Treg cells culture conditions were similar to those 
described for Th1 and Th2 cells except that cells were cultured in 96-well plates and 
volumes scaled down accordingly. Cells were treated with plate-bound α-CD3 and α-
CD28 (0.4µg/ml) along with IL-2 (20ng/ml) and varying concentrations of 
recombinant human TGF-β1 (0.01-10ng/ml; gift from R. Maziels lab). Tregs were 
differentiated for 72 hours and then stained for Foxp3 expression. 
 
For proliferation studies 3H-thymidine was added to cultures (0.5miC/well) 24 hours 
after seeding and incorporation analysed after an additional 24 hours by scintillation 
counting. Alternatively, cells were labelled with CFSE (final concentration 5µM) 
prior to seeding, then stimulated as normal. After 72 hours the CFSE signal was 
visualised by FACS.  
 
Note: Treg generation and proliferation experiments were carried out as part of a 
collaboration with John Grainger. 
 
Isolation of T cells from schistosome-infected mice 
Six spleens were harvested from mice that had been infected with Schistosoma 
mansoni for 8 weeks (infection carried out by P. Cook and L. Jones). Splenocytes 
were isolated as described above and CD4 cells purified by MACS. Cells were plated 
in “Ex vivo media” at a density of 4x106 cells per well in a 24-well plate. The CD4 
cells were stimulated for 4 hours with 10ng/ml PMA and 1µg/ml ionomycin at 37°C, 
5% CO2 and 2 hours prior to harvest 1:1000 GolgiStop was added. Cells were stained 
for IL-4 and IFN-γ production and IL-4+ and IL-4+ IFN-γ+ cell populations were 
FACS sorted. 
 
FACS staining and sorting 
All FACS procedures were carried out at 4°C. FACS staining for cell surface 
markers (i.e. CD4, CD44, CD62L, CD11c, PDCA, CD19) was carried out as follows. 
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Cells were washed once in FACS buffer and then stained with the appropriate 
fluorescent antibodies diluted in FACS buffer for 20min protected from light 
(fluorophores and antibody concentrations are given in Table 2.2.6). Cells were then 
washed three times in FACS buffer to remove excess antibody and resuspended in an 
appropriate volume of buffer for FACS analysis or sorting.  
 
Intracellular staining (i.e. for IFN-γ and IL-4) was carried out as follows. Cells were 
washed in PBS and fixed in 4% paraformaldehyde for 15min. Cells were then 
washed three times in Perm buffer and stained for cytokine production using 
fluorescent antibodies diluted in Perm buffer (see Table 2.2.6). Staining was carried 
out for 30min protected from light. After staining, cells were washed twice in Perm 
buffer and resuspended in PBS for FACS analysis or sorting. Foxp3 staining was 
carried out in a similar manner except that a commercial fixation and 
permeabilisation kit was used (Foxp3 Fixation/Permeabilization Buffer; 
eBioscience).  
 
Unstained and single colour controls were prepared for each FACS experiment. 
FACS analysis was carried out using a BD FACS Canto machine and FACS sorting 
was carried out with the help of Martin Waterfall using a BD FACS Aria. 
 
2.1.2 DNA manipulation 
 
Genomic DNA extraction 
To extract genomic DNA from immune cells, cells were washed in PBS then 
resuspended in an appropriate volume of genomic DNA extraction buffer (500µl per 
3x106 cells) supplemented with proteinase K (40µg/ml) and incubated at 55°C 
overnight. RNase A (20µg/ml) was then added and the solution was incubated for a 
further 1 hour at 37°C. DNA was extracted by adding an equal volume of 
phenol:choloroform:isoamylalcohol (25:24:1, Sigma), vortexing and centrifuging for 
15min at 12000g. The aqueous phase was recovered and DNA precipitated by 
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addition of an equal volume of isopropanol. The DNA pellet was washed in 70% 
ethanol, dried and resuspended in an appropriate volume of dH2O. DNA 
concentration was determined by measuring the absorbance of the solution at 260nm 
(OD260nm) using a Nanodrop-1000 spectrophotometer. DNA concentration was 
automatically calculated according to Beer’s law (concentration = OD260nm x molar 
absorptivity constant/path length) whereby an OD260nm value of one indicates a DNA 
concentration of 50ng/µl. 
 
Polymerase Chain reaction (PCR) 
PCR was used to amplify DNA molecules of interest from a starting template and 
was used primarily to test primers for qPCR, verify enrichment of methylated 
sequences in MAP fractions and in bisulfite genomic sequencing. Reactions were 
generally carried out in a 20µl volume and consisted of DNA template (0.1-50ng), 
400nM forward and reverse primers, 400µM dNTPs (Abgene), 2.5mM MgCl2, Red 
Hot Taq reaction buffer (Abgene) and 1.5U Red Hot Taq (Abgene). PCR 
amplification of bisulfite-treated DNA was carried out in the presence of 3% 
dimethyl sulfoxide (DMSO). PCR reactions were set up on ice. PCR cycling was 
carried out on a G-Storm thermal cycler and typical conditions were as follows: 
initial denaturation at 94°C for 2min followed by 30 cycles of denaturation at 94°C 
for 30sec, primer annealing at Tanneal for 30sec and primer extension at 72°C for 
30sec. An additional 72°C primer extension phase for 5min was carried out at the 
end of the 30 cycles to amplify any incomplete DNA molecules. In general, to 
determine the optimal annealing temperature (Tanneal) for a particular primer pair a 
range of temperatures was tested (using the gradient feature of the thermal cycler 
over a range of 53-64°C). PCR amplification of bisulfite-treated DNA was carried 
out for 40 cycles with longer step times: 94°C for 40sec, Tanneal for 50sec and 72°C 






Quantitative PCR (qPCR) 
Quantitative PCR (qPCR) was used to accurately quantify a target region in a DNA 
sample of interest and was used to assess enrichment of specific regions in ChIP 
samples and to measure relative expression of genes by qRT-PCR (see 2.1.3). To 
carry out qPCR I used SYBR Green technology. SYBR Green I is a fluorescent dye 
that binds to DNA and, when included in a PCR reaction, allows fluorescence to be 
used as a read-out for the amount of DNA synthesised in real-time. qPCR reactions 
(25µl) contained SYBR Green SensiMix (Quantace), 250nM primers and 0.1-10ng 
template DNA. PCR was carried out using a Roche Lightcycler and cycling 
conditions were as follows; initial denaturation at 94°C for 10min followed by 45 
cycles of denaturation at 94°C for 10sec, primer annealing at Tanneal for 10sec and 
primer extension at 72°C for 15sec. Data were collected at the end of each 
amplification cycle. After amplification, melting curves for PCR products were 
generated by denaturing the DNA at 94°C for 1min and then increasing the 
temperature from 35°C to 95°C in increments of 0.1°C. A single melt curve indicates 
the presence of a single PCR product whilst multiple melt curves could indicate the 
presence of multiple PCR products or primer dimers that would interfere with DNA 
quantification.  
 
Using the Roche Lightcycler software, SYBR Green fluorescence measurements 
were plotted relative to cycle number to generate curves for each PCR reaction and 
the 2nd derivative maximum method was used to determine the cycle threshold values 
(Ct) for each sample. An arbitrary measure of DNA quantity was calculated using the 
formula 2-Ct. This value was then compared to that of a reference sample (for 
example input DNA in a ChIP reaction or expression of a reference gene in qRT-
PCR). qPCR reactions were carried out in duplicate or triplicate and the standard 






DNA gel electrophoresis 
DNA was resolved by gel electrophoresis using the Bio-Rad Sub-Gel system. 
Agarose gels (1-2%; depending on the size of the DNA fragment to be resolved) 
were prepared with TAE containing 0.5µg/ml ethidium bromide, a DNA intercalating 
agent that fluoresces in ultraviolet (UV) light. DNA samples and appropriate size 
markers (100bp or 1kb ladder; NEB) prepared in orange G loading buffer were 
loaded into the wells of the gel. Gels were run at constant voltage (80-110V) in TAE 
electrophoresis buffer and visualised under UV light.  
 
Bisulfite genomic sequencing 
Genomic DNA was sonicated using a Diagenode Bioruptor for 10sec on high power 
in order to break up DNA and facilitate bisulfite treatment. 2µg of this DNA (25µl 
volume) was used in each bisulfite reaction. DNA was denatured by adding 2.5µl of 
freshly prepared 3M NaOH and incubating at 37°C for 20mins. 270µl of bisulfite 
solution was added to the DNA and the reaction was overlaid with 200µl of mineral 
oil to prevent evaporation. The bisulfite reaction was incubated at 55°C for 5 hours 
protected from light. DNA was then isopropanol precipitated (including 50µg 
glycogen carrier; Roche) and resuspended in 25µl TE buffer. DNA was desulfonated 
by the addition of 2.5µl 3M NaOH and incubation at 37°C for 15min. The DNA was 
then precipitated with three volumes of 100% ethanol and 1/10 volume 5M 
ammonium acetate pH 7, washed in 70% ethanol and resuspended in 50µl of TE.  
Typically 0.5µl of this DNA was used in a PCR reaction containing primers specific 
for bisulfite modified DNA and other reaction components as detailed above. PCR 
products were resolved by agarose gel electrophoresis and gel extracted as follows. 
The product of interest was excised from the gel, placed at -80°C and subject to a 
number of freeze-thaw cycles. After this the gel fragment was centrifuged for 15min 
at 12000g to liberate DNA in solution from the gel. 
 
Bisulfite PCR products were then cloned using the StrataClone PCR Cloning Kit 
(Stratagene) and transformed into StrataClone Solo Pack Competent Cells 
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(Stratagene) according to manufacturers’ instructions. Transformed cells were spread 
onto ampicillin LB agar plates containing X-gal for blue/white selection. Colonies 
positive for inserts appeared white in colour due to disruption of the β-galactosidase 
gene by the cloned insert. These colonies were selected and the cloned insert 
amplified by PCR using the T7 and M13 reverse primers designed against the 
cloning vector backbone. A proportion (5µl) of each PCR reaction was analysed by 
gel electrophoresis to verify that cloned inserts were of the correct size. To prepare 
PCR products for sequencing, exonuclease I (5U; NEB) and Antarctic phosphatase 
(5U; NEB) were added to the remaining 15µl along with 11.75µl of dH2O. The 
reaction was incubated at 37°C for 15min followed by heat inactivation of the 
enzymes. This step degrades single-stranded primers and removes the phosphate 
groups from dNTPs thus preventing residual PCR components from interfering with 
the sequencing reaction. DNA sequencing of these PCR products was carried out as 
outlined below using the T7 primer. Bisulfite sequencing results were analysed using 
the BiQ Analyzer software package (Bock et al., 2005). 
 
DNA sequencing 
DNA sequencing was performed using the BigDye Terminator v3.1 Cycle 
Sequencing kit (Applied Biosystems). Sequencing reactions were carried out in a 
volume of 10µl and contained 4µl of 2.5x sequencing buffer, 2µl BigDye Terminator, 
500nM primer and 3.5µl DNA (prepared for sequencing as above). Reaction 
conditions consisted of initial DNA denaturation at 94°C for 10sec followed by 24 
cycles of DNA denaturation at 94°C for 30sec, primer annealing at 50°C for 20sec 
and extension at 60°C for 4min. Sequencing reactions were then passed onto the 
Gene Pool Sequencing Service (School of Biological Sciences) where they were 
cleaned up and run on an ABI 3730 capillary sequencer. 
 
Preparation of DNA for MAP-seq and ChIP-seq 
Prior to purification by MAP, genomic DNA was sonicated to an average size of 
500bp using a Diagenode Bioruptor on medium setting for approximately 2 minutes. 
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Fragmentation was verified by gel electrophoresis and Illumina sequencing adaptors 
were attached to the DNA as follows. To repair DNA ends after sonication DNA 
(25µg) was incubated with 400µM dNTPs, T4 DNA Polymerase (30U; NEB), DNA 
Polymerase I Large (Klenow) fragment (17U; NEB), T4 polynucleotide kinase (10U; 
NEB) and T4 DNA ligase buffer (NEB) in a volume of 150µl for 30min at 20°C. 
Enzymes were heat-inactivated, DNA ethanol precipitated (using 50µg glycogen as a 
carrier) and resuspended in 85µl dH2O. A tail of ‘A’ bases was added to the end of 
repaired fragments to facilitate attachment of adaptors. This was carried out by 
incubating DNA with 200µM dATP and Klenow 3’ to 5’ exo- fragment (30U; NEB) 
in the presence of NEB buffer 2 for 30min at 37°C. DNA was ethanol precipitated 
and resuspended in 32µl dH2O. Illumina paired end adaptors were annealed to each 
other in a reaction containing 28µl of each adaptor (100µM stock), 7µl 10x Red Hot 
Taq buffer and 7µl dH2O. The reaction was incubated at 94°C for 2min and the 
temperature was then decreased from 94°C to 20°C over a period of 25min to allow 
the adaptors to anneal. These adaptors were ligated to DNA in a 200µl reaction 
containing; 32µl DNA, 70µl annealed adaptors, 50µl PEG 6000 (final concentration 
7.5%), T4 DNA ligase (300U) and T4 DNA ligase buffer (NEB). The reaction was 
incubated for 15min at 20°C, enzymes heat-inactivated and reactions stored at -20°C 
until required for MAP. 
 
For ChIP-seq experiments adaptors were attached to the small quantities of DNA 
recovered after ChIP. Reactions were carried out in a similar manner to the protocol 
described above except that enzyme concentrations and reaction volumes were 
adjusted as follows to account for the small amount of DNA present. End repair: 
14.8µl ChIP DNA (10-20ng), 400µM dNTPs, T4 DNA Polymerase (3U; NEB), 
Klenow (2U; NEB), T4 polynucleotide kinase (1U; NEB) and T4 DNA ligase buffer 
(NEB) in a volume of 20µl. Addition of ‘A’ bases: 200µM dATP, Klenow 3’ to 5’ 
exo- fragment (5U; NEB) and NEB buffer 2 in a final volume of 20µl. Ligation: 
0.5µl of annealed adaptors (1:10 dilution), 5µl PEG 6000, T4 DNA ligase (30U) and 
T4 DNA ligase buffer (NEB) in a volume of 20µl. The ligation reaction was carried 
out for 2 hours at R/T with gentle agitation. Reactions were cleaned up after adaptor 
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ligation using the Qiagen MinElute kit and DNA eluted in 10µl dH2O. All reactions 
were carried out in siliconised PCR tubes or low-bind tubes (Eppendorf).  
 
2.1.3 RNA manipulation 
 
RNA extraction  
RNA was extracted using TRI Reagent (Sigma) according to manufacturer’s 
instructions. Cell pellets were resuspended in 1ml TRI Reagent (for 1-6 x 106 cells) 
and incubated for 5min to disrupt nucleoprotein complexes. Chloroform (200µl) was 
added and the solution was mixed vigorously and incubated for 10min. The mixture 
was centrifuged for 15min at 12,000g at 4°C and the aqueous phase containing the 
RNA recovered. RNA was precipitated using isopropanol, pelleted by centrifugation 
for 10min at 12,000g at 4°C, washed with 70% ethanol and resuspended in 25-50µl 
of nuclease free water (Ambion). To extract RNA from oesophagus tissue was 
harvested and immediately snap frozen in liquid nitrogen. Tissue was then 
homogenised in TRI Reagent using a Polytron homogeniser and extraction carried 
out as detailed above. RNA concentration was determined using a Nanodrop-1000 
spectrophotometer. An OD260nm value of one indicated an RNA concentration of 
40ng/µl. 
 
RNA gel electrophoresis 
Integrity of the recovered RNA was determined by agarose gel electrophoresis. 
Electrophoresis was carried out as for DNA except that TBE buffer was used instead 
of TAE and was made using DEPC-treated dH2O. RNA loading buffer (NEB) was 
added to samples which were then denatured at 65°C for 5min and snap chilled on 
ice. Samples and marker (RNA ladder; NEB) were loaded onto the gel which was 





DNase treatment of RNA 
For cDNA synthesis and NimbleGen microarrays RNA was DNase treated prior to 
use in order to remove contaminating genomic DNA. This was carried out using the 
DNA-free kit (Ambion). Briefly, up to 2µg RNA was treated in a 50µl volume 
containing 4U DNase I and DNase I reaction buffer for 30min at 37°C. DNase was 
then inactivated by treating with DNase inactivation reagent according to 
manufacturers’ instructions. 
 
cDNA synthesis (reverse transcription) 
Prior to reverse transcription (RT) RNA was denatured at 65°C for 5min and snap 
chilled on ice. RNA (250ng) was added to a 25µl reaction containing M-MLV 
reaction buffer (Promega), 5µM random hexamers (Roche), 1mM dNTPs, 40U 
RNasin (RNase inhibitor; Promega) and 200U of M-MLV reverse transcriptase 
(RNase H minus; Promega). A minus (-)RT reaction was set up in parallel containing 
all the reaction components except for the reverse transcriptase to control for 
contaminating DNA. cDNA was synthesised by carrying out 4 cycles of 20°C for 
8min, 25°C for 8min and 37°C for 30min followed by heat inactivation of the 
enzyme at 70°C for 15min.  
 
Quantitative Reverse Transcription-PCR (qRT-PCR) 
qRT-PCR was used to determine the expression levels of particular genes. cDNA (1-
2µl, synthesised as outlined above) from a sample of interest was added to each qRT-
PCR reaction and additional reactions were carried out with the (-) RT controls. 
qRT-PCR was carried out using Quantace Sensimix as described above and gene 
expression was expressed relative to that of a control gene (usually Eef1A1). Three 





2.1.4 Protein extraction, Western blotting and chromatin 
immunoprecipitation 
 
Protein extraction  
To prepare protein extracts for SDS-PAGE and Western blot, cells were harvested, 
washed in PBS and counted. They were then resuspended in Laemmli buffer (100µl 
per 1x106 cells) and stored at -20°C until needed. Immediately prior to use, SDS-
loading buffer was added, the samples boiled for 10min and snap chilled on ice.  
 
SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was used to separate proteins based on size and was employed for 
analysis of purified recombinant protein and Western blotting. The Mini-PROTEAN 
3 system (Bio-Rad) was utilized for SDS-PAGE. Stacking gels contained 5% 
acrylamide and resolving gels contained 8 to 15% acrylamide depending on the 
molecular weight of the proteins of interest. Protein samples (prepared as above) 
were loaded into the wells of the stacking gel alongside pre-stained protein ladder 
(Fermentas). Electrophoresis was carried out at 110V in Tris-glycine buffer. 
 
Coomassie staining 
To visualise proteins on an SDS-PAGE gel, gels were stained with Coomassie Blue 
solution for 20min with agitation. Gels were de-stained in dH2O by boiling for 3min. 
The dH2O was then replaced and the procedure repeated twice more until the last 
traces of dye had been removed. Gels were scanned and dried between two sheets of 
cellulose film (Bio-Rad). 
 
Western Blotting 
For Western blot analysis protein from SDS-PAGE gels was transferred to 
nitrocellulose membrane (Protran, Schleier & Schull) or PVDF membrane (Bio-
Rad). PVDF membrane was used for analysis of histone proteins due to its smaller 
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pore size while nitrocellulose was used when blotting for MBD2. PVDF membrane 
was pre-activated prior to use by soaking in 100% methanol. Semi-dry transfer was 
carried out in transfer buffer for 60min at 250mA using the Trans-Blot SD system 
(Bio-Rad). Membranes were then Ponceau stained to verify that protein had been 
transferred, de-stained in dH2O and blocked in 5% milk solution for 2 hours. Primary 
antibody diluted in 1% milk was then added (for antibody information see Table 
2.2.7) and the membrane incubated overnight at 4°C with agitation. The membrane 
was washed in TBS-T three times for 10min before addition of peroxidise-
conjugated secondary antibody. Incubation with secondary antibody was carried out 
for one hour at R/T, the membrane washed in TBS-T as before and ECL solution 
added for 2min. Signal was then captured by exposing the membrane to X-ray film. 
Western blots were quantified using Scion Image software. 
 
2.1.5 Chromatin immunoprecipitation (ChIP) and cross-linked IP 
Cells were harvested, washed and cross-linked in 1% formaldehyde for 10min at 
R/T. Cross-linking was stopped by adding 125mM glycine. The cells were then 
pelleted by centrifugation at 300g for 4min at 4°C and washed in cold PBS 
containing protease inhibitors. 4-6x106 cells were used per ChIP reaction (4x106 for 
histone modifications and 6x106 for MBD2). Cells were resuspended in 150µl lysis 
buffer per reaction and incubated on ice for 10min. Lysates were sonicated to give an 
average DNA fragment size of 250bp using a Bransen digital sonifier (25% power 
for 3min – 2.5sec, 5sec off) and then centrifuged at 12,000g for 10min at 4°C. The 
sonicated lysates were diluted 1:10 in IP-dilution buffer and chromatin pre-cleared 
by incubating with protein A (rabbit antibodies) or protein G (sheep antibodies) 
sepharose beads (200µl slurry for up to five reactions) for 2 hours at 4°C. Chromatin 
was then filtered using a 0.8µm syringe filter. An input sample (5%) was retained 
and 1300µl of pre-cleared chromatin was used per ChIP reaction. The appropriate 
antibody was added to each sample (see Table 2.2.7) and incubated overnight at 4°C 
with rotation. Protein A or protein G beads (100µl slurry) were then added for 2 
hours at 4°C to capture antibody-protein complexes. Beads were washed as follows: 
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1x TSE I, 4x TSE II, 1x LiCl buffer, 3x TE. Washes were carried out for 4min at R/T 
with rotation and all buffers were kept at 4°C.  
 
For cross-linked IP, protein was recovered by boiling beads in SDS-loading buffer 
for 10min and then analysed by Western blot.  
 
To recover DNA, ChIP extraction buffer (200µl) was added to the beads and 
incubated at 55°C for 15min followed by 15min on a shaking platform at R/T. Beads 
were removed by passing the mixture through a QIA-Shredder column (Qiagen). 
Cross-links were reversed by treating input and ChIP samples with 300mM NaCl 
overnight at 65°C. DNA was purified by proteinase K and RNase A treatment at 
37°C for 1 hour, phenol:chloroform extraction and ethanol precipitation. Typically 
DNA was resuspended in 100µl (histone modification ChIP) or 50µl (MBD2 ChIP) 
0.1x TE and analysed using qPCR (2µl of DNA per reaction). For ChIP-seq and 
ChIP-chip analysis DNA was resuspended in 25µl dH2O. 
 
FLAG ChIP and cross-linked IP were carried out as described above except that pre-
cleared chromatin extracts were incubated with α-FLAG M2 agarose beads (20µl of 
a 50% slurry; Sigma) for 2 hours at 4°C and then washed as usual. 
 
2.1.6 Recombinant protein production  
 
Plasmid constructs 
The pet30b-MBD construct was a gift from R. Illingworth and codes for the MBD of 
human MeCP2 (amino acids 77-167) tagged with 6x histidine residues. 
 
The pGex-MBD2 construct was a gift from H.H. Ng and codes for glutathione-S-
transferase (GST)-tagged human MBD2 (amino acids 1-151). 
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Bacterial expression of recombinant proteins 
The BL21 E. coli strain was used for over-expression of target genes under the 
control of a T7 promoter regulated by the lacO system. BL21 cells and cloning 
vectors encode the lac repressor protein which prevents gene expression. Addition of 
IPTG to the culture media prevents binding of the lac repressor and allows 
expression of recombinant protein.  
 
An overnight culture of BL21 cells transformed with the desired construct was 
diluted 1:100 into LB media and the appropriate antibiotics. The culture was 
incubated at 37°C until reaching an OD600nm
 of 0.45-0.6. 1mM IPTG was added to 
the media to induce recombinant protein expression and cultures were incubated for 
a further 2-3 hours. 
 
Preparation of bacterial whole cell lysate 
Bacterial cells were centrifuged at 4200rpm for 30min at 4°C and washed with cold 
PBS. The bacterial pellets were resuspended in cold bacterial lysis buffer containing 
1mg/ml lysozyme and incubated on ice for 30min. The lysates were sonicated 
(Branson sonifier 250) at a duty cycle of 30% and an output setting of 5 for 5min on 
ice. Lysates were then centrifuged at 17,000g for 40min at 4°C and the supernatant 
retained. 
 
Nickel purification of MBD protein for MAP experiments 
All stages of this protocol were carried out at 4°C unless otherwise stated. Nickel 
sepharose beads (made in-house) were washed with two volumes of N10 buffer and 
added to the bacterial lysate (0.5ml of beads per litre of initial bacterial culture). The 
mixture was incubated for 2 hours and then pelleted at 500g for 5min. Beads were 
washed twice with 10 bed volumes of N20 buffer and then transferred to a disposable 
chromatography column (GE Healthcare) and washed once more. His-tagged protein 
was eluted from the column with imidazole as follows. One bed volume of N250 
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buffer was added to the beads, equilibrated for 10min and then allowed to flow from 
the column. This process was repeated five times and fractions containing 
appreciable quantities of purified protein were pooled and dialyzed overnight in N20 
buffer to remove imidazole.         
 
Note: MBD protein production was primarily carried out by U. Gruenewald-
Schneider.  
 
Glutathione purification of MBD2-GST for antibody affinity purification 
Purification of GST-tagged MBD2 protein was carried out in a similar manner to the 
nickel purification outlined above except that glutathione-sepharose beads (GE 
Healthcare) were used for purification. Equilibration and washing steps were carried 
out using GST purification buffer and elution was carried out with GST elution 
buffer containing reduced glutathione. Purified protein was dialysed into GST 
dialysis buffer overnight prior to use for antibody affinity purification. 
 
2.1.7 Antibody purification 
 
All solutions were kept at 4°C and all procedures were carried out at 4°C. 
 
Affinity purification 
As MBD2 has a high isoelectric point (pI ~ 10) Affi-Gel 10 (Bio-Rad) was selected 
as a matrix to which to bind recombinant MBD2. Affi-Gel (600µl) was washed in 
coupling buffer three times. GST-MBD2 (amino acids 1-151) was then added to give 
a 1:1 slurry with the Affi-Gel beads and a final protein concentration of 1.3mg/ml. 
Protein was coupled to Affi-Gel for 1 hour at 4°C and the coupling reaction was 
stopped by adding 50mM ethanolamine pH 7.5. MBD2-coupled beads were then 
washed with five bed volumes of the following solutions: 0.1M NaHCO3, 1M 
NaHCO3, dH2O, 0.2M glycine, 150mM NaCl and TBS. S923 serum (2ml) was then 
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diluted 1:1 in TBS+0.01% azide and bound to the beads for 2 hours at 4°C with 
rotation. Beads were washed as follows: 1x TBS, 2x column wash buffer, 4x TBS 
and then loaded onto a disposable chromatography column (GE Healthcare). 
Antibody was eluted using low pH buffer and immediately neutralised in 1/10 
volume 1M Tris-HCl pH 8. Antibody was dialysed against TBS+0.01% azide and 
antibody concentration assessed by carrying out SDS-PAGE alongside BSA 
standards of known protein concentration. Glycerol (50%) was added and the 
antibody stored at -20°C in aliquots. 
 
Protein G purification 
Protein G sepharose beads were washed twice in 100mM Tris-HCl pH 8. The pH of 
the S923 serum was adjusted by adding 1/10 volume of 1M Tris-HCl pH 8. Serum 
(2ml), protein G sepharose (2ml) and 100mM Tris-HCl pH 8 (36ml) were mixed and 
incubated at 4°C for 2 hours with rotation. The beads were then washed three times 
with 10 bed volumes of binding buffer, loaded onto a disposable chromatography 
column and washed three more times with 100mM Tris-HCl pH 8 and then three 
times with 10mM Tris-HCl. Antibody was eluted with 1M glycine pH 2.7 and 
neutralized with 1/10 volume 1M Tris-HCl pH 8. Antibody was dialysed against 
TBS+ 0.01% azide, 50% glycerol added and the antibody was stored at -20°C in 
aliquots. 
 
2.1.8 MAP chromatography 
 
Preparation of MBD chromatography columns 
MBD columns were prepared in batches in order to minimize variation between 
different columns. Recombinant MBD protein was bound to nickel charged 
sepharose (50mg of protein per 0.5ml beads) in N20 buffer at 4°C for 2 hours. The 
beads were washed with 10 bed volumes of wash buffer 1, 10 bed volumes of wash 
buffer 2 and then 10 bed volumes of wash buffer 1 again. The beads were packed 
onto a 0.5ml chromatography column (Tricorn 5/20; GE Healthcare) at a constant 
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1ml/min linear flow rate. Once assembled, the chromatography column was 
equilibrated with a 200ml linear salt gradient (0.1-1M NaCl; gradient formed 
between column buffers A and B) at a 1ml/min flow rate on an AKTA purifier (GE 
Healthcare). This equilibration served to pack the beads and remove any bacterial 
DNA from the matrix.     
 
MAP Chromatography 
Chromatography steps were carried out on an AKTA purifier (GE Healthcare) at a 
linear flow rate of 1ml/min and a maximum back pressure of 0.3MPa. Column 
buffers A and B were mixed to get appropriate salt concentrations. Fragmented DNA 
(25µg) was bound to the column in 10ml 0.1M NaCl (90% buffer A and 10% buffer 
B). The salt concentration was then increased to 0.75M NaCl and non-specifically 
bound DNA eluted. The column was washed (18 column volumes) with 0.75M NaCl 
before increasing the salt concentration to 1M NaCl and eluting specifically bound 
DNA. 3ml fractions were collected and 300µl of each fraction was ethanol 
precipitated, resuspended in 40µl TE buffer and used for PCR analysis (2µl per PCR; 
for primer sequences see Table 2.2.1). Fractions containing methylated CGIs (i.e. 
those eluted between 0.75M-1M NaCl) were pooled, concentrated using a Amicon 
Ultra-15 centrifugal filter unit (30kDa cut off; Millipore) and subject to a second 
round of purification. After PCR analysis, methylated fractions from the second 
purification were pooled and concentrated. DNA was then precipitated and passed 
onto the Wellcome Trust Sanger Institute for Illumina library production and 
sequencing. Two biological replicates were carried out for each cell type of interest. 
 
CAP chromatography 
CAP-seq was carried out for CD4 cells using a CxxC chromatography column gifted 
by R. Illingworth. This column consists of recombinant CxxC3 domain from MBD1 
bound to a sepharose matrix and was prepared in a similar manner to the MBD 
columns described above. CAP chromatography was carried out in a similar way to 
MAP except that non-specifically bound DNA was eluted at 0.1-0.6M NaCl, the 
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wash was carried out at 0.6M NaCl and specifically bound unmethylated CGIs were 
eluted over 0.6-1M NaCl. Only one round of CAP was necessary to sufficiently 
enrich unmethylated CGIs prior to sequencing. 
 
2.1.9 Illumina library production and sequencing 
Illumina library production and sequencing were carried out by the Wellcome Trust 
Sanger Institute, Hinxton, Cambridge. The project was co-ordinated by K. Auger and 
mapping done by R. Andrews. To produce illumine libraries for sequencing, ligated 
DNA was amplified by 10-12 cycles of PCR with primers complementary to the 
adaptor sequences using Phusion DNA polymerase mastermix (Finnzymes) and the 
DNA was purified using QIAquick PCR Purification columns (Qiagen). The purified 
DNA was attached to an Illumina flow cell for cluster generation. Libraries were 
sequenced on the Illumina Genome Analyzer following the standard protocol to 
generate single-end 37bp reads. Reads were mapped to the mouse genome (mm9 – 
NCBI37; repeat-masked) using Maq software (http://maq.sourceforge.net/) and reads 
with a mapping ≥ 30 were retained. Replicate samples were combined to give two 
lanes of sequencing for each sample of interest. 
 
2.1.10 Bioinformatic analysis (MAP-seq and ChIP-seq) 
Sequencing data were received as .wig files and analysed using custom 
bioinformatics tools developed in conjunction with R. Illingworth and S. Webb. 
Tools were accessed via an in-house version of the Galaxy application (Blankenberg 
et al., 2007; Taylor et al., 2007) which can be found at http://bifx-
core.bio.ed.ac.uk:8080/. Raw sequencing data were normalised to the average read 
number across all samples of a given purification type in order to account for 
variable sequence depth. Peakfinding was then carried out to identify regions of 
prominent enrichment using the following parameters; read height (H), length in bp 
(L) and gap permitted in the length parameter (G). These were adjusted for each 
purification type so that regions of known methylation or histone modification status 
were isolated. Details of parameters used for the various purification types (e.g. 




To identify regions showing differential enrichment for a particular modification, 
peaks for each sample were combined to give a set of regions of interest over which 
a sliding window analysis was performed. For each region the average number of 
hits per base was calculated in 100bp windows with a 20bp slide. Values were then 
compared between samples giving a ratio for each window. If both windows being 
compared contained less than 4 reads this ratio was set to 1 in order to remove 
spurious hits attributed to small fluctuations at low read depth. Differentially 
enriched regions were identified according to parameters listed in the results sections 
but in general were defined as those containing 9 out of 13 contiguous windows with 
a log2 ratio ≥1.7, 1.8 or 2 (depending on the purification) between samples. The X 
and Y chromosomes were excluded from analyses in order to avoid spurious results 
due to fluctuations in the proportion of male and female DNA in samples.  
 
Peaks and differentially modified regions were examined for association with CGIs, 
RefSeq genes, TSSs and other genomic features using standard tools available on 
Galaxy. An association was defined as direct overlap with a particular feature by at 
least 1bp. The CGIs examined were from the mouse CGI set characterised by 
Illingworth and colleagues (2010) and RefSeq annotated genes were used as the gene 
set. Brain methylation data was obtained from MAP-seq carried out on cerebellum 
DNA from wild-type C57/BL6 mice (Skene et al., 2010) and was analysed in parallel 
with the other MAP-seq samples. Brain H3K4me3 data was from Thomson et al. 
(2010) and was analysed in the same manner as the immune cell H3K4me3 samples. 
ES cell Pol II ChIP-seq data was from Illingworth et al. (2010) and CAGE data was 
from a study by Faulkner et al. (2009). Pol II peaks, as defined by Illingworth and 






2.1.11 Microarray procedures and analysis 
 
NimbleGen expression arrays (oesophagus expression) 
Oesophagus RNA samples were DNase treated and then purified and concentrated 
using an RNAeasy column (Qiagen). Total RNA (20µg) was sent to NimbleGen for 
hybridisation to whole genome mouse expression arrays (mm8_60mer_expr). Three 
biological replicates were carried out for each condition of interest (in this case wild-
type and Mbd2-/- oesophagus). Arrays were RMA normalized and the results 
analysed using GeneSpring GX8 (Agilent Technologies). Briefly, genes with 
constitutively low expression were eliminated, genes showing a statistically 
significant change in gene expression (student’s t-test, p≤0.05) retained and genes 
showing at least a two-fold change in expression selected as differentially expressed. 
 
Illumina BeadChip arrays (immune cells) 
RNA (300ng) was amplified and labelled using the TotalPrep RNA Amplification kit 
(Ambion) and passed to the Wellcome Trust Clinical Research Facility, Edinburgh 
for hybridisation to Illumina MouseWG-6 BeadChips. Three biological replicates 
were carried out for each cell type. Bead level data were summarised using Illumina 
BeadStudio and data were normalised using the average normalisation method in 
BeadStudio. This scales each array based on a scaling factor derived from the 
average intensity across all arrays. Subsequent analysis was carried out using 
GeneSpring GX10 (Agilent technologies). Genes with signal below the 50th 
percentile of signal values on a particular array were categorised as “not expressed” 
and this was consistent with the expression values for silent tissue-specific genes and 
the background signal level of the array. In order to identify changes in gene 
expression between cell types, genes with low expression (Flags absent) across all 
cell types were removed and statistical analysis was carried out to find genes that 
were differentially expressed between any of the cell types (one-way ANOVA, 
p≤0.5). Pair-wise comparisons were performed on this gene set and genes changing 




Brain expression data was obtained from BeadChip arrays carried out on whole brain 
from wild-type C57/BL6 mice (J. Guy; unpublished) and were analysed as outlined 
above. 
 




Input DNA and MAP/ChIP DNA were fluorescently labelled prior to microarray 
hybridisation using the BioPrime labelling kit (Invitrogen). 2.5x random primer mix 
was added to DNA samples (100ng input, entire MAP/ChIP sample) and made up to 
a final volume of 130.5µl, denatured at 100°C for 10min and immediately chilled on 
ice. On ice, 15µl of dNTP mix (1 mM dCTP, 2 mM dATP, dTTP and dGTP), 1.5µl 
Cyanine 3 or 5-dCTP (Cy3 for MAP/ChIP and Cy5 for input DNA; GE Healthcare) 
and 3µl of Klenow (120U; Invitrogen) was added to each reaction. These were 
incubated at 37°C for 4 hours protected from light. Labelled DNA was purified using 
the Purelink PCR cleanup kit (Invitrogen) according to manufacturers’ instructions 
and labelled DNA eluted in 100µl elution buffer. Cyanine incorporation was 
calculated using a Nanodrop spectrophotometer and labelled samples were stored 
short-term at -20°C.   
 
Hybridisation and washing 
Labelled DNA and 100µg of mouse Cot-1 DNA (Invitrogen) were ethanol 
precipitated and resuspended in 60µl of hybridisation buffer. Samples were 
denatured at 100°C for 10mins and snap chilled on ice protected from light. A 
prehybridization step was carried out whereby 60µl hybridisation buffer was 
incubated at 70°C for 10mins, applied to the microarray (NimbleGen mouse CpG 
island plus promoter arrays) and incubated in a humidified chamber for 1 hour at 
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37°C. The array was washed once in MWA buffer for 2min, once in MWB buffer for 
2min and rinsed twice in dH2O. The hybridisation mix was incubated for 1 hour at 
37°C and then applied to the microarray. Hybridisation was carried out for 24 hours 
at 37°C in a humidified chamber protected from light. The array was then washed 4x 
2min in 37°C MWA buffer, 3x 2min in 52°C MWB buffer, 2x 2min in R/T MWA 
buffer and twice in dH2O. Hybridised microarrays were then dried and scanned using 




Microarray analysis was carried out by R. Illingworth and J. de las Heras using the 
Limma package in the R statistical environment. Cy3 and Cy5 signals were 
transformed into M values (log2 [Cy5/Cy3]) and quantile normalisation was carried 
out. Male and female samples (MAP) or wild-type and Mbd2-/- samples (ChIP) were 
then compared to find differences. 
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2.2 Materials and reagents 
 
All reagents were stored at R/T unless otherwise stated. 
 
2.2.1 Immune cell purification and FACS staining 
 
Hanks media: Hanks Balanced Salt Solution (Sigma) supplemented with 2% (v/v) 
foetal bovine serum (FBS) and penicillin/streptomycin (P/S; Gibco). Stored at 4°C. 
 
Hanks with DNase: Hanks Balanced Salt Solution (Sigma) supplemented with 
P/S, 1mM MgCl2, 1mM CaCl2 and 8U/ml DNase (Roche). DNase added immediately 
prior to use. 
 
Phosphate buffered saline (PBS 1x): 140mM NaCl, 3mM KCl, 2mM KH2PO4, 
10mM Na2HPO4. 
 
T cell media: Iscove’s media (Sigma), 10% (v/v) FBS, 1x glutamine (Gibco), 1x β-
mercaptoethanol (Gibco). 
 
Ex vivo media: X-Vivo 15 medium (Lonza, BioWhittaker), 1x glutamine (Gibco), 
1x β-mercaptoethanol (Gibco). 
 
PMA (phorbol 12-myristate 13-acetate) stock solution: PMA was diluted to 
1mg/ml in ethanol and then diluted to a working stock of 100µg/ml in T cell media. 




Ionomycin stock solution: Ionomycin was diluted to 1mg/ml in ethanol. Stored 
at -20°C.  
 
CFSE stock solution: 5mM 5-carboxyfluorescein diacetate succinimidyl ester 
(CFSE; Molecular Probes) in DMSO at a final concentration of 5mM. Stored at -
20°C. 
 
FACS buffer: PBS, 0.5% (v/v) FBS. Stored at 4°C. 
 
4% paraformaldehyde: 4% (w/v) paraformaldehyde in PBS, pH adjusted to 7.3. 
Stored at -20°C. 
 
Permeabilisation buffer: 0.1% (w/v) saponin (Fluka) and 1% (v/v) FBS in PBS, 
pH adjusted to 7.0. Stored at 4°C. 
 
2.2.2 DNA manipulation 
 
Genomic DNA extraction buffer: 10mM Tris-HCl pH 8.0, 400mM NaCl, 3mM 
EDTA pH 8.0, 1% (w/v) SDS. 
 
Proteinase K stock solution: 20mg/ml proteinase K, 100mM EDTA pH 7.5, 2% 
(w/v) SDS. Stored at −20°C.  
 
RNase A stock solution: 10mg/ml RNase A in dH2O. Stored at −20°C. 
 




Orange G loading buffer (6×): 0.2% (w/v) orange G, 12% (w/v) Ficoll, 120mM 
EDTA pH 8.0, 4.2% (w/v) SDS. Stored at −20°C (long-term) or 4°C (short-term). 
 
Bisulfite solution: 3.8g sodium bisulfite (NaHSO3) was dissolved in 5ml dH2O 
and 1.5ml 2M NaOH (protected from light). 110mg hydroquinone was dissolved in 
1ml dH2O at 55°C for ten minutes and added to the sodium bisulfite solution. 
Bisulfite solution was prepared immediately prior to use. 
 
TE buffer: 10mM Tris HCl pH 7.5, 1mM EDTA. 
 
DNA Sequencing Buffer (2.5x): 20mM Tris-HCl pH8.0, 5mM MgCl2. 
 
Polyethylene glycol (PEG) 6000: 30% (w/v) PEG 6000 in dH2O. Stored in 
aliquots at -20°C. 
 
2.2.3 RNA manipulation 
 
TBE buffer (1x):  45mM Tris-borate, 1mM EDTA. 
 
DEPC-dH2O: 1ml diethylpyrocarbonate (DEPC) added to 1L dH2O, treated 
overnight and autoclaved to inactivate DEPC. 
 
2.2.4 Protein extraction, Western blotting and chromatin 
immunoprecipitation 
 




SDS-PAGE loading buffer (6x): 300mM Tris-HCl pH 6.8, 12% (w/v) SDS, 20% 
(v/v) glycerol, 0.2% (w/v) bromophenol blue. Stored at −20°C.  
 
SDS-PAGE stacking gel: 5% (w/v) 29:1 acrylamide:bis-acrylamide (Bio-Rad), 
0.1% (w/v) SDS, 129mM Tris-HCl pH 6.8, 0.1% (v/v) TEMED, 0.1% (w/v) 
ammonium persulfate.  
 
SDS-PAGE resolving gel: 8-15% (w/v) 29:1 acrylamide:bis-acrylamide (Bio-
Rad), 0.1% (w/v) SDS, 390mM Tris-HCl pH8.8, 0.08% (v/v) TEMED, 0.1% (w/v) 
ammonium persulfate.  
Tris-glycine electrophoresis buffer: 25mM Tris, 250mM glycine, 0.1% (w/v) 
SDS. 
 
Coomassie Blue staining solution: 50% (v/v) methanol, 10% (v/v) glacial 
acetic acid, 0.1% (w/v) Coomassie Brilliant Blue R-250. Filtered prior to use.  
 
Transfer Buffer: 25mM Tris, 250mM glycine, 20% (v/v) methanol (for 
nitrocellulose membranes only). 
 
TBS-T (1x): 50mM Tris-HCl pH 7.4, 150mM NaCl, 0.1% (v/v) s 20.  
 
Milk solution: 1% or 5% (w/v) dried milk powder (Marvel) in TBS-T. Stored at 
4°C. 
 
ECL: Equal volumes of solution I [2.5mM (w/v) luminol, 396µM ρ-coumaric acid, 
100mM Tris-HCl pH 8.5] and solution II [0.2% (v/v) hydrogen peroxide, 100mM 
Tris-HCl pH 8.5] were mixed immediately prior to use. Solutions were stored at 4°C. 
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2.2.5 ChIP  
 
Protease inhibitors (Protease inhibitors, complete EDTA-free; Roche) were added to 
lysis and IP dilution buffers before use. All ChIP solutions were kept at 4°C. 
 
Lysis buffer: 2% (w/v) SDS, 20mM EDTA, 100mM Tris-HCl pH 8. 
 
IP dilution buffer: 1% (v/v) Triton-X 100, 2mM EDTA, 150mM NaCl, 20mM 
Tris-HCl pH 8. 
 
Protein A/G sepharose: Protein A or G sepharose (GE Healthcare) was washed 
three times in IP dilution buffer and blocked by addition of one-fifth the bed volume 
of tRNA (stock solution 20mg/ml) and BSA (stock solution 10mg/ml). IP dilution 
buffer was added to give a 50% slurry and the mixture incubated for 2 hours at 4°C 
with rotation. Beads were then washed into IP dilution buffer and stored as 50% 
slurry at 4°C until needed. 
 
TSE I: 0.1% (w/v) SDS, 1% (v/v) Triton-X 100, 2mM EDTA, 150mM NaCl, 20mM 
Tris-HCl pH 8. 
 
TSE II: 0.1% (w/v) SDS, 1% (v/v) Triton-X 100, 2mM EDTA, 500mM NaCl, 
20mM Tris-HCl pH 8. 
 
LiCl buffer: 0.25 M LiCl, 1% (v/v) NP-40, 1% deoxycholate (w/v), 1mM EDTA, 
10mM Tris-HCl pH8. 
 
ChIP extraction buffer: 1% (w/v) SDS, 0.1M NaHCO3. 
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2.2.6 Bacterial reagents (for cloning and protein expression) 
 
LB medium: Bacto tryptone (10g/l; Difco), Bacto yeast extract (5g/l Difco), NaCl 
(10g/l), pH adjusted to 7.0 with NaOH. Bacto agar (20g/l; Difco) was added if 
making LB agar. Solutions were autoclaved prior to use. LB agar plates were stored 
inverted at 4°C and LB broth was stored at R/T. 
 
Ampicillin stock solution: 50mg/ml ampicillin in dH2O. Filter sterilised (0.2µm 
filter) and stored at −20°C. Added to LB medium at a final concentration of 50µg/ml.  
 
Kanamycin stock solution: 50mg/ml kanamycin in dH2O. Filter sterilised 
(0.2µm filter) and stored at −20°C. Added to LB medium at a final concentration of 
50µg/ml.  
 
Choramphenicol stock solution: 34mg/ml chloramphenicol in 96% ethanol. 
Stored at −20°C protected from light. Added to LB medium at a final concentration 
of 34µg/ml. 
 
Blue/white selection plates: LB plates containing the appropriate antibiotic were 
spread with 40µl 100mM IPTG and 40µl X-gal (5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside; 40mg/ml) and dried at 37°C. Prepared on day of use. 
 
IPTG stock solution: 1M IPTG (isopropyl-β-D-thiogalactoside) in dH2O. Filter 





2.2.7 Recombinant protein purification 
 
All solutions for recombinant protein purification were kept at 4°C. 
 
N10 buffer: 50mM sodium phosphate buffer pH8.0, 300mM NaCl, 10% (v/v) 
glycerol, 10mM imidazole, 15mM β-mercaptoethanol and 0.5mM PMSF. β-
mercaptoethanol and PMSF were added immediately prior to use.  
 
N20 buffer: As per N10 buffer but with 20mM imidazole.  
 
N250 buffer:  As per N10 buffer but with 250mM imidazole.  
 
GST purification buffer: 500mM KCl, 50mM Hepes pH 8.0, 1mM DTT, 0.1% 
(v/v) Triton X-100. 
 
GST elution buffer: As above with 100mM reduced glutathione, pH adjusted to 
8.0. 
 
GST dialysis buffer: 50mM Hepes pH 7.6, 100mM KCl, 30% (v/v) glycerol. 
 
2.2.8 Antibody purification 
 
All solutions for antibody purification were kept at 4°C. 
 




Column wash buffer: 500mM NaCl, 0.2% (v/v) Triton X-100, 20mM Tris pH 
7.5. 
 
TBS (1x): 50mM Tris-HCl pH 7.4, 150mM NaCl. 
 
Low pH buffer: 2M glycine pH 2, 150mM NaCl. 
 
2.2.9 MAP chromatography 
 
For chromatography all solutions were filtered prior to use (0.2µm filter) and stored 
at 4°C. 
 
Wash buffer 1: 20mM Hepes pH 7.9, 10% (v/v) Glycerol, 0.1% (v/v) Triton X-
100, 100mM NaCl, 0.5mM PMSF and 10mM β-mercaptoethanol. β-mercaptoethanol 
and PMSF were added immediately prior to use.  
 
Wash buffer 2: As for buffer 1 + 10mM imidazole. 
 
Column buffer A: 20mM Hepes pH 7.9, 10% (v/v) Glycerol, 0.1% (v/v) TritonX-
100, 0.5mM PMSF and 10mM β -mercaptoethanol. β-mercaptoethanol and PMSF 
were added immediately prior to use.  
 
Column buffer B: As for buffer A + 1M NaCl.  
 
2.2.10 Microarray Reagents 
 
SSC (20x): 3M NaCl, 0.3M Na citrate, pH adjusted to 7.0. 
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Hybridisation buffer: 2x SSC, 50% (v/v) deionised formamide, 10mM Tris-HCl 
pH 7.5, 0.1% (v/v) Tween 20. Filtered (0.2µm) prior to use. 
 
MWA buffer (Microarray Wash A): 1x PBS, 0.05% (v/v) Tween 20. Filtered 
(0.2µm) prior to use.  
 
MWB buffer (Microarray Wash B): 1x SSC. Filtered (0.2µm) prior to use. 
 
2.2.11 Mouse lines 
 
Wild-type mice:  
Wild-type C57/BL6 male and female mice aged 6-12 weeks were used for all 
experiments in Chapter 3. Wild-type BALB/c male and female mice were used in the 
Treg experiments (aged 6-12 weeks) and oesophagus experiments (aged 85 days on 
average) in Chapter 4.  
 
Mbd2-/- mice: 
Mbd2-/- C57/BL6 mice were produced from a heterozygous cross and, where 
possible, wild-type littermates were used as controls. Mbd2-/- C57/BL6 male and 
female mice aged 6-12 weeks were used for all experiments in Chapter 4 except 
where indicated. Mbd2-/- BALB/c mice were maintained as a homozygous line and 
used for the Treg and oesophagus experiments. 
 







Table 2.2.1 MAP PCR primers 
Name Genomic location Sequence forward Sequence reverse 
meCGI1 chr1:188786630 - 
188793725 
GGATGCCTACAGCAGCTTCG CGACCAGTCATCCTCGTCTG 































Table 2.2.2 Bisulfite Primers 
Name Genomic 
location  














































Table 2.2.3 qRT-PCR primers 
Name Sequence forward Sequence reverse 
Eef1A1 TTGGTTCAAGGGATGGAAAG AGCAAAGGTAACCACCATGC 
Kctd17 GAATTTCCTCAGGCATGGAA GTGTGAGCTCCTCCTCTTGG 
Klf2 GCCTGTGGGTTCGCTATAAA AAGGAATGGTCAGCCACATC 
Kcnn4 AAGCACACTCGAAGGAAGGA CCGTCGATTCTCTTCTCCAG 
Gata3 GTGGTCACACTCGGATTCCT GCAAAAAGGAGGGTTTAGGG 
Sema4a CCCTGACTCTGAGCCTGTTC AGGCTTGGTAGAGCCAGACA 
Il4 TCAACCCCCAGCTAGTTGTC TGTTCTTCGTTGCTGTGAGG 
Ifng ACTGGCAAAAGGATGGTGAC TGAGCTCATTGAATGCTTGG 
Ccl11 (eotaxin-1) TCCACAGCGCTTCTATTCCT CTATGGCTTTCAGGGTGCAT 
Gapdh TACCCCCAATGTGTCCGTCG CCTGCTTCACCACCTTCTTG 
Ppic TGATTGGCCTCTTTGGAAAC CCTCCAGTGCCATCTCTAGC 
Il4i1 AAGCCCCAGAAGGTGGTAGT GCTTGTGCAAGATCCTGTGA 
Il8ra CCGTCATGGATGTCTACGTG CAGCAGCAGGATACCACTGA 
Ptpn14 GACTCCTCGCCTGATACTGC CTGGGTGGACAAAGTGACCT 
Socs3 CCTTTGACAAGCGGACTCTC GCCAGCATAAAAACCCTTCA 
Tnfaip2 AAAAAGGACCAGCCCAGATT TACAGAGCCTCCACCTTGCT 
 





Sequence forward Sequence reverse 
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Kcnn4  chr7: 
25155333 - 
25170220  
ex2  GTGCTGTACCTGCTCCTGGT TGGCATGGAAGACCACAATA 
int2  GTCGGGAGAAGTGAAAATGG ACAATAGTGCCGACCCCTAA 
ex3 1 ATGCTCCTGCGTCTCTACCT ATGTACAGCTTGGCCACGAA 
ex3 2  ACACAGGGAGGAGACACCAG TTCTGGGTGGCTCAGAAGTT 
int3  CTCTGGATGGTTCCTGCTTC GTTGCGCTAGAGCCTGTTTG 
 








5’ 1 CTTAATCCCGGGCCTTTTAG TTTGACCAACCCATCTCTCC 
ex1 AGCTGTCTGCGAACACTGAG GCGTAGAGGAGGAGGAGGAG 
int1 TGTTTGGGGGTTTGTTTGTT AGCCCAGGACTGACTAAGCA 
ex2 GTGGTCACACTCGGATTCCT GCAAAAAGGAGGGTTTAGGG 
int2 3 TTGTGTGGTCGAGACAGGAG GCGGCTCTAGGGTAGAGGAT 
int2 2 ACCTTCTGGAAGCAGCTTTG TTTCAATGGCCCTGATTCTC 
ex3 2 CGGCTTCATCCTCTTCTCTG GCAGCTGCACCTGATACTTG 
int3 1 TTCCAAGACCAAATGGAAGG CCCAGTGACCCTCTGTGAGT 
int3 2 CGGCTGGAAACATTTCATTC TGGCCCTGTAGTACCCTCTG 
 















13 CTCAACCCAAGGACTCTGCC CCAGGATCAACTTAGCAGTGG 
 










int11 TAAAAAGACGGCTGGGAATG CACTGCTGGATTTGCAGGTA 
ex13 TCTGGAGGCATCTGGAGAGT CCAGACAGAAGGCTGCAGAG 
int13 GTGAGTGCTGACCCTGAATG GCTGGAATCTGGGAGTGAGA 
int14 GGAGGAGGTAACCAGGCACT CCACAGTCCACTTCACATCG 
ex15 TCTGCCAGTGACGTAGATGC GCAGAAGAGAGTCCCACAGG 
3’ 1 CTCTTTGAGCCCCTGTGGTA ACTCAGGTCAAATGGGCTTG 
 









-2 GTGGTCTCATTGGTTGGCAC GGAACATTTTATGTGGATAATCC 




2.1 GCACTGTAAGAGACTATGAACG CGCATGCTTGCAATTCTAACAC 
3 CCTGTACGACCTAAATGTCC GTATTAGTGTGCGGTGTTGC 
3.1 CTCAGTTTAAGAGCAAAGTCGT GCTTGGTGGATGGAAATATGG 
4 CAAAAAGTATGGAGGACATGTC CGTGCAACGGCTTGCTCCAG 
4.1 AGGTCACACACCTGTCTATGC CCAAGGAGCCATTTTGTGAGG 
5 GTCTCGTTGATTCACGCTGAC GTTTATTCAGTCTGTGTGCATC 
6 CCTCCATTCCTGTACACTTAAC CTTAATGTTAAGAATATGCAATG 
7 GCTACTGCTCATAGGTAGGC CATGATCTTTGGTAGATTGATTTC 
FR2 GTGTCCAAGACGCGGAGATAC CAAACATGGCTGGAGCAAGCC 
 





TFF2A GATGGAGCCCTGGAGAATG GAAAAGTGTGGTGGGAAGGAC 
 
 TFF2B AGCACATCCTACCCCAGGAAG GTACAGGCCAGCAGATAGCAT 
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4 CCTAATACGGCTTTTAACACCC CCTGAGGATCACTCAGAACGG 
 
Table 2.2.5 Other primers 















2.2.13 Antibodies  
 
Table 2.2.6 Antibodies for immune cell isolation and FACS 
Antibody Fluorophore Source Cat no. Concentration 
α-CD3 N/A; purified for culture BD Pharmingen 553057 1.6µg per well 
α-CD28 N/A; purified for culture BD Pharmingen 553294 1.6µg per well 
α-IL-4 N/A; purified for culture BD Pharmingen 554432 5µg/ml 
α-IL-12 N/A; purified for culture Biolegend 505304 5µg/ml 
α-FcR N/A Gift from A. 
MacDonald 
N/A 10µg/ml 
α-CD4 FITC Biolegend 100405 1:100 
α-CD4 PerCP BD Pharmingen 553052 1:100 
α-CD44 PE Biolegend 103007 1:250 
α-CD62L APC Biolegend 104411 1:100 
α-CD11c Alexa Fluor 647 eBioscience 51-0114-82 1:200 
α-PDCA PE Miltenyi Biotec 130-091-962 1:25 
α-CD19 PE BD Pharmingen 557399 1:200 
α-Ifng APC Biolegend 505809 1:100 
α-IL-4 PE BD Pharmingen 554435 1:100 
α-Foxp3 APC eBioscience  17-5773 1:200 
α-CD103 PE BD Pharmingen 557495 1:200 
 
Table 2.2.7 Antibodies for ChIP and Western blot 
Antibody Application Source Cat no./Ref Concentration 
α-H3K4me3 ChIP Millipore 07-473 5µg/IP  
α-H3K27me3 ChIP Millipore 07-499 5µg/IP 





α-H3 ChIP, Western blot Abcam ab1791 10µg/IP, 
1:20000 for 
Western 
α-MBD2, S923 ChIP Self-made, sheep 
polyclonal. IgG purified 
where indicated 






ChIP Sheep, isolated prior to 
S923 production.  






α-MBD2, R593 ChIP, Western blot Self-made, rabbit 
polyclonal 
Ng et al. 1999 10µl /IP,         
1:1000 for 
Western 
α-MBD2 ChIP Abcam ab3754 20µl/IP 
α-MBD2 ChIP Imgenex IMG-147 10µl/IP 
α-FLAG M2 
agarose 
ChIP Sigma A2220 10µl beads/IP 
Rabbit control 
IgG 











Western Blot GE Healthcare NA934 1:10000 
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Chapter 3 Differential CGI methylation in an  




The functional implications of cell-type specific CGI methylation are still unclear. 
The well-characterised changes in DNA methylation that take place during T cell 
differentiation make immune cells an attractive system in which to study this 
phenomenon and its relationship to gene expression. This investigation will be 
facilitated by the fact that a comprehensive CGI set for mouse now exists which 
includes non-promoter CGIs. In addition, the advent of high throughput sequencing 
technology means that DNA methylation in the genome can be more 
comprehensively investigated as analysis is no longer limited to the range of features 
included on a microarray. 
 
3.1.1 Differential CGI methylation and its relationship to gene 
expression 
Differences in CGI methylation between somatic cells and tissues have been well-
documented although these are small in number [section 1.5 and (Eckhardt et al., 
2006; Illingworth et al., 2008; Meissner et al., 2008; Schilling and Rehli, 2007)]. 
Less clear is their functional significance and how they relate to gene expression. 
Differential methylation in different cells and tissues is not always associated with 
differential gene expression (Illingworth et al., 2008; Schilling and Rehli, 2007). This 
could be due to the fact that differential methylation is a relic of previous 
development (i.e. differential expression earlier in the developmental lineage), an 
indication of transcription potential or stochastically acquired as a result of a 
transcriptionally silent state. The situation is further complicated by the existence of 
non-promoter-associated “orphan” CGIs many of which seem to be unannotated 
promoters (Illingworth et al., 2010; Maunakea et al., 2010). A large proportion of 
these reside in gene bodies where they have the potential to affect expression of the 
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associated gene. In addition, analysis in complex tissues such as brain and blood is 
complicated by the presence of multiple cell types which may have distinct 
methylation and gene expression profiles. Illingworth and colleagues found 
composite methylation patterns at many CGIs in human blood, brain, muscle and 
spleen and in some cases this was shown to be due to distinct methylation patterns in 
different cell types (Illingworth et al., 2008). To avoid this complication, 
homogenous cell cultures could be used. However, methylation profiling of cultured 
cell lines is not ideal because cultured cells frequently have abnormal methylation 
patterns (Jones et al., 1990; Meissner et al., 2008; Smiraglia et al., 2001). To address 
these concerns I will use pure primary cells from the mouse hematopoietic lineage 
for methylation analysis. Some of these cell types have previously reported DNA 
methylation differences although many occur outside CGIs (section 1.6).  The extent 
of CGI methylation differences between these developmentally related cell types and 
how this relates to gene expression will be investigated. Such analysis has been 
facilitated by the coupling of affinity chromatography methods for isolating 
unmethylated and methylated CGIs to next generation sequencing technology. 
 
3.1.2 Existence of a comprehensive CGI set 
Accurate identification of CGIs is of paramount importance for elucidating the extent 
and function of CGI methylation. As discussed in section 1.5, algorithms for 
predicting CGI position on the basis of sequence composition show high variability 
and fail to take into account methylation status. Early studies aimed to biochemically 
purify human CGIs using an affinity column containing the MBD from MeCP2 
which binds methylated CpG-rich sequence. Methylated CpG-rich sequences bind 
specifically to this column and thus can be separated from unmethylated CGIs and 
bulk methylated genomic DNA which elute from the column at low salt 
concentrations. The fractions containing unmethylated CGIs and bulk genome were 
then artificially methylated and reapplied to the column. Previously unmethylated 
CGIs were converted to methylated CGIs and thus bound specifically to the MBD 
column. These could be now be separated from CpG-poor bulk DNA and cloned 
giving a human CGI library (Cross et al., 1994). This technique for identifying CGIs 
 
 104 
was superseded by CxxC affinity purification (CAP) which takes advantage of the 
CxxC protein domain which has specific affinity for unmethylated CpGs. In CAP, 
genomic DNA is applied to a CxxC domain-containing affinity column and 
unmethylated CpG-rich sequences (CGIs) specifically bind and can be eluted at high 
salt concentrations. An initial CGI library was generated from human blood using 
this method and sequenced using conventional Sanger sequencing but a high rate of 
sequence failure meant that all CGIs were not included (Illingworth et al., 2008). In 
addition, any CGIs constitutively methylated in blood were excluded because of the 
specific affinity of the CxxC column for unmethylated CpGs. Our lab has recently 
generated comprehensive CGI sets for both human and mouse by coupling CAP to 
high throughput sequencing (CAP-seq). This was carried out in a range of tissues 
including sperm where CGIs are hypomethylated (Weber et al., 2007) so that 
somatically methylated CGIs would not be excluded. These sets are thought to 
represent the full CGI complement for human and mouse and contain 25,495 and 
23,021 CGIs respectively. Significantly, many of these CGIs do not associate with 
annotated gene promoters. In both human and mouse approximately half of CGIs 
occur at annotated transcription start sites (TSS) with the remainder located between 
genes (intergenic) or within gene bodies (intragenic) (Illingworth et al., 2010). The 
generation of a mouse CGI set is of particular advantage since mouse is a genetically 
tractable and widely used model organism, mouse cells can be acquired more easily 
and in greater numbers than human cells and are not subject to the same ethical 
constraints. In addition, mouse CGIs are less CpG-dense than human CGIs so many 
are missed by prediction algorithms (Illingworth et al., 2010). Now that the location 
and sequence composition of mouse CGIs is known their methylation status can be 
comprehensively investigated. 
  
3.1.3 Methods of determining DNA methylation state 
A number of methods can been used to assess DNA methylation. These include 
bisulfite conversion of DNA, methyl-sensitive restriction digestion, antibody pull-
down of methyl-cytosine and affinity purification using a methyl-binding domain. 
Such techniques can be used to assess the methylation status of candidate loci or be 
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applied genome-wide through the use of microarrays or next generation sequencing. 
Each of these techniques differs with respect to resolution, methylation context (CpG 
or non-CpG) and CpG density observable. Significantly, when using high throughput 
sequencing as a read-out, the depth of sequence necessary to obtain good coverage 
over regions of interest is of paramount importance.  
 
Sodium bisulfite treatment of DNA converts unmodified cytosine to uracil but does 
not affect methyl-cytosine. When bisulfite-treated DNA is amplified uracil is read as 
thymine and methylation can be assessed by sequencing and examining which 
cytosines remain unconverted and which have been converted to thymine (Frommer 
et al., 1992). Bisulfite-sequencing allows detection of methylated cytosine at single 
base-pair resolution in any sequence context (i.e. CpG and non-CpG), at any region 
of the genome. Whole-genome bisulfite sequencing (BS-seq) has recently provided 
valuable information about the extent of non-CpG methylation, the role of gene body 
methylation and DNA methylation differences between cell types as well as 
uncovering a potential function for DNA methylation in splicing (Laurent et al., 
2010; Lister et al., 2009). However, when using bisulfite sequencing to examine 
methylation genome-wide, a huge amount of sequencing is necessary in order to 
obtain adequate coverage over the whole genome (Laurent et al., 2010; Lister et al., 
2009). Restriction digestion and size selection that preferentially enriches for CGIs 
has been used in combination with bisulfite-sequencing to examine methylation at 
approximately half the CGIs in mouse as well as some other genomic regions and 
this approach required a much smaller amount of sequencing [a technique know as 
reduced representation bisulfite sequencing or RRBS (Meissner et al., 2008)].  
 
Restriction enzymes that are sensitive to methylation can be used to assess DNA 
methylation status at regions containing the relevant restriction site. One technique 
taking advantage of this is restriction landmark genome scanning (RLGS) which 
involves digesting DNA with the methyl-sensitive enzyme NotIiii and separating 
                                                 
iii Methyl-sensitive restriction enzymes do not cut methylated DNA. 
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restriction products by two-dimensional electrophoresis (Song et al., 2005). The 
HELP (HpaII tiny fragment enrichment by ligation-mediated PCR) assay digests 
DNA with the methyl-sensitive enzyme HpaII, and co-hybridises this along with 
DNA digested by the methyl-insensitive enzyme MspI to a microarray (Khulan et al., 
2006). In contrast, CHARM (comprehensive high-throughput array-based relative 
methylation) analysis is a technique which uses an enzyme, McrBC, which 
specifically cuts methylated DNA. Unmethylated DNA, resistant to digestion is 
hybridised to a microarray along with mock-digested DNA (Irizarry et al., 2008). 
CHARM has recently been used to identify tissue- and cancer-specific methylation 
occurring at the edges of CGIs (Irizarry et al., 2009). A major limitation when using 
digestion-based methods to analyse methylation is that they are limited to genomic 
regions containing the restriction site of interest. For example, only 20% of mouse 
and human CGIs contain the NotI sites that are used in RLGS and only 3.9% of non-
repetitive DNA contains sites for HpaII (Fazzari and Greally, 2004). McrBC cuts 
more promiscuously in the genome and cleaves all methylated CGIs and half of all 
methylated CpG sites (Irizarry et al., 2008). However, detection of the methylation 
status of multiple CpG sites is desirable in order to be able to quantitatively assess 
CGI methylation and this would require several restriction sites in each CGI.  
 
Methylated DNA immunoprecipitation (MeDIP) uses an antibody directed against 
methyl-cytosine to immunoprecipitate single-stranded methylated DNA and mC in 
any sequence context can be recognised. MeDIP has been effectively used in 
combination with microarrays to look at genome-wide methylation in cancer cells 
(Weber et al., 2005), at promoter methylation in normal cells (Weber et al., 2007) 
and at methylation of promoters occurring during ES cell differentiation (Mohn et 
al., 2008). MeDIP is well suited to characterising methylation at CGIs because 
methylated CGIs are efficiently immunoprecipitated by the mC-antibody due to a 
high density of mCpG. However, when applying next generation sequencing 
methods to immunoprecipitated DNA, more sequencing is necessary than for 
techniques that only enrich for CpG-dense methylation because MeDIP also 
identifies methylation in the bulk genome. In principle, the methylation status of the 
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entire genome could be determined by MeDIP-seq; however, to accurately quantify 
methylation in CpG-poor regions a lot of sequencing would be necessary. Two recent 
studies coupled MeDIP-seq to high throughput sequencing and reported good 
coverage of CpG residues. However, both studies carried out a large amount of 
sequencing and, in addition, artificially extended their reads to the average fragment 
size of DNA used for immunoprecipitation which increases CpG coverage (Down et 
al., 2008; Ruike et al., 2010).  
 
Methylated DNA can also be isolated through its affinity for the MBD domain of a 
methyl-binding protein. The MBD of MeCP2 used as an early means of identifying 
CGIs in the genome has been utilised to profile CGI methylation, a technique known 
as MBD affinity purification (MAP). A chromatography column containing 
recombinant MBD protein is prepared and when genomic DNA is applied, CpG-rich 
methylated sequences bind with high affinity to the MBD. This methylated CpG-rich 
fraction has been used to probe human CGI arrays (Illingworth et al., 2008) and, 
more recently, been sequenced directly to profile CGI methylation in human and 
mouse [MAP-seq; (Illingworth et al., 2010)]. Other MBD-affinity techniques use an 
immunoprecipitation-like method which involves incubating genomic DNA with 
MBD-coupled beads, washing and eluting specifically bound DNA. This can be 
applied to microarrays or directly sequenced (Gebhard et al., 2006; Rauch et al., 
2009; Serre et al., 2009). MBD affinity methods are best suited to the isolation of 
methylated CGIs and other CpG-rich methylated DNA because the MBD binds 
clusters of methyl-CpG with high specificity. For a CGI-centric study, MAP provides 
good coverage of CGIs for a relatively small amount of sequencing (Illingworth et 




I will use immune cells as a model system in which to investigate the extent of cell 
type-specific DNA methylation in the immune system and how this relates to gene 
expression and chromatin modification. This system is particularly suitable as it is 
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possible to study homogenous primary cell populations which have already been 
shown to have sites of differential methylation (section 1.6). Although not all of 
these sites are located at CGIs, CGIs will be focused on in this chapter because they 
represent a distinct and functionally important fraction of the genome.  
 
3.2 Results: Isolation of immune cell subtypes 
 
3.2.1 The immune cell lineage 
Immune cells arise from a self-renewing progenitor, the hematopoietic stem cell 
(HSC), which gives rise to myeloid and lymphoid progenitor cells that can 
differentiate into a variety of mature cell types. Cells of the myeloid lineage include 
granulocytes and macrophages which are involved in destroying and engulfing 
invading bacteria as well as specialised antigen presenting dendritic cellsiv. The 
lymphoid lineage primarily consists of B and T cells. B cells are involved mainly in 
antibody production as well as in antigen presentation. T cells consist of two 
subtypes; cytotoxic CD8 T cells which destroy virally infected cells and CD4 T 
helper cells which coordinate the immune response (Elgert, 2009). T helper cells 
further specialise into effector cells designed to deal with particular types of 
infection. Th1 cells are produced in response to intracellular bacteria and viruses 
while Th2 cells mediate the immune response to extracellular parasites. Additional 
varieties of specialised T cell have been characterised in recent years including Th17 
cells which have been implicated in autoimmunity and Treg cells involved in 
immune modulation [T helper cell subsets are reviewed in (Reiner, 2007; 
Romagnani, 2006)]. After infection, some B and T cells persist as memory cells, and 
these can respond rapidly if the same antigen is encountered again. The cell types 
analysed in this study are from both the myeloid and lymphoid lineage, they are; 
dendritic cells, B cells, CD4 T cells, Th1 and Th2 cells (Figure 3.2.1). 
                                                 
iv Some kinds of dendritic cell can also develop from the lymphoid lineage and these express the cell 

























3.2.2 Isolation of immune cells 
A major advantage of immune cells is that they represent primary cell types which 
can be easily purified. Dendritic cells, B cells and CD4 T cells were purified from 
mouse spleen on the basis of cell surface markers using fluorescence activated cell 
sorting (FACS) and magnetic cell sorting (MACS). The following markers were used 
for selection; myeloid dendritic cells CD11c+ PDCA-, B cells CD19+ and T cells 
CD4+. For gene expression analysis naïve CD4 T cells (CD44 low, CD62L high) 
were specifically selected (Swain et al., 1991). T helper cell differentiation is of 
particular interest as DNA methylation changes occur during this process (see section 
1.6). I have taken advantage of an in vitro differentiation system for T cells to look 
for DNA methylation changes globally with a focus on CGIs. CD4 T cells were 
activated by mimicking TCR signalling and cytokines and antibodies were added that 
skewed cells towards Th1 (IL-12, α-IL-4) or Th2 (IL-4, α-IL-12) cell fate. This was 
Figure 3.2.1 The immune cell lineage 
Immune cells derive from a hematopoietic stem cell (HSC) which can develop into myeloid and lymphoid 
progenitors. Myeloid cells include granulocytes, macrophages and dendritic cells whilst the lymphoid lineage 
consists mainly of B and T cells. CD4 T cells can further differentiate into Th1 and Th2 cells and this process 
can be recapitulated using an in vitro culture system. Cells examined in this study are marked with red 
boxes and markers used to characterise them are indicated below the cell name. 
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characterised by staining for cytokine production; Th1 cells produce IFN-γ and Th2 
cells produce IL-4. For methylation analysis, Th1 and Th2 cells were sorted on the 
basis of signature cytokine production using FACS. Purification of all immune cell 
types was assessed by FACS analysis (Figure 3.2.2). 
Th1 cells
(CD4+ gate)
























































































































































































B DNA methylation Gene expression 
cell type markers purity markers purity 
DC CD11c+ PDCA- 85-90% CD11c+ PDCA- 73-85% 
B cell CD19+ 97-98% CD19+ 93-97% 
CD4 T cell CD4+ 87-97% CD4+  
CD44 hi, CD62L lo 
93-97% 
Th1 CD4+ IFN-γ+ 90-96% CD4+ IFN-γ+ 70-89% 
Th2 CD4+ IL-4+ 92-95% CD4+ IL-4+ 40-52% 
 
3.3 Results: Profiling CGI methylation in immune cells by MAP-seq 
MAP was used to isolate methylated CpG-rich DNA from dendritic cells, B cells, 
CD4 T cells, Th1 and Th2 cells. Genomic DNA from each cell type of interest was 
applied to an MBD affinity column, weakly bound DNA washed off and specifically 
bound fractions eluted at high salt concentrations. These methylated CpG-rich 
fractions were then sequenced and differential methylation assessed using custom 
bioinformatic tools. 
  
3.3.1 Preparation and testing of the MBD column 
MBD affinity columns were prepared as per Illingworth et al using the MBD domain 
(amino acids 77-167) of human MeCP2 (Illingworth et al., 2008)v. Histidine-tagged 
MBD protein was expressed in bacteria and isolated using nickel affinity 
Figure 3.2.2 Purification of immune cells 
A) Representative purifications of each cell type are shown. Dendritic cells (DCs) were purified using 
MACS by depleting for PDCA+ cells and selecting for CD11c+. B cells were FACS sorted on the 
basis of CD19+. CD4 cells were purified by MACS and then stained and sorted for naïve cell 
markers (CD44 lo, CD62L hi). Th1 and Th2 cells were generated in culture from CD4 cells, stained 
and FACS sorted for cytokine production. 
B) Table detailing the purity of cells used for DNA methylation and gene expression analysis. 
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purification. MBD protein was then adsorbed onto nickel-charged sepharose via the 
histidine tag and packed onto 0.5ml chromatography columns for use on an AKTA 
purifier system (GE Healthcare). Prior to use, MBD columns were washed with 1M 
NaCl to remove bacterial DNA and other contaminants.  
 
MAP was carried out as follows. Genomic DNA (25µg) was sonicated to an average 
size of 500bp and bound to the MBD column at a low salt concentration (100mM 
NaCl). The salt concentration was then increased to 750mM NaCl and unmethylated 
CGIs and bulk genomic DNA were eluted and retained for analysis. The column was 
then washed at 750mM NaCl to ensure separation between bulk and specifically-
bound DNA. Methylated CGIs were eluted by increasing the salt concentration to 
1M NaCl. A schematic outlining the MAP procedure is shown in Figure 3.3.1. For 
each new batch of columns small adjustments, based on PCR analysis of purified 
DNA, had to be made to the salt concentration at which the wash step was carried out 
in order to account for variation in column packing and density of recombinant MBD 
protein. Where practical, MBD protein from the same large-scale purification was 
used and was bound to nickel sepharose beads in batches in order to minimise 
variation between columns. A maximum of 8 runs was carried out on each MBD 
column to avoid purification differences due to column degeneration. 
Sonicated genomic 
DNA








Elute at increased [NaCl] 
 
                                                                                                                                          
v The majority of the MBD protein production was carried out by U. Gruenewald-Schneider. 
Figure 3.3.1 MBD affinity purification (MAP) 
Genomic DNA from a cell type of interest is sonicated and applied to an MBD affinity chromatography 
column. DNA is eluted by increasing the salt concentration as methylated CpG-rich fractions elute at high 
salt concentrations.  
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Specific enrichment of methylated sequences was tested by carrying out PCR for 
regions of known methylation status and CpG-density. Unmethylated CGIs were 
eluted at low salt concentrations along with bulk CpG-deficient genomic DNA while 
methylated CGIs eluted at high salt concentrations. Three somatically methylated 
CGIs (meCGI 1, meCGI 2, meCGI 6) and associated regions of bulk genomic DNA 
(bulk 1, bulk 2, bulk 6) were used for PCR testing of MAP fractions (identified by R. 
Illingworth, see “Materials and Methods” for genomic location). Using associated 
CGI and bulk regions allowed us to assess whether DNA fragmentation was 
sufficient to separate nearby regions. As a further verification of the MAP technique 
methylated CGI fractions isolated from male and female mice were labelled and 
hybridised to microarrays containing all mouse promoters and CGIs (NimbleGen 
mouse promoter+CpG island arras). X-linked CGIs which are specifically 
methylated on the female inactive X chromosome were, as expected, enriched in the 
female sample compared to the male. There was no such sex-specific enrichment of 
autosomal CGIs (Figure 3.3.2; microarray analysis carried out by R. Illingworth and 






















Figure 3.3.2 MAP identifies methylated X-linked CGIs in females 
Genomic DNA from male and female mice was purified by MAP, labelled and hybridised to NimbleGen 
mouse promoter+CpG island arrays. Chromosome X shows specific enrichment for methylation in females 
due to the presence of methylated CGIs on the inactive X chromosome. Chromosome 16 shows no 
difference in methylation between males and females. 
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3.3.2 Optimisation of MAP purification for high throughput 
sequencing 
Although the MAP protocol detailed above was sufficient to detect differential 
methylation using microarrays additional optimisation was necessary in order to 
analyse methylated fractions using Illumina sequencing technology. Initial 
sequencing of methylated CpG-rich fractions gave a high level of background 
(female CD4 cells, data not shown). Sequencing is more sensitive to background 
than microarrays as the entire genome is analysed rather than a defined subset of 
features. Background was substantially reduced by carrying out a second MBD 
column purification. Specifically bound fractions from the first affinity purification 
were reapplied to the column and washing and elution of specifically-bound DNA 
was carried out as before. PCR testing of column fractions confirmed a complete 
absence of signal for bulk genomic DNA and enrichment for methylated CGIs after 
the second purification (Figure 3.3.3A). AKTA run traces show the amount of DNA 
eluted at each purification stage (Figure 3.3.3B). For high throughput sequencing 
adaptors are attached to fragmented DNA to allow amplification and attachment to 
the flow cell. The small amount of DNA obtained from MAPvi made attachment of 
adaptors after purification problematic. To circumvent this issue, adaptors were 
attached to total input DNA before it was applied to the column.  
 
                                                 








































































































































































3.3.3 Generation of methylation profiles using MAP-seq  
Genomic DNA was isolated from dendritic cells, B cells, CD4 T cells, Th1 and Th2 
cells. For each cell type two biological replicates were generated and purified 
separately using MAP as outlined above. Methylated CpG-rich fractions from the 
second column purification were pooled, precipitated and passed on to the Wellcome 
Trust Sanger Institute for Illumina library production and sequencing.  37bp single-
end reads were generated using an Illumina Genome Analyzer according to the 
standard Illumina protocol. Reads were mapped to the mouse genome (mm9 – 
NCBI37; repeat masked) using Maq (http://maq.sourceforge.net) and only high 
Figure 3.3.3 Two rounds of MAP are carried out prior to high throughput sequencing 
A) Fractions eluted from the MBD column over different salt concentrations were tested by PCR to 
verify enrichment for methylated CGIs over bulk DNA. Here PCR for meCGI 6 is shown along with 
PCR for an associated region of bulk genome (bulk6). Methylated fractions were pooled and 
subject to a 2
nd
 round of purification followed by PCR testing.  
B) Run traces from MAP carried out on an AKTA purifier. The upper panel depicts the first column 
purification where UV absorbance (dark blue trace) shows that the majority of DNA elutes at less 
than 0.75M [NaCl] (green line) and a small amount of methylated DNA elutes at higher 
concentrations. The lower panel is representative of a second round of purification where a smaller 




quality read placements (Maq score ≥ 30) were retained (mapping carried out by R. 
Andrews, Wellcome Trust Sanger Institute). For each replicate one lane of 
sequencing was carried out and each lane gave an average of 16.2 million sequencing 
reads. Data were received as .wig files containing the number of sequencing hits for 
each location in the genome. These were visualised using the Integrative Genome 
Browser (IGB; Affymetrix) (Nicol et al., 2009) and each lane was inspected to 
ensure comparability between samples in terms of background reads and signal over 
CGIs of known methylation status. The two lanes of sequencing carried out for each 
sample were then combined and all analysis performed on the combined data. An 
average of 429 million base pairs of sequence was generated per cell type. 
Sequencing data generated for each cell type is summarised in Table 3.3.1.  
 
Sample Number of reads generated 
(Maq ≥ 30) 
Number of bp mapped 
DC 32,699,330 448,7184,25 
B 48,087,285 613,253,355 
CD4 1 25,005,336 427,865,743 
CD4 2 39,376,768 426,508,805 
Th1 21,903,336 291,476,713 
Th2 24,343,600 364,400,346 
 
Regions highly enriched using MAP included methylated CGIs, as expected, as well 
as other CpG-dense methylated regions. Methylated CGIs were identified by 
comparing the MAP-seq data to the mouse CGI set generated by CAP-seq 
(Illingworth et al., 2010). Figure 3.3.4 shows representative profiles of MAP-seq 
reads for CD4 cells, Th1 cells and dendritic cells along with the CAP-seq profile for 
sperm which indicates the position of CGIs. Plotting the CpG frequency (in 300bp 
windows with a 10bp slide) shows that regions identified by MAP-seq are CpG-rich 
compared to the bulk genome. It is also worth noting that MAP-seq profiles for the 
Table 3.3.1 Summary of MAP-seq data generated  
Number of 37bp sequencing reads generated for each cell type and the number of base pairs (bp) of 
mapped sequence obtained. For CD4 cells two samples were generated (see section 3.3.4). 
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different cell types are strikingly similar indicating that, in general, the methylation 
























3.3.4 Analysis of MAP-seq data using custom bioinformatic tools 
In order to analyse the MAP-seq data, a number of custom bioinformatic tools were 
developed. These were designed in conjunction with R. Illingworth and S. Webb and 
accessed via an in-house version of the Galaxy application (Blankenberg et al., 2007; 
Taylor et al., 2007). Analysis was performed on .wig files. Initial analysis involved 
normalisation of .wig files in order to make read depth between samples comparable 
and peak-finding to identify regions enriched by MAP-seq. The parameters used in 
each analysis step are outlined in Table 3.3.2. They are; read height (H), length in bp 
(L) and gap permitted in the length parameter (G). The gap parameter allows small 
gaps in read coverage occurring in otherwise contiguous regions. 
 
Figure 3.3.4 MAP-seq identifies methylated CGIs and CpG-rich methylated regions 
Typical MAP-seq read density profiles (red) are shown for CD4 T cells (CD4), Th1 cells (Th1) and dendritic 
cells (DC). The CAP-seq profile for sperm is shown to indicate the position of CGIs (CGIs, blue) and the 
CpG density of the genome calculated in 300bp windows with a 10bp slide is also shown (CpG; scale 0-64 
CpGs per 300bp). RefSeq genes are annotated below the sequence profiles. The asterisk denotes a 
methylated CGI. Unmethylated CGIs are also evident (in CGI profile) along with non-CGI-associated MAP-
seq peaks (in MAP-seq profile). 
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Analysis step Parameters 
Background removal H: 2   L: 90   G: 20 
Normalisation Scale to 250 million reads 
Peak-finding H: 4   L: 90   G: 250 
Sliding window 100bp window, 20bp slide 
Identification of differences log2 difference > 1.8 in 9/13 contiguous windows  
Data normalisation 
Raw sequencing data were normalised in order to make different samples directly 
comparable. MAP data for each cell type were scaled to the average read number 
across all the MAP samples generated in the lab (approximately 250 million after 
background removal) in order to account for variable sequence depth. Background 
was removed prior to normalisation as fluctuations in the number of background 
reads could skew the normalisation procedure.  
 
Peak-finding 
Regions of prominent enrichment, or “peaks”, were identified using the parameters 
listed in Table 3.3.2. Regions with a height of at least 4 reads for a length of at least 
90bp were deemed to be enriched. This was verified by identification of regions of 
known methylation state as well as by bisulfite sequencing. Peaks of enrichment 
were then examined to assess the CpG density and gene association of regions 
identified by MAP-seq (section 3.3.5). MAP peaks from all of the mouse MAP 
samples generated in the lab were combined with the mouse CGI set to give a set of 




Table 3.3.2 Parameters for analysis of MAP-seq data 
Parameters for each analysis step are shown (described in section 3.3.4). H = height in number of reads, L 
= length in bp, G = gap in bp. 
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Identification of differentially methylated regions 
In order to accurately identify differentially methylated CGIs, a sensitive “sliding 
window” analysis was carried out over each of these regions of interest. For each 
region the average number of hits per base was calculated in 100bp windows with a 
20bp slide. Values for each window were then compared between samples. This gave 
a ratio for each window. If both windows being compared contained less than 4 reads 
this ratio was set to 1 in order to remove spurious hits attributed to small fluctuations 
at low read depth. Differentially methylated regions were defined as those containing 
9 out of 13 contiguous windows with a log2 ratio of >1.8 (i.e. 3.5-fold). Contiguous 
differentially methylated regions were knitted together. These parameters were 
verified by manual scoring of false positives and false negatives and also by correct 
identification of CGIs on the X chromosome which are differentially methylated 
between males and females (tested by comparing MAP-seq data for male and female 
blood). Individual examples were also tested by bisulfite sequencing and a selection 
of these is shown in Figure 3.3.7 as well as in section 3.6. An entire analysis scheme 





mouse chr2: 31,756,970 - 31,761,875














3.3.5 MAP-seq identifies methylated CGIs and other CpG-rich 
methylated DNA 
After the analysis method had been developed it was necessary to characterise the 
regions that could be identified by MAP. It was evident from the read density 
profiles (Figure 3.3.4) and peak-finding analysis that, in addition to methylated CGIs, 
MAP also enriches for other CpG-rich methylated DNA. All peaks of enrichment 
identified in CD4 T cells were analysed for genomic location and CpG density to 
give an idea of what a typical MAP purification identifies. MAP-seq in CD4 cells 
identified 50,778 regions; 9.3% (4,738) of which were located at CGIs and 90.7% 
(46,040) which were located elsewhere in the genome (non-CGI) (Figure 3.3.6A). 
Figure 3.3.5 Analysis scheme for MAP-seq data 
Example of a region differentially methylated in dendritic cells (DC) and Th1 cells (Th1) identified by analysis 
of MAP-seq data. Read density profiles are shown for raw (raw) and normalised (norm) data along with 
peaks of enrichment (peaks). Sliding window analysis on each sample (100bp window, 20bp slide) 
calculated the average number of hits per bp in a given window (DC windows and Th1 windows) and was 
carried out for all regions of interest. Values for these windows were then compared between samples (DC 
vs Th1 windows) and used to identify differential methylation (DC vs Th1 differences). RefSeq genes are 
plotted below the profiles. Data were visualised in IGB. 
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Methylated CGI peaks, as expected, showed strong association with genes (66.3% 
gene-associated – defined as location anywhere in a transcription unit) and non-CGI 
peaks were also preferentially gene-associated (66.9% gene-associated) compared to 
the whole genome (27%) (Figure 3.3.6B). The gene-association of non-CGI MAP-
seq peaks is most likely due to elevated CpG content in exons due to coding 
restraints although this could also indicate a functional importance for DNA 
methylation in these regions. The CpG density of MAP-seq peaks in CD4 cells was 
assessed by calculating the number of CpG sites per 100bp in each peak. The tenth 
percentile of these data was 3.3 CpGs per 100bp and this CpG density was taken to 
represent the minimum CpG density necessary for binding to the MBD column 
(Figure 3.3.6C). To put these figures in context mouse CGIs contain, on average, 6.7 
CpGs per 100bp while the bulk genome has less than 1 CpG per 100bp. The fraction 
of the non-repetitive genome interrogated using MAP-seq was also calculated. For a 
single MAP-seq analysis in CD4 cells, peaks of enrichment covered 0.6% of the 
repeat-masked mouse genome. This corresponds to 674,000 CpG sites or 3.2% of all 






































































































3.3.6 MAP-seq identifies methylation differences between cell 
types 
Differential methylation was assessed between cell types as described (section 3.3.4). 
Cell types were compared pair-wise and differential methylation was categorised as 
CGI (overlapping a CGI) or non-CGI (not overlapping a CGI). Some variation 
between MBD columns was observed meaning that some of the samples run on 
different batches of column were too variable to be compared using my quantitative 
analysis method. In practise this meant that B cell and CD4 cell MAP samples run on 
the same MBD column were only comparable to each other and CD4, Th1, Th2 and 
Figure 3.3.6 Regions identified by MAP-seq  
A) Number of CGI-associated (CGI) and non-CGI-associated (nonCGI) methylated peaks identified by MAP-
seq in CD4 cells. B) Gene-association of MAP-seq peaks. The percentage of the genome that occurs within 
transcription units (genome) is indicated along with the percentage of CGI and non-CGI peaks in CD4 cells 
that overlap genes. C) CpG density of regions identified by MAP-seq in CD4 cells. The 10
th
 percentile is 
taken to represent the CpG density necessary for detection of a region by MAP-seq. 
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dendritic cells samples run at a separate time were comparable. As most of the 
samples contained pools of male and female DNA the sex chromosomes were 
excluded from the analysis in case fluctuations in the proportion of male and female 
DNA between samples skewed the results. CD4, Th1 and Th2 cells which are all 
highly developmentally related showed a very small number of methylation 
differences between them. In particular, Th1 and Th2 cells had almost identical 
methylation patterns with just one CGI showing a methylation difference. More 
differences were seen between T cells and less related B and dendritic cells (Table 
3.3.3).  
 
Comparison CGI changes Non-CGI changes 
DC vs Th1 102 249 
DC vs Th2 59 175 
DC vs CD4 37 79 
B cell vs CD4 83 187 
Th1 vs CD4 16 75 
Th2 vs CD4 5 42 
Th1 vs Th2 1 0 
 
3.3.7 Verification of MAP-seq results by bisulfite sequencing 
The methylation status of 11 CGIs showing differential methylation between cell 
types by MAP-seq was checked using bisulfite sequencing and all regions tested 
confirmed MAP-seq results (summarised in Table 3.3.4).  
 
 
Table 3.3.3 Methylation differences between cell-types as identified by MAP-seq 
Cell types were compared pair-wise and for each comparison the number of methylation differences at CGIs 
and non-CGI regions is indicated. Differences were calculated using sliding window analysis on normalised 
.wig files as outlined in section 3.3.4. 
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Gene Genomic region 
MAP-seq  
(cell types showing increased 
methylation listed first) 
Bisulfite  
(% methylation) 




Th1 (vs CD4/DC) 
55% Th1, 30% CD4, 17% 
DC 
Kcnn4 chr7: 25161961 - 25162900 DC, B cell, CD4 (vs Th1) 
66% DC, 70% B, 32% CD4, 
20% Th1 
Npb 
chr11: 120469741 - 
120470220 
Th1 (vs DC) 54% Th1, 9% DC 
Sema4a chr3: 88240621 - 88241160 CD4, Th1, Th2 (vs DC) 80% Th1, 29% DC 
Tnfaip2 
chr12: 112683701 - 
112684060 
DC (vs Th1) 66% DC, 26% Th1 
Csf2ra chr19: 61304341-61304760 Th1 (vs DC) 81% Th1, 60% DC 
Nr4a3 chr4: 48064301-48065140 Th1 (vs DC) 73% Th1, 16% DC 
Hic1 chr11:74979221-74979660 Th1 (vs DC) 33% Th1, 7% DC 
Sgms2 chr3:131033081-131033520 DC (vs Th1) 44% DC, 25% Th1 
Klf2 chr8: 74844581-74845040 DC (vs Th1) 80% DC, 47% Th1 
Two examples of bisulfite sequencing carried out on regions which are differentially 
methylated in dendritic cells compared to Th1 cells are shown in Figure 3.3.7. 
Additional MAP-seq verification by bisulfite sequencing is shown for the examples 
discussed in section 3.6. 
 
Table 3.3.4 Bisulfite verification of methylation differences 




























3.4 Results: Profiling gene expression in immune cells 
Gene expression was profiled in dendritic cells, B cells, naïve CD4 cells, Th1 and 
Th2 cells using Illumina Whole-Genome Expression BeadChips and used to identify 
genes showing differential expression between cell types.  
 
3.4.1 Analysis of gene expression data 
RNA was extracted from cells of interest, labelled and passed on to the Wellcome 
Trust Clinical Research Facility, Edinburgh (WTCRF) for hybridisation to Illumina 
MouseWG-6 BeadChips. These chips contain probes for all RefSeq transcripts as 
well as probes for some other transcripts from additional databases. BeadChip arrays 
consist of beads to which probes for each transcript have been covalently attached. 
Approximately 30 different beads are present for every probe sequence giving a high 
level of redundancy. Six RNA samples can be hybridised to a chip in parallel which 
gives high reproducibility and makes this a cost effective way of interrogating gene 
expression. For each cell type three biological replicates were carried out. Data for 
each identical probe sequence were summarised using Illumina BeadStudio. Data 
were normalised using the average normalisation method in BeadStudio which scales 
each array based on a scaling factor derived from the average intensity across all 
arrays. Background was not removed from samples during normalisation as this has 
been shown to artificially bias BeadChip gene expression results (Dunning et al., 
2008). Subsequent analysis was carried out using GeneSpring GX10 (Agilent 
technologies). For analysis of differential gene expression, genes with low 
expression (Flags absent) across all cell types were removed. Statistical analysis was 
carried out to find genes that were differentially expressed between any of the cell 
Figure 3.3.7 Verification of differential methylation using bisulfite sequencing 
A) The Npb CGI is hypermethylated and B) the Tnfaip CGI is hypomethylated in Th1 cells compared to 
dendritic cells (DC). For each example the upper panel shows read density profiles generated by MAP-seq 
(red), CGIs (blue) and the region interrogated by bisulfite sequencing (bs, grey bars). The lower panel shows 
the bisulfite sequencing result; a blue dash indicates a CpG site, filled circle = methylated CpG, empty circle 
= unmethylated CpG. 
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types (one-way ANOVA, p≤0.05). Pair-wise comparisons were performed on this 
gene set and genes changing at least two-fold between cell types were deemed to be 
differentially expressed. Where multiple probes for the same gene indicated 
differential expression this was counted as one change. Only RefSeq genes from the 
array were examined further as they represent a well-defined gene set which is easy 
to overlay with CGIs and other genomic features. 
 
3.4.2 There are large gene expression differences between 
immune cell types. 
Many changes in gene expression were observed between different immune cell 
types. For example, over 2,000 differences of at least two-fold were observed 
between most cell types. The exception to this was Th1 and Th2 cells which showed 
more similar gene expression profiles having just 362 expression differences 
between them. Strikingly, naïve CD4 cells had a similar number of gene expression 
differences compared to developmentally-related Th1 cells as they did compared to 
more developmentally and functionally distinct dendritic cells (Table 3.4.1 and 
Figure 3.4.1). 
 
Comparison RefSeq genes changed 
DC vs Th1 2782 
DC vs Th2 2677 
DC vs CD4 2059 
B cell vs CD4 1352 
Th1 vs CD4 2811 
Th2 vs CD4 2518 
Th1 vs Th2 362 
 
Table 3.4.1 Gene expression difference between cell types  
Cell types were compared pair-wise and genes showing at least a two-fold expression change were 







































































Figure 3.4.1 Pair-wise plots comparing gene expression between cell types 
Scatter plots showing pair-wise comparisons of gene expression between cell types. Each dot 
represents a unique probe on the array and probes located outside of the green lines show at least a 
two-fold difference in expression. The scale is log2 of intensity values. 
 
3.4.3 Validation of expression arrays 
A number of the gene expression differences detected by the microarray analysis 
were verified by quantitative reverse transcription PCR (qRT-PCR). In qRT-PCR, 
expression of the gene being tested is compared to that of a reference gene that is not 
expected to change its expression under the conditions tested. This accounts for 
variability in RNA quality or in the efficiency of the reverse transcription reaction. 
Common references include housekeeping genes such as Gapdh and ActB, however, 
these genes change expression upon T cell activation (Hamalainen et al., 2001) 
making them an unsuitable choice for analyses involving T cells. The gene for 
elongation factor 1 α-1 (Eef1A1) was chosen as a reference based on its use in a 
published study (Hamalainen et al., 2001) as well as relatively consistent expression 




A total of 12 genes showing differential expression in the microarray experiment 
were verified by qRT-PCR and results were found to be consistent between the two 
techniques. qRT-PCR and microarray results for two of the genes tested; Kctd17 and 
Klf2 are shown in Figure 3.4.2. Additional qRT-PCR verification is shown for 



















































































































































































































































































Figure 3.4.2 Verification of expression array data by qRT-PCR 
A) Kcd17 and B) Klf2. For each, the top panel shows qRT-PCR relative to Eef1A1 (error bars = standard 
deviation from PCR replicates) and the bottom panel shows the absolute intensity value from the BeadChip 
arrays averaged across replicates. 
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3.5 Results: Analysis and comparison of DNA methylation and gene 
expression 
Methylation results were analysed in detail with respect to location of changes, 
function of associated genes and categories of CGI that showed differential 
methylation. These were then related to changes in gene expression between cell 
types. MAP-seq and gene expression data for brain have been generated in our lab 
and this allowed brain to be used as a distantly related tissue with which to compare 
data for immune cells. 
 
3.5.1 Methylation differences between immune cells are small in 
number and show an association with developmental 
similarity  
The number of methylation differences between immune cells was relatively small 
ranging from 351 changes between dendritic cells and Th1 cells to just one change 
between Th1 and Th2 cells (Table 3.3.3). In general, the number of methylation 
differences between cells was associated with developmental similarity as the most 
related cell types, CD4, Th1 and Th2 cells, showed the fewest differences. In 
addition, these changes were smaller in magnitude than those between more distantly 
related immune cells. For example, regions differentially methylated in Th1 and CD4 
cells showed, on average, a 3.1-fold difference in the number of sequencing hits 
while differentially methylated regions in more distantly related Th1 and dendritic 
cells showed, on average, a 4-fold difference. In terms of the number of methylation 
differences that were identified between particular cell types, CGIs showed the same 
trend with respect to developmental similarity as non-CGI-associated regions 
although the number of methylation changes at CGIs was smaller (Figure 3.5.1A and 
B).  
 
MAP-seq data for immune cells were compared to data generated for brain in our lab 
(Skene et al., 2010). In contrast to the similar patterns of methylation seen between 
different immune cells, MAP-seq identified large numbers of methylation differences 
between immune cells and brain. Over 2,000 CGIs and 20,000 non-CGI regions 
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showed differential methylation between CD4 cells and brain further illustrating the 
correlation between DNA methylation and developmental proximity (Figure 3.5.1A 
and B). Interestingly, brain was hypomethylated at both CGI and non-CGI regions 
compared to CD4 cells. 
 
Gene expression differences between immune cell-types were much more numerous 
than methylation differences. Up to 2811 genes were differentially expressed 
between immune cell types and changes had little correlation with developmental 
similarity; Th1 and CD4 cells showed the same number of gene expression 
differences as Th1 and dendritic cells (Table 3.4.1 and Figure 3.5.1C). The exception 
to this was Th1 and Th2 cells which showed the most similar gene expression 
profiles (362 changes) indicating functional similarity (Figure 3.5.1C). Although 
naïve CD4 and Th1/Th2 cells are very close developmentally and show similar DNA 
methylation profiles naïve CD4 cells are quiescent while Th1 and Th2 cells have 
been stimulated to respond to infection. Evidently stimulation elicits large changes in 
the transcriptional program and therefore seems to play a larger part than 
developmental relationship in determining gene expression. Like non-activated CD4 
cells, the majority of B cells and dendritic cells examined in this study are quiescent 
as they have been taken from the spleens of uninfected animals. Non-activated B and 
CD4 cells profiled here are more similar in terms of gene expression than naïve CD4 
cells and activated Th1 or Th2 cells. Methylation on the other hand does not seem to 
be substantially affected by T cell activation (Table 3.3.3 and Figure 3.5.1A and B) 
consistent with a report that resting ex vivo T cells and T cells activated and 
expanded in culture retain the same T cell-specific methylation patterns (Schmidl et 
al., 2009).  
 
Immune cell gene expression data were compared to expression data generated for 
brain using BeadChip arrays (J. Guy, unpublished). Nearly 6,000 differentially 
expressed genes were detected between naïve CD4 cells and brain indicative of their 
drastically different functions (Figure 3.5.1C). The observation that there are fewer 
gene expression changes (~5,719) than methylation changes (~23,029) when CD4 
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cells are compared to brain is in contrast to the situation when different immune cells 
are compared. There are 2,811 gene expression differences but only 91 methylation 
differences between CD4 and Th1 cells. This suggests a developmental origin for 
DNA methylation patterns. Cells with a common developmental origin such as cells 
of the hematopoietic lineage share similar DNA methylation profiles despite large 
differences in gene expression while developmentally distinct tissues such as brain 


























Figure 3.5.1 DNA methylation and gene expression differences between CD4 cells and 
other cell types 
A) The number of differences in CGI methylation detected between CD4 cells and brain, dendritic cells (DC), 
B cells, Th1 and Th2 cells.  B) Number of non-CGI methylation differences C) Number gene expression 
differences of at least two-fold. 
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3.5.2 Methylation differences preferentially occur in genes with 
immune system function 
Although the number of methylation changes between different immune cells is 
small these changes may be functionally important. I assessed this by examining the 
function of genes that were associated with cell-specific methylation occurring at 
both CGI and non-CGI regions (i.e. genes with a methylation change located 
anywhere within the transcription unit). 78% of CGI and 71% of non-CGI 
methylation changes occurred within genes. Gene ontology (GO) terms for these 
genes were investigated and overrepresented categories identified using the Panther 
Database (http://www.pantherdb.org). Genes showing differential CGI methylation 
were enriched for functions in immunity and defence, developmental processes and 
cytokine/chemokine-mediated immunity when all CGI-associated genes were used as 
a reference (binomial test with multiple testing correction, p≤0.05 taken to indicate 
significant enrichment). Genes differentially methylated at non-CGI regions showed 
an overrepresentation of GO terms associated with various signalling pathways 
including T cell activation and inflammation when compared to all genes associated 
with a MAP-seq peak (Table 3.5.1). These results suggest that DNA methylation 
changes in immune system cells may play a functional role and have not simply 













GO biological process enriched in genes w CGI changes p-value 
Immunity and defence 0.0075 
Developmental processes 0.014 
Cytokine/chemokine mediated immunity 0.043 
GO pathways enriched in genes w non-CGI changes p-value 
T cell activation 0.0048 
Apoptosis signalling pathway 0.026 
EGF receptor signalling pathway 0.035 
Inflammation 0.04 
 
Genes that show differential methylation in immune system cells were then 
examined individually with respect to function and many key immune system genes 
were identified. Significantly, the only methylation difference between Th1 and Th2 
cells occurred in a CGI in exon 3 of the Gata3 gene, a key determinant of Th2 cell 
fate (Nawijn et al., 2001). Although changes between Th1 and Th2 cells at the Ifng 
and Il4 loci have been extensively documented, it is important to note that these loci 
are CpG-poor and therefore can not be investigated by MAP-seq. The only gene-
associated CGIs to show methylation differences between CD4 cells and both Th1 
and Th2 cells are located in Dtx1, a gene which suppresses T cell activation and thus 
is down regulated when T cells are activated (Liu and Lai, 2005), and Kcnn4, which 
codes for a calcium-activated potassium channel involved in T cell activation 
(Begenisich et al., 2004). Other genes with an immune system role that show 
differential CGI methylation include Fgr which negatively regulates myeloid cell 
chemokine signalling (Zhang et al., 2005), Sema4a which provides a co-stimulatory 
signal to T cells and is necessary for Th1 cell differentiation (Kumanogoh et al., 
Table 3.5.1 Over-represented GO terms for genes showing differential methylation in the 
immune system 
GO term analysis was carried out using tools available on the Panther database. GO terms for genes 
associated with differentially methylated CGIs were compared to GO terms for all CGI-associated genes. 
GO terms for genes showing non-CGI differential methylation were compared to all genes containing a peak 




2005), Bcl11b which regulates thymocyte development (Wakabayashi et al., 2003), 
Runx3 which promotes Th1 cell fate (Djuretic et al., 2007), Klf2 which regulates the 
Il2 promoter (Wu and Lingrel, 2005), interleukin-10 receptor subunit alpha (Il10ra) 
and many more (see Table 3.5.2). In addition, many genes that show cell-specific 
methylation at non-CGI regions also function in the immune system. Some of these 
are genes that also show methylation changes at their CGIs such as Kcnn4 and 
Bcl11b. Other genes showing differential non-CGI methylation include Tcf4, a 
transcription factor with roles in dendritic cell, T cell and B cell development (Cisse 
et al., 2008; Wikstrom et al., 2006; Wikstrom et al., 2008), the chemokine receptor 
Ccr7 (Worbs and Forster, 2007) and the interleukin-17 receptor Il17ra (Toy et al., 
2006). 
 
Gene Cell types showing CGI 
hypermethylation (comparison in 
brackets)  
Function References 
Gata3 Th1 (vs Th2) Th2-specific transcription 
factor 
(Nawijn et al., 
2001) 
Dtx1 Th1, Th2 (vs CD4/DC) Suppression of T cell 
activation 
(Liu and Lai, 
2005) 
Kcnn4 CD4, DC, B cell (vs Th1/Th2) Potassium channel involved in 
T cell activation 
(Begenisich et al., 
2004) 
Fgr CD4 (vs DC) Regulation of myeloid cell 
chemokine signalling 
(Zhang et al., 
2005) 




Bcl11b Th1 (vs DC) Thymocyte development (Wakabayashi et 
al., 2003) 
Runx3 B cell (vs CD4) Transcription factor, promotes 
Th1 cell fate  
(Djuretic et al., 
2007) 
Klf2 DC (vs Th1) Transcription factor regulating 
IL-2 production early in T cell 
activation 
(Wu and Lingrel, 
2005) 
Il10ra CD4 (vs B cell) Interleukin-10 receptor, 
regulation of immune 
response. 
(Pils et al., 2010) 




Cxcr5 CD4 (vs B cell) Chemokine receptor (Hardtke et al., 
2005; Junt et al., 
2005) 
Notch 2 Th1,Th2,CD4 (vs DC)  Signalling during immune cell 
differentiation  
(Cheng et al., 
2003; Fiorini et 
al., 2009) 
Il16 Th1 (vs DC)  T cell chemoattractant. 




3.5.3 Cell type-specific methylation preferentially occurs at CGIs 
MAP-seq identified CGI and non-CGI regions showing cell type-specific 
methylation. A recent study examining tissue- and cancer-specific methylation using 
the restriction digestion-based CHARM method reported that the majority of 
methylation differences occurred not at CGIs but at the edges of CGIs, so-called 
“CpG island shores” (Irizarry et al., 2009). In order to explore this possibility the 
location of differential methylation was examined in more detail to see if it occurred 
at the edges of CGIs. I categorised my differentially methylated regions as occurring; 
in a CGI (any overlap with a CGI), 0-2kb from a CGI (not overlapping a CGI but 
within 2kb of a CGI, counted as a shore region by Irizarry et al.) or greater than 2kb 
from a CGI (>2kb). The greatest number of differentially methylated regions 
belonged to the >2kb category (Figure 3.5.2B) but regions more than 2kb away from 
a CGI also made up the majority of genomic regions that could be identified by 
MAP-seq (Figure 3.5.2A). For each category of genomic region, the number of 
differentially methylated regions was expressed as a percentage of MAP-seq regions 
interrogated. The reference set of MAP-seq regions interrogated was obtained by 
combining MAP-seq peaks from all mouse MAP-seq experiments carried out in the 
Table 3.5.2  Many differentially methylated CGIs are associated with immune system 
genes 
A selection of the immune system genes that display differential CGI methylation is shown although this list 
is by no means exhaustive. For each example the first cell type shows increased methylation 
(hypermethylation) compared to the cell type(s) in brackets.  
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labvii (Figure 3.5.2A). Using this set as a reference ensures that these regions can be 
identified by MAP and are amenable to detection by Illumina sequencing (i.e. not 
filtered out by repeat masking).  
 
When all regions showing differential methylation between immune cell types were 
examined, 3.1% of CGI regions showed a change in methylation while just 0.76% of 
0-2kb and 0.49% of >2kb regions showed cell-specific methylation differences 
(Figure 3.5.2B). To verify that this observation was not biased by the small number 
of methylation changes investigated and that it was not specific to the immune 
system, methylation changes occurring between CD4 cells and brain were also 
categorised. In this comparison CGIs still showed preferential differential 
methylation although the distinction between the categories was less pronounced; 
37% of methylated CGI regions, 30% of 0-2kb regions and 18% of regions distal to 
CGIs showed differential methylation (Figure 3.5.2C). This result suggests a 
functional importance for differential CGI methylation as methylation differs more at 
these regions than elsewhere in the genome. The rest of this study will focus on CGI 
methylation both because differential methylation in immune cells occurs 
preferentially at CGIs and because cell type-specific CGI methylation is of particular 
interest. Importantly, if all CGIs are promoters as has been suggested (Illingworth et 
al., 2010; Maunakea et al., 2010) then methylation at these sites will have an obvious 
repressive function. 
                                                 






































































































































































































































































3.5.4 Intragenic CGIs show the most methylation changes 
CGIs can be located at the transcription start sites of genes (TSS), within gene bodies 
(intragenic) or outside of annotated genes (intergenic) (Figure 3.5.3A). 
Approximately half of mouse CGIs are located at a TSS consistent with their 
function as promoters while the rest are divided equally between intra- and intergenic 
locations (Figure 3.5.3B). The function of these non-TSS-associated “orphan” CGIs 
is unclear though many show evidence for promoter function (Illingworth et al., 
2010; Maunakea et al., 2010). A recent study comparing CGI methylation in mouse 
Figure 3.5.2 Cell-specific methylation preferentially occurs at CGIs 
A) The number of CGIs, regions 0-2kb and >2kb away from CGIs interrogated by MAP-seq. These figures 
were used to calculate the percentages in B and C. B) Location of differential immune cell methylation with 
respect to CGIs. C) Location of differential methylation between brain and CD4 cells. The left panel shows 
the absolute number of changes occurring at each category while the right panel shows the percentage of 
each category showing a methylation change. 
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sperm to that in brain and blood has shown that intra- and intergenic CGIs 
preferentially acquire methylation in somatic tissues. Approximately 26% of 
intragenic and 13% of intergenic CGIs became methylated compared to only 2.4% of 
TSS CGIs (Illingworth et al., 2010). Similar findings have been observed for 
methylation in human brain (Maunakea et al., 2010). I found that preferential 
methylation of “orphan” CGIs also occurs in immune cells where 2.8% of TSS CGIs, 
33% of intragenic and 16% of intergenic CGIs are methylated in CD4 cells compared 
to sperm (data not shown). However, I am interested not in CGIs that are 
constitutively methylated in somatic cells but in those whose methylation varies 
between cell types. I examined the location of all CGIs that showed cell type-specific 
methylation in the immune system and found that 63% of these were intragenic 
despite the fact that only 25% of all CGIs are located in intragenic regions (Figure 
3.5.3B). This trend was the same for all immune cell comparisons (Figure 3.5.3C). 
This makes intragenic CGIs seven times more likely than TSS CGIs and three times 
more likely than intergenic CGIs to be differentially methylated in the immune 
system. Therefore, examining intragenic CGIs is crucial with respect to elucidating 
the function of cell type-specific CGI methylation in the immune system as this is 
where most of the methylation differences occur. Many of the differentially 
methylated genes with immune system function mentioned in section 3.5.2 showed 
changes at intragenic CGIs including Gata3, Kcnn4, Sema4a and Notch2.  
 
 140 























































































It is known that methylation of promoter CGIs is incompatible with transcription yet 
it is unclear what the effect of CGI methylation in gene bodies might be. As 
intragenic CGIs have recently been associated with novel TSSs (Illingworth et al., 
Figure 3.5.3 Most differential CGI methylation in the immune system is intragenic 
A) CGIs can be located at transcription start sites (TSS), in gene bodies (intragenic) or between genes 
(intergenic). CGIs are shown here as unmethylated although intra- and intergenic CGIs are susceptible to 
methylation. Filled circles = methylated CpGs, empty circles = unmethylated CpGs.  B) Location of all CGIs 
in the mouse genome (left; taken from Illingworth et al., 2010) and location of all CGIs that are differentially 
methylated in immune system cells (right; each CGI was only counted once even if it changed in multiple 
comparisons. C) Pair-wise comparisons of immune cell types showing the number and location of CGIs that 
are differentially methylated. 
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2010; Maunakea et al., 2010) it is tempting to speculate that these could represent a 
distinct class of promoter that is susceptible to regulation by methylation. To try and 
elucidate the effects of differential intragenic methylation I examined its relationship 
with gene expression. 
 
3.5.5 Differential intragenic CGI methylation negatively correlates 
with gene expression 
Differential intragenic CGI methylation was associated with differential expression 
of the associated gene in an average of 26% of cases. For these genes, an increase in 
methylation tended to correspond to a reduction in gene expression. This was the 
case for 33 out of 47 (70%) intragenic CGIs showing cell-specific methylation in the 
immune system (Figure 3.5.4A). Several CGIs did not follow this trend but this is not 
surprising given that the functional relationship between intragenic CGIs and their 
associated genes is not clear. 
 
To see if the negative correlation between increased intragenic CGI methylation and 
gene expression was a general phenomenon, the relationship between differential 
intragenic CGI methylation and differential gene expression in brain and CD4 cells 
was examined as a much larger number of CGI methylation changes occur here 
(2,304). Almost 70% of these changes occurred at intragenic locations and brain 
showed less methylation than CD4 cells. When a loss of intragenic CGI methylation 
in brain was accompanied by a gene expression change, expression was increased in 
brain compared to CD4 cells in the vast majority (82%) of cases (Figure 3.5.4B). 
Thus, when differential intragenic CGI methylation is associated with a gene 
expression change, methylation negatively correlates with expression consistent with 















































































































However, most cell-specific intragenic CGI methylation is not associated with a 
change in gene expression. I examined whether these genes were likely to function in 
the immune system or whether genes showing both a methylation and expression 
change showed a greater enrichment for GO terms associated with immune system 
function. Intragenic CGIs that associated with both cell-specific methylation and 
cell-specific gene expression were preferentially located in genes with functions in 
“immunity and defense” and “cytokine/chemokine-mediated immunity” (p = 0.001 
and p = 0.00146 respectively) while differentially methylated genes that did not 
change their expression showed no enrichment for terms associated with immune 
system function. This suggests that the CGI methylation changes associated with a 
gene expression change may be more likely to have a functional role in the immune 
Figure 3.5.4 Cell type-specific intragenic CGI methylation negatively correlates with 
gene expression 
The relationship between differential intragenic CGI methylation and differential gene expression is shown 
for A) All immune cell comparisons B) Brain versus CD4 cells. In the left panel the number of changes are 
shown, “+” denotes an increase and “-“denotes a decrease in expression/methylation. In the right panel the 
percentage of methylation changes showing a positive or negative correlation with gene expression is 
shown. Red = negative correlation and green = positive correlation between methylation and expression. 
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system. I then investigated whether the differentially methylated intragenic CGIs not 
associated with an expression change were located in genes that were expressed. 
When dendritic cells and Th1 cells were compared, 70% of differentially methylated 
intragenic CGIs were associated with genes that were silent in both cell types. In 
contrast, when all genes were examined, 46% were silent in both dendritic cells and 
Th1 cells. This indicates a tendency for genes associated with differentially 
methylated intragenic CGIs to be repressed.  
 
As the relationship between intragenic CGIs and the associated gene is unclear it is 
not known if or how methylation at intragenic sites might impact on gene expression. 
It is possible that in the instances where cell-specific methylation negatively 
correlates with gene expression, the intragenic CGI might be involved in 
transcriptional regulation of the associated gene but in other cases its function may 
be completely independent of this gene. 
 
3.6 Results: Association between differential methylation and histone 
modification 
One way to explain the negative correlation between intragenic CGI methylation and 
gene expression is that unmethylated CGIs facilitate transcription through the setting 
up of a permissive chromatin environment in the gene body which is lost when the 
CGI becomes methylated. Unmethylated CGIs are associated with the active histone 
modification H3K4me3 (Illingworth et al., 2010) which is a common feature of 
promoters and deemed to be a mark of transcriptional competence. H3K4me3 is 
recruited to CGIs, at least in part, by the CxxC domain protein CFP1 (Thomson et 
al., 2010). I examined examples of differential intragenic CGI methylation occurring 
in immune system genes and investigated how this impacted the chromatin state. 
Results obtained from analysis of candidate genes prompted us to look genome-wide 




3.6.1 Differential intragenic CGI methylation coincides with a 
difference in H3K4me3 at Kcnn4 and Gata3. 
I examined methylation, gene expression and H3K4me3 levels for a number of 
intragenic CGIs that show cell type-specific methylation in the immune system. An 
intragenic CGI in the Kcnn4 gene which codes for a potassium channel involved in T 
cell activation, shows increased expression and decreased methylation in Th1 cells 
compared to dendritic cells and B cells (Figure 3.6.1A). I verified the MAP-seq 
methylation data using bisulfite sequencing and found that the Kcnn4 CGI was 20% 
methylated in Th1 cells but 66% and 70% methylated in dendritic and B cells 
respectively (Figure 3.6.1B). The gene expression difference between the cell types 
was confirmed using qRT-PCR (Figure 3.6.1C). H3K4me3 was then profiled across 
the Kcnn4 intragenic CGI using ChIP followed by qPCR. In Th1 cells where the CGI 
is hypomethylated, there is a peak of H3K4me3 enrichment over the CGI. However, 
H3K4me3 is not enriched over this CGI in B cells and dendritic cells where it is 
heavily methylated (Figure 3.6.1D). There is also a methylation difference at the 
Kcnn4 intragenic CGI between CD4 cells and Th1/Th2 cells; consistent with the role 









































































CD4 32% methylated Th1 20% methylated



















































Figure 3.6.1 Decreased CGI methylation corresponds to increased H3K4me3 at the 
Kcnn4 intragenic CGI 
A) MAP-seq profiles (red) for Kcnn4 in CD4, Th1, dendritic and B cells, CGIs (blue bars), region examined 
by bisulfite sequencing (bs, grey bar). B) Confirmation of methylation difference by bisulfite genomic 
sequencing. C) Verification of Kcnn4 gene expression by qRT-PCR. D) ChIP for H3K4me3 across the 
Kcnn4 intragenic CGI in Th1, dendritic cells and B cells. Blue dashes underneath the profile indicate CpG 
density and a schematic of the gene is shown with the direction of transcription indicated by the arrow. 
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A particularly interesting example is that of the Gata3 intragenic CGI as it shows the 
only methylation difference detected between Th1 and Th2 cells (Figure 3.6.2A). 
Bisulfite sequencing was used to more quantitatively assess the extent of this 
methylation difference. In Th1 cells, the Gata3 intragenic CGI was 72% methylated 
and this dropped to 54% in Th2 cells (Figure 3.6.2B; bisulfite sequencing over an 
additional region of this CGI gave a similar result – 76% methylation in Th1 cells 
and 57% in Th2 cells) concomitant with a large increase in Gata3 expression (Figure 
3.6.2C). This drop in methylation associated with an increased level of H3K4me3 
over the CGI in Th2 cells (Figure 3.6.2D). Interestingly, H3K4me3 over the Gata3 
promoter CGI is unchanged in Th1 and Th2 cells despite a difference in gene 
expression and this may be explained by reports that the Gata3 promoter is bivalent 
(i.e. marked by H3K4me3 and the repressive mark H3K27me3) in Th1 cells (Wei et 
al., 2009). Although the Gata3 methylation change in Th2 cells generated in vitro is 
subtle, its biological relevance was confirmed by examining Th2 cells isolated from 
mice infected with the parasitic worm Schistosoma mansoni. CD4+ cells were 
harvested from the spleens of mice that had been infected for 8 weeks and re-
stimulated to produce cytokines. IL-4-producing (i.e. Th2) cells were isolated 
through intracellular staining and FACS sorting. Bisulfite sequencing of the Gata3 
intragenic CGI in IL-4-producing cells showed complete demethylation (8%) of the 
region (Figure 3.6.2B). This may indicate that a longer time period is necessary to 
see methylation changes (the length of the infection is 8 weeks and in vitro Th2 cells 
are differentiated for just one week) which would be consistent with a passive 
demethylation mechanism. Alternatively, Th2 cells generated in culture may be 
phenotypically and functionally distinct from ex vivo Th2 cells generated in response 
to a real infection. When cells from the schistosome infection were re-stimulated a 
population of cells expressing both IL-4 and IFN-γ was generated in addition to IL-4 
single positive cells. The function of these cells is unclear although double positive 
cells have been reported previously (Hegazy et al., 2010). When IL-4+ IFN-γ+ cells 
were examined for methylation at Gata3 they were found to be 44% methylated 












































































































3.6.2 Genome-wide analysis of H3K4me3 in dendritic cells and 
Th1 cells 
These observations prompted us to look genome-wide at H3K4me3 in Th1 and 
dendritic cells to see if increased intragenic CGI methylation always associated with 
decreased H3K4me3 as is the case at the Kcnn4 and Gata3 CGIs. This also allowed 
us to look more generally at patterns of H3K4me3 at intragenic CGIs. ChIP for 
H3K4me3 was carried out in both cell types and enrichment was tested by examining 
the H3K4me3 profile over the c-myc locus which contains an unmethylated CGI. The 
H3K4me3 profile at c-myc was virtually identical in Th1 and dendritic cells with 

























































Figure 3.6.2 Demethylation of the Gata3 intragenic CGI occurs in Th2 cells generated in 
vitro, those isolated from an infection and is associated with increased H3K4me3 
A) MAP-seq profiles (red) for Gata3 in Th1 and Th2 cells. Gata3 is on the antisense strand running 3’ to 5’. 
B) Bisulfite sequencing showing a moderate methylation difference between cultured Th1 and Th2 cells (in 
vitro) and an even greater loss of methylation in IL-4+Ifnγ+ cells and IL-4+ cells from a Schistosome 
infection (infection). C) Verification of increased Gata3 expression in Th2 cells by qRT-PCR. D) ChIP for 
H3K4me3 across the Gata3 promoter and intragenic CGI in Th1and Th2 cells. Both cell types show high 
H3K4me3 at the promoter but Th2 cells alone show a peak over the intragenic CGI in exon 3 (asterisk).  
Figure 3.6.3 Verification of H3K4me3 enrichment at c-myc prior to high throughput 
sequencing 
ChIP for H3K4me3 in dendritic cells and Th1 cells was tested by examining enrichment over the c-myc CGI. 
Blue dashes underneath the profile indicate CpG density and a schematic of the gene is shown with the 
direction of transcription indicated by the arrow. 
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Illumina adaptors were ligated to the ChIP DNA using a protocol optimised in our 
lab for attachment of adaptors to small amounts of DNA. One lane of sequencing 
was carried out for each replicate as described previously and, as before, replicate 
lanes were combined to give two lanes of sequencing for each cell type. Analysis 
was performed on .wig files in a similar manner to that described for MAP-seq data 
in section 3.3. In brief, each sample was normalised to the average amount of 
sequence across all the samples and prominent peaks of enrichment identified. To 
identify regions containing differential H3K4me3 enrichment a sliding window 
analysis over regions of interest was performed. Analysis parameters are outlined in 
Table 3.6.1.  
 
Analysis step Parameters 
Normalisation Scaled to 1.025x10
9
 reads 
Peak-finding H: 4   L: 150   G: 250 
Sliding window 100bp window, 20bp slide 
Identification of differences log2 difference > 2 in 9/13 contiguous windows  
Intragenic CGIs show tissue-specific H3K4me3 
88% of TSS CGIs but just 35% of intragenic CGIs associate with a peak of H3K4 tri-
methylation in dendritic cells and a similar percentage associate with H3K4me3 in 
Th1 cells (Figure 3.6.4A). This is consistent with the fact that intragenic CGIs are 
more frequently methylated than TSS CGIs as dense DNA methylation is not 
compatible with H3K4me3 (Illingworth et al., 2010; Thomson et al., 2010) although 
this is not accounted for by methylation alone. I examined whether intragenic CGIs 
that are not marked by H3K4me3 in immune cells are marked by H3K4me3 in other 
cell types by examining H3K4me3 data for brain (Thomson et al., 2010). 13% of 
intragenic CGIs that were negative for H3K4me3 in dendritic cells were positive for 
H3K4me3 in brain and, similarly, 11.5% of intragenic CGIs lacking H3K4me3 in 
brain were marked by H3K4me3 in dendritic cells (Figure 3.6.4B). This 
Table 3.6.1 Parameters for analysis of H3K4me3 ChIP-seq data 




demonstrates that intragenic CGIs tend to show tissue-specific methylation. In 
contrast, the vast majority of TSS CGIs in both dendritic cells and brain were marked 
by H3K4me3 (88% and 92% respectively) with most TSS CGIs positive for 















































Increased intragenic CGI methylation does not always associate with a decrease in 
H3K4me3 
I looked to see if differential methylation at intragenic CGIs tended to associate with 
changes in H3K4 tri-methylation. 63 intragenic CGIs are differentially methylated in 
dendritic cells compared to Th1 cells and for 11 of these increased DNA methylation 
associated with a decreased level of H3K4me3 similar to what was seen at the Kcnn4 
and Gata3 intragenic CGIs (Figure 3.6.5). Four of these CGIs showed an associated 
decrease in gene expression, for example Kcnn4, but the rest occurred in genes 
whose expression did not change between cell types. Surprisingly, the majority of 
differentially methylated intragenic CGIs (55% or 35 CGIs) lacked H3K4me3 in 
Figure 3.6.4 Intragenic CGIs show tissue-specific H3K4me3 
A) Association of TSS CGIs (left) and intragenic CGIs (right) with H3K4me3 in dendritic cells (DC) and Th1 
cells. B) Most TSS CGIs associate with H3K4me3 in both dendritic cells and brain (left) while intragenic 
CGIs show more tissue-specific H3K4me3 (right).  
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both Th1 and dendritic cells indicating that these CGIs are not permissive for 
transcription in either cell type despite a difference in DNA methylation (Figure 
3.6.5). In addition, some cell-specific methylation occurred at CGIs positive for 
H3K4me3 in both immune cell types (Figure 3.6.5). This observation is, at first 
glance, contradictory to reports that H3K4me3 is not compatible with DNA 
methylation (Illingworth et al., 2010). However, the majority of these CGIs appear to 
be compositely methylated (70% based on CAP-seq data for CD4 T cells; data not 
shown) meaning that they contain unmethylated CpGs that can associate with 


























3.6.3 Differential methylation at intragenic CGIs can reflect a 
difference in silencing mechanism 
Differential methylation frequently occurs at CGIs that lack the “active” chromatin 
mark H3K4me3. For example, a CGI at the 3’ end of the Sema4a gene lacks 
H3K4me3 in both dendritic cells and Th1 cells despite being differentially 
methylated (Figure 3.6.6A and B). This suggests that this CGI is silenced in both cell 
types. An alternative mechanism of repression to DNA methylation is polycomb-
mediated silencing characterised by the presence of H3K27me3. Thomson and 
Figure 3.6.5 Increased intragenic CGI methylation does not always associate with 
decreased H3K4me3 
The number of differentially methylated intragenic CGIs where; increased methylation is associated with a 
decrease in H3K4me3 (yellow), the CGI is negative (red) or positive (green) for H3K4me3 in both cell types 
or either a non-significant change in H3K4me3 is observed (n=5) or increased methylation is associated with 
increased H3K4me3 (n=2) (grey). 
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colleagues found that 58% of CGIs lacking H3K4me3 in mouse brain were marked 
by H3K27me3 (Thomson et al, 2010). In addition, studies have shown that 
H3K27me3 and DNA methylation of CGIs tend to be mutually exclusive (Fouse et 
al., 2008; Mohn et al., 2008). 
Therefore, I used ChIP to look for presence of the repressive mark H3K27me3 at the 
Sema4a intragenic CGI. In dendritic cells, H3K27me3 was detected across the 
Sema4a CGI but this was absent in heavily methylated Th1 cells (Figure 3.6.6D). 
Therefore, this intragenic CGI seems to be repressed by different mechanisms in 
different cell types – DNA methylation in Th1 cells and polycomb in dendritic cells. 
The Sema4a gene is expressed in both Th1 and dendritic cells although expression is 
lower in Th1 cells where the CGI is methylated (Figure 3.6.6C). Another 
differentially methylated CGI lacking H3K4me3 occurs in an intron of the Bcl11b 
gene and this was found to behave like the Sema4a CGI with the unmethylated CGI 
marked by H3K27me3 (data not shown). 
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Figure 3.6.6 The Sema4a intragenic CGI is repressed by DNA methylation in Th1 cells 
and H3K27me3 in dendritic cells 
A) H3K4me3 ChIP-seq (green) and MAP-seq profiles (red) for Sema4a in Th1 and dendritic cells, CGIs 
(blue bars), bisulfite amplicon (grey bar). Sema4a is on the antisense strand running 3’ to 5’. B) Bisulfite 
sequencing confirming the methylation difference between Th1 cells and dendritic cells. C) Sema4a 
expression in Th1 and dendritic cells quantified using qRT-PCR. D) ChIP for H3K27me3 across the CGI.  
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3.7 Intragenic CGIs showing immune-cell specific methylation may 
function as promoters in other cell types 
It has been proposed that intragenic CGIs act as alternative promoters for the 
associated annotated gene (Maunakea et al., 2010) and this would explain the 
observation that cell-specific methylation of these CGI sometimes correlates with 
gene repression. At some intragenic CGIs, for example those associated with Kcnn4 
and Gata3, an association between decreased DNA methylation, increased gene 
expression and increased H3K4me3 was observed. These CGIs represent good 
candidates to act as alternative promoters in immune cells. However, such examples 
represent the minority of cases (4 out of 63 differentially methylated intragenic CGIs 
when dendritic cells and Th1 cells are compared). Based on the fact that the majority 
of differentially methylated intragenic CGIs do not possess H3K4me3 it is unlikely 
that they act as promoters in the immune cells studied. However, these CGIs may act 
as promoters for genes expressed elsewhere, for example during development or in 
other tissue types. To investigate this possibility I examined whether there was 
evidence for promoter function for these intragenic CGIs using Pol II ChIP-seq data 
for ES cells (Illingworth et al., 2010) and CAGE tag data from a panel of mouse 
tissues (Faulkner et al., 2009). Nearly half of intragenic CGIs differentially 
methylated in dendritic cells and Th1 cells (30 out of 63) showed Pol II binding in 
ES cells (which are reflective of an early developmental stage) or showed a cluster of 
CAGE tags, indicative of the 5’ end of a transcript, in a library compiled from a 
panel of tissues that did not include the immune cell types investigated hereviii 
(Figure 3.7.1).  
                                                 
viii The CAGE tag set consisted of data from brain, urogenital tissue, embryonic fibroblasts, muscle, 
hippocampus, liver, lung, hepatoma, embryonic testis, neuroblastoma, adipose tissue, whole embryo 




























In light of a number of recent reports on tissue-specific CGI methylation (Illingworth 
et al., 2008; Meissner et al., 2008; Mohn et al., 2008; Schilling and Rehli, 2007) this 
chapter has examined developmentally related somatic cell types for methylation 
differences and investigated how these relate to gene expression. Cells of the 
immune system were used as a model partly because there have been a number of 
reports of cell-type specific methylation in this lineage (Ivascu et al., 2007; Schmidl 
et al., 2009) and also because pure immune cell types can easily be isolated. 
 
3.8.1 DNA methylation differences reflect developmental 
similarity rather than the gene expression programme 
MAP-seq gave robust methylation profiles of immune system cells which covered 
methylated CGIs as well as other CpG-rich methylated regions. Samples were 
normalised in order to account for variable read depth which allowed quantitative 
assessment of methylation differences between cell types. Methylation differences 
between closely related immune cell types were small in number, both at CGIs and 
non-CGI regions, but may be functionally important given the role of many 
differentially methylated genes in the immune system. Methylation differences 
Figure 3.7.1 Intragenic CGIs differentially methylated in the immune system show 
evidence for promoter function in other tissues 
Intragenic CGIs differentially methylated in dendritic cells and Th1 cells (DC vs Th1) that show evidence for 
function as a TSS based on ES cell Pol II ChIP-seq data or CAGE data from a panel of tissues. 
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showed an inverse correlation with developmental similarity. Closely related Th1 
and Th2 cells showed just a single methylation difference whilst more differences 
were observed between more distantly related immune cells types. Examination of a 
developmentally distinct tissue, brain, revealed thousands of differences compared to 
immune cells. Gene expression differences, however, did not follow the same trend. 
Even closely related cells types such as naïve CD4 and Th1 cells showed a 
considerable difference in their gene expression profiles. Given the sizable number 
of genes that show differential expression in immune cells and the small number of 
methylation changes that occur, it is clear that differential methylation at CpG-rich 
regions does not make a major contribution to regulation of gene expression in 
immune cells.  
 
It is possible that methylation follows developmental similarity because methylation 
patterns are established over the extended time period of development. The large 
gene expression changes associated with immune cell activation are likely to be rapid 
and dependent on transcription factors whereas such a short time frame is insufficient 
to allow extensive methylation changes to take place. However, differential 
methylation of a small number of key immune system genes may be important as 
indicated by the fact that genes showing cell-specific methylation often have immune 
system function. 
 
3.8.2 Cell-specific methylation occurs preferentially at CGIs 
Given that MAP-seq identifies both CGI and non-CGI-associated methylated regions 
and in light of a recent report claiming that the majority of tissue-specific 
methylation occurs at the edges of CGIs (Irizarry et al., 2009), I examined the 
genomic location of the methylation changes. When the small number of methylation 
changes occurring in the immune system were examined these preferentially 
occurred in CGIs rather than at CGI “shores”. As this is a much smaller set of 
changes than those examined by Irizarry et al., I also examined the location of 
differential methylation between brain and CD4 cells. Here, differential methylation 
was also found to be preferentially located in CGIs. Differences between my 
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observations and those of Irizarry and colleagues could be due the fact different 
techniques were used to assess methylation, that different sets of features were 
interrogated (i.e. the features present on a microarray compared to all genomic 
regions amenable to analysis by MAP-seq) or the fact that I have related the data to a 
biochemically identified CGI set rather than a set defined by prediction algorithms. 
For the remainder of the study I chose to focus on differential methylation at CGIs 
both because there is enrichment for methylation changes at CGIs and because CGIs 
represent a distinct and functionally important fraction of the genome.  
 
3.8.3 Intragenic CGIs show the most cell type-specific 
methylation 
Most cell type-specific CGI methylation in the immune system occurs at intragenic 
CGIs which are located in gene bodies but not associated with an annotated TSS. The 
functional implications of methylation at these regions are unclear. Promoter CGI 
methylation has long been associated with gene repression and two recent studies 
have suggested that many intra- and intergenic CGIs represent novel promoters 
(Illingworth et al., 2010; Maunakea et al., 2010). Intragenic and intergenic CGIs 
seem to be distinct with respect to cell type-specific methylation as intragenic CGIs 
more frequently show differential methylation. I examined whether differential 
intragenic methylation affects expression of the associated gene despite the fact that 
it is not located at the TSS. When cell-specific intragenic CGI methylation associated 
with a change in gene expression, in general, increased methylation correlated with 
decreased gene expression suggesting a repressive role for intragenic CGI 
methylation.  
 
3.8.4 Intragenic CGIs showing differential H3K4me3 may act as 
alternative promoters or enhancers 
Why intragenic CGI methylation associates with transcriptional repression is unclear 
given that the relationship between intragenic CGIs and their associated genes is not 
known. I examined if differential methylation at these regions is associated with an 
altered chromatin state. For a number of intragenic CGIs (17.5%) decreased DNA 
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methylation was accompanied by an increase in H3K4 tri-methylation. H3K4me3 
can be targeted to unmethylated CGIs by CFP1 (Thomson et al., 2010). H3K4me3 is 
thought to contribute to a transcriptionally permissive chromatin environment in a 
number of ways including the recruitment of activities involved in histone 
acetylation and ATP-dependent chromatin remodelling (Kim et al., 2006; Li et al., 
2007; Ruthenburg et al., 2007). It has also been reported to target the basal 
transcription machinery (TFIID) to nucleosomes in vitro (Vermeulen et al., 2007). 
How might this chromatin structure affect transcription if it is not located at an 
annotated transcription start site? It has been suggested that the majority of intragenic 
CGIs act as alternative promoters for the associated gene (Maunakea et al., 2010). 
Indeed, this has been found to be the case for an exonic CGI in the MHC class II I-
Aβ gene (Macleod et al., 1998) and intragenic CGIs in the SHANK3 and Nfix genes 
(Maunakea et al., 2010). It is possible that this may also be the case for intragenic 
CGIs such as those located in the Kcnn4 and Gata3 genes where a decrease in 
methylation is associated with an increase in H3K4me3 and an increase in gene 
expression. ChIP for the hypophosphorylated form of Pol II that is recruited to the 
promoter (Brookes and Pombo, 2009), however, gave low signal over the Kcnn4 and 
Gata3 CGIs (data not shown). ChIP with alternative Pol II antibodies or 5’ RACE to 
map transcription start sites will be necessary to determine if these CGIs do indeed 
act as promoters. 
 
Alternatively, intragenic CGIs may function as regulatory elements such that an open 
chromatin conformation helps to promote transcription. Recent studies have 
classified the chromatin state of enhancers occupied by the co-activator p300 and 
found them to lack H3K4me3 but be enriched for H3K4me1 (Heintzman et al., 
2007). Therefore, if intragenic CGIs have enhancer function they must represent a 
distinct class of enhancer which is marked by H3K4me3 and located downstream of 
the transcription start site. Indeed, a study last year identified differentially 
methylated regions in immune cells located outside of promoters but often associated 
with differential H3K4me3. Some of these regions showed evidence for enhancer 




3.8.5 Many intragenic CGIs showing immune cell-specific 
methylation may act as promoters in other cell types 
The majority of differentially methylated intragenic CGIs lack H3K4me3 in immune 
cells, however, implying that they do not act as promoters (or indeed enhancers) in 
the immune system. It is possible that these CGIs act as promoters in other tissues or 
during development. Indeed Pol II binding and CAGE tag data suggest that this is the 
case for many of these differentially methylated intragenic CGIs, consistent with 
reports that the majority of intragenic CGIs associate with sites of transcriptional 
initiation (Illingworth et al., 2010; Maunakea et al., 2010). An attractive hypothesis is 
that expression in early development could help keep intragenic CGIs free of 
methylation and thus maintain their CpG density but that a developmentally 
restricted or highly tissue-specific expression pattern makes them susceptible to 
methylation in somatic cells. Intragenic CGIs as well as showing cell type-specific 
DNA methylation in the immune system are also frequently subject to tissue-specific 
H3K4me3. For example, I have observed that many intragenic CGIs show 
differential H3K4me3 between dendritic cells and brain. These observations imply 
that intragenic CGIs represent a distinct category of genomic element more 
susceptible to tissue-specific regulation than TSS CGIs which frequently associate 
with ubiquitously expressed genes. It is tempting to speculate that many of these 
CGIs may act as promoters for ncRNAs or genes with restricted expression patterns 
which would explain why they have escaped annotation by conventional means. 
  
For intragenic CGIs lacking H3K4me3 differential methylation can reflect the use of 
alternative silencing mechanisms. For example the Sema4a 3’ CGI and a CGI in an 
intron of the Bcl11b gene are marked by H3K27me3 in dendritic cells but subject to 
DNA methylation in Th1 cells. This is consistent with previous reports that at CGIs 
H3K27me3 and DNA methylation tend to act as mutually exclusive silencing 
mechanisms (Fouse et al., 2008; Mohn et al., 2008). 
 
 160 
3.8.6 Intragenic CGI methylation may affect gene expression by 
an indirect mechanism 
A key question remaining is why cell-specific intragenic methylation often associates 
with gene repression. For intragenic CGIs acting as alternative promoters the reason 
for this association is clear, however, most differentially methylated CGIs identified 
here do not seem to act as promoters in immune cells. Intriguingly, it has been 
reported that transcription elongation through densely methylated CpGs is less 
efficient than through unmethylated CpG-rich sequences. Lorincz and colleagues 
inserted a transgene encoding GFP specifically methylated or unmethylated in the 
intragenic region into a defined genomic site. Expression of the transgene was 
reduced by 60% when it was methylated and, consistent with this, levels of 
elongating Pol II were also reduced. Methylation coincided with a four-fold decrease 
in histone acetylation and formation of a more compact chromatin structure (Lorincz 
et al., 2004). This may have been due to the recruitment of MBD proteins to 
methylated DNA which could bring in HDACs and chromatin remodelling activities 
and result in formation of a less accessible chromatin environment which inhibits 
elongation by Pol II. Methylation of intragenic CGIs might also have a similar effect 
and, in some cases, impair transcription elongation through creation of a repressive 
chromatin environment. It is also possible that densely methylated DNA physically 
impairs the passage of Pol II. Such dense intragenic CpG methylation may have 
different effects to the relatively sparse methylation of the bulk genome where gene 
body methylation has been reported to associate with gene activity (Ball et al., 2009; 
Deng et al., 2009; Rauch et al., 2009). Since many intragenic CGIs have evidence for 
promoter function one hypothesis is that they differentially acquire methylation as a 
means of repressing a novel promoter which can sometimes influence expression of 
the associated annotated gene. Mechanistic studies are needed to fully elucidate the 
role of dense intragenic methylation on transcription.  
 
A speculative model to explain the relationship between intragenic CGI methylation 
and gene expression is illustrated in Figure 3.8.1. One hypothesis is that intragenic 
CGIs are promoters for genes expressed only at a particular developmental stage 
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(Figure 3.8.1A) and that these CGIs are silenced in somatic tissues resulting in a loss 
of H3K4me3 and a gain in either DNA methylation (Figure 3.8.1B) or H3K27me3 
(3.8.1C). Intragenic DNA methylation might then, in certain cases, impair 
transcription of the associated annotated gene (Figure 3.8.1B) leading to a 
methylation-dependent reduction in gene expression. However, this model does not 
take into account the fact that polycomb proteins may also impair transcriptional 
elongation (Simon and Kingston, 2009). 
 
TSS Intragenic













I have observed that most cell type-specific methylation occurs at CGIs located in 
intragenic regions and that this is often associated with gene repression. It is likely 
Figure 3.8.1 A possible model to explain differential intragenic CGI methylation 
TSS CGIs are promoters for housekeeping genes or genes with broad expression patterns (grey) and are 
generally unmethylated and marked by H3K4me3 while intragenic CGIs act as promoters for genes 
expressed in early development or in particular cell-types (blue). A) In early development the intragenic CGI 
is unmethylated, marked by H3K4me3 and is an active promoter for this novel gene. B) The intragenic CGI 
is silenced by DNA methylation in a tissue-specific manner which then interferes with transcription of the 
associated annotated gene. C) Alternatively, the CGI can be silencing by polycomb (H3K27me3 mark). K4 = 
H3K4me3, K27 = H3K27me3. The arrow indicates a promoter and the direction of transcription. 
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that there are a number of reasons for this phenomenon but it is clear that intragenic 
CGIs represent a distinct class of genomic element particularly susceptible to cell 




Chapter 4 Regulation of gene expression by  




4.1.1 MBD2 is involved in gene regulation in the immune system 
One of the ways in which methylation exerts its repressive effects is through MBD 
proteins which specifically recognise methylated DNA and recruit chromatin 
modifying activities. Surprisingly, depletion of MBD1 or MeCP2 does not lead to 
many changes in genes expression (Nuber et al., 2005; Tudor et al., 2002; Zhao et al., 
2003). Knockout of MBD2 on the other hand results in gene expression changes in 
all systems tested to date, consistent with a role as a methylation-dependent 
transcriptional repressor (Barr et al., 2007; Berger et al., 2007; Hutchins et al., 2002). 
However, Mbd2-/- mice are viable and fertile suggesting that MBD2 may regulate 
genes involved in inducible processes such as the immune response. In keeping with 
this, a number of immune system defects have been observed in Mbd2-/- mice. In 
vitro T helper cell differentiation is disordered with Mbd2-/- Th1 and Th2 cells 
aberrantly expressing both IFN-γ and IL-4. MBD2 has been reported to directly 
silence the Il4 gene by competing for binding with the Th2 transcription factor Gata-
3 (Hutchins et al., 2002). A follow on study looking at Th1- and Th2-inducing 
infections in vivo showed that Mbd2-/- mice were defective in mounting a Th2 
response against the intestinal worm Trichuris muris but showed enhanced immunity 
to a Th1-type Leishmania infection due to excessive IFN-γ production (Hutchins et 
al., 2005). Defects in the production of CD8 memory T cells in Mbd2-/- mice have 
been reported (Kersh, 2006) and impaired induction of Th2 responses by Mbd2-/- 




4.1.2 Elucidating MBD2 function 
The extent of MBD2’s role in regulating gene expression and the mechanisms 
governing this remain to be elucidated. A major question is the degree to which gene 
expression is perturbed when MBD2 is removed from a physiologically relevant cell 
type and whether this has an effect on chromatin modification. MBD2 exerts its 
repressive effect via the NuRD chromatin remodelling and HDAC complex so it is 
anticipated that changes in gene expression in the absence of MBD2 will also be 
accompanied by changes in the chromatin state. In addition, it is unclear whether 
different patterns of DNA methylation between cell types instruct MBD2 to regulate 
distinct sets of target genes. In many studies cancer cell lines have been used to look 
for MBD2 targets (Auriol et al., 2005; Bakker et al., 2002; Lin and Nelson, 2003; 
Martin et al., 2008; Pulukuri and Rao, 2006). However, as cancer cells frequently 
show abnormal DNA methylation (Jones et al., 1990; Meissner et al., 2008; 
Smiraglia et al., 2001) they are not a suitable system for elucidating the role of a 
methyl-binding protein in a normal cellular context. It is also an advantage to study 
pure cell types rather than tissues as heterogeneous cell populations could mask the 
effects of MBD2 deficiency in a particular cell type. Cells of the immune system are 
primary cell types that can be isolated as relatively homogenous cell populations. In 
addition, MBD2 has been shown to be important for immune system function and 
DNA methylation data already exists for immune cells (chapter 3). For these reasons 
the immune system was chosen as a model in which to study the function of MBD2.  
 
4.1.3 Aim 
The aim of this work is to examine gene expression in Mbd2-/- immune system cells, 
determine histone acetylation patterns genome-wide in Mbd2-/- compared to wild-
type cells as well as to identify where MBD2 binds in the genome and how this 
relates to DNA methylation. It is hoped that this study will help elucidate the role of 





4.2 Results: Mbd2-/- mice show T cell differentiation defects 
 
4.2.1 Intracellular FACS staining confirms previously reported T 
cell differentiation phenotype 
Experiments were carried out with CD4 T cells harvested from the spleens of wild-
type and Mbd2-/- C57/BL6 mice in order to confirm reported differentiation defects 
in the absence of MBD2 (Hutchins et al., 2002). Cells were treated with α-CD3 and 
α-CD28 to mimic T cell activation as well as IL-2 which is important for T cell 
proliferation and either: not treated further (Th0 conditions); treated with IL-12 and 
α-IL-4 (Th1 conditions); or treated with IL-4 and α-IL-12 (Th2 conditions). Cells 
were cultured for 7 days, re-stimulated and cytokine production was assessed by 
intracellular FACS staining. In general, wild-type cells showed production of IFN-γ 
only under Th1 conditions and expression of IL-4 under Th2 conditions. Under both 
Th1 and Th2 conditions, however, Mbd2-/- cells showed a large number of IFN-γ+ 
IL-4+ double positive cells (15% and 38% respectively) compared to wild-type cells 
(1.25% and 7.42%). Mbd2-/- cells also showed a larger number of double positive 
cells under Th0 conditions (Figure 4.2.1). Aberrant expression of the Th1 and Th2 
signature cytokines during in vitro differentiation of Mbd2-/- T helper cells has 
previously been reported (Hutchins et al., 2002). This confirms previous reports that 
Mbd2-/- T cells fail to appropriately silence the Ifng and Il4 genes during 
differentiation (Hutchins et al., 2002). It was also noted that proliferation of Mbd2-/- 















4.2.2 qRT-PCR shows that the Ifng and Il4 genes are mis-
expressed in the absence of MBD2 
RNA was extracted from Th1 and Th2 cell cultures as well as from naïve CD4 cells 
and the expression levels of Ifng and Il4 in wild-type and MBD2-deficient animals 
assessed by qRT-PCR. Although this technique can not assess the proportion of cells 
expressing both IFN-γ and IL-4 it gives a measure of the magnitude of the difference 
in Ifng and Il4 RNA levels between wild-type and Mbd2-/- cells. As expected, Mbd2-
/- Th1 cells mis-expressed the Th2 cytokine gene Il4 (8-fold increase compared to 
wild-type; Figure 4.2.2B) while Mbd2-/- Th2 cells expressed twice as much of the 
Th1 cytokine gene Ifng as wild-type Th2 cells (Figure 4.2.2A). Both wild-type and 
Mbd2-/- Th1 and Th2 cells appropriately expressed their own signature cytokine 
Figure 4.2.1 Recapitulation of T cell differentiation defects in Mbd2-/- cells 
Results of T cell differentiation under different conditions (Th0, Th1, Th2) are shown for wild-type cells (WT; 
top) and Mbd2-/- cells (Mbd2-/-; bottom). Staining for IFN-γ production is shown on the x-axis with IL-4 on 
the y-axis. IFN-γ+ IL-4+ double positive cells are located in the top right hand quadrant. 
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gene (Figure 4.2.2A and B) but levels were slightly lower in the Mbd2 nulls, 
although not to a statistically significant degree. This reduction may be due to 
inhibition mediated by over-expression of the opposing signature cytokine in the 
Mbd2 nulls.  

















































































































































































































































































































































































































































4.3 Mbd2-/- mice show additional immune system phenotypes 
 
4.3.1 T helper cell proliferation is reduced in the absence of MBD2 
During T helper cell differentiation experiments it was observed that Mbd2-/- CD4 
cells exhibit reduced proliferation in response to stimulation and IL-2 treatment. We 
therefore examined proliferation of Mbd2-/- CD4 cells (C57/BL6 background) more 
closely by monitoring incorporation of tritiated (3H) thymidine after stimulation 
Figure 4.2.2 qRT-PCR shows that mis-expression of Ifng and Il4 in Mbd2-/- T cells 
occurs at the RNA level 
A) Ifng expression and B) Il4 expression in wt and Mbd2-/- naïve CD4, Th1 and Th2 cells relative to Eef1A1 




under Th0, Th1, Th2 and Treg conditionsix. Regulatory T cells (Tregs) are a distinct 
class of CD4  T cell which are involved in modulation of the immune response (Tang 
and Bluestone, 2008). Mbd2-/- cells showed reduced incorporation of 3H compared 
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The proliferation defect was examined further under Treg differentiation conditions 
by labelling CD4 cells with the fluorescent molecule CFSE (carboxyfluorescein 
diacetate succinimidyl ester) and FACS staining to follow cell division after 
stimulation and treatment with TGF-β. After three days, Mbd2-/- Treg cell cultures 
contained more cells that had under gone 0, 1 or 2 cell divisions and less that had 
undergone 3 or more divisions compared to cultures of wild-type cells (Figure 4.3.2). 
                                                 
ix Note: All proliferation (section 4.3.1) and Treg (section 4.3.2) experiments were carried out in 
conjunction with John Grainger (Institute for Immunology and Infection Research, University of 
Figure 4.3.1 Mbd2-/- CD4 cells show reduced proliferation during T cell differentiation 
CD4 cells from wild-type, Mbd2+/- and Mbd2-/- cells were stimulated, treated with IL-2 and cultured under 
Th0 (no skewing cytokines), Th1 (IL-12, α-IL-4), Th2 (IL-4, α-IL-12) or Treg (TGF-β1) conditions. 
3
H-
thymidine was added to the media and incorporation assessed after 48 hours by scintillation counting. CPM 







4.3.2 Mbd2-/- mice show altered Treg cell phenotypes both in vitro 
and in vivo 
Expression of the key transcription factor controlling Treg cell fate, Foxp3 has been 
reported to be regulated by DNA methylation (Baron et al., 2007; Floess et al., 2007; 
Josefowicz et al., 2009; Kim and Leonard, 2007; Lal et al., 2009; Nagar et al., 2008; 
Polansky et al., 2008). This prompted us to examine whether removal of MBD2 
would affect generation of Treg cells. It is possible to differentiate Tregs from CD4 
cells in vitro in a similar manner to Th1 and Th2 cells through activation of cells and 
treatment with recombinant TGF-β (Chen et al., 2003; Fantini et al., 2004). We 
assessed Treg generation (on a BALB/c background) at various concentrations of 
TGF-β1 (0.01-10ng/ml) by FACS staining for Foxp3 expression. Mbd2-/- CD4 cells 
gave rise to more Tregs than wild-type cells with the greatest difference seen at a 
concentration of 1ng/ml TGF-β1 (69% versus 34%; Figure 4.3.3A). Minimal 
expression of Foxp3 was seen in the absence of TGF-β1 in both cell types (data not 
shown). This suggests that either Mbd2-/- CD4 cells are hyper-responsive to TGF-β 
                                                                                                                                          
Edinburgh). 
Figure 4.3.2 CFSE labelling shows that Mbd2-/- T cells divide less in response to 
stimulation and TGF-β  
CD4 cells from wild-type and Mbd2-/- cells were stimulated, treated with IL-2 and cultured under Treg 
conditions (TGF-β1; 1ng/ml). CFSE was added to the cultures so that cell division could be followed by 
examining associated reduction of the fluorescent signal by FACS staining. “Generation” represents the 
number of cell divisions undergone by a population of cells. Wild-type = white bars, Mbd2-/- = pink bars. 
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or that they have a propensity to activate Foxp3 perhaps due to ineffective Foxp3 
silencing in the absence of MBD2. Increased Treg differentiation in the absence of 
MBD2 was observed in three separate experiments but did not occur in two 
subsequent experiments performed. This could perhaps be due to incomplete 
penetrance of the phenotype (perhaps related to individual variation between mice) 
or a change in the health status of the Mbd2-/- animals.  
 
Although Tregs can be generated from naïve CD4 cells as described above, they are 
also produced as a distinct cell lineage in the thymus (Tang and Bluestone, 2008). 
We therefore looked at CD4 T cells isolated from the mesenteric lymph nodes of 
naïve mice to see if the absence of MBD2 had an effect on the number of Tregs 
generated in vivo. A greater proportion of Foxp3+ Tregs were found in Mbd2-/- mice 
than in wild-type animals (on average 18% versus 14%) but, in particular, more 
“active” Tregs were produced as indicated by the presence of the homing marker 
CD103 (Finney et al., 2007) on Foxp3+ cells (71% versus 28% CD103+; Figure 
4.3.3B). Infection by the intestinal helminth Heligmosomoides polygyrus results in 
production of Treg cells which are induced by the parasite in order to suppress the 
immune response and thus evade elimination (Finney et al., 2007). We examined 
whether the increased number of Foxp3+ CD103+ Tregs in Mbd2-/- mice led to an 
increased susceptibility to H. polygyrus infection. A trend towards increased worm 
burden was seen in the duodenum of Mbd2-/- compared to wild-type mice after a 2 
week H. polygyrus infection (Figure 4.3.3C). However, this difference did not reach 
statistical significance (p>0.05; Student’s t-test) and survival and cytokine 
production in Mbd2-/- mice were not compromised (data not shown). Interestingly, 
the difference in the number of Foxp3+ CD103+ cells between wild-type and Mbd2-
































































































Figure 4.3.3 Mbd2-/- mice show altered generation of Tregs in vitro and altered Treg 
phenotypes in vivo 
A) Generation of Tregs in vitro by treatment with TGF-β. CD4 cells from wild-type and Mbd2-/- mice were 
treated with various concentrations of TGF-β (0.01-10ng/ml) and Treg production assessed by intracellular 
FACS staining for Foxp3. B) Staining of CD4 cells isolated from the mesenteric lymph nodes for Foxp3 and 
CD103. The left hand panels show representative cytokine stains from one wild-type and one Mbd2-/- 
mouse while the graphs on the right summarise data obtained from 10 mice of each genotype in two 
independent experiments. Results of Student’s t-test: * *p<0.01 C) Number of worms isolated from wild-type 
and Mbd2-/- H. polygyrus-infected mice. Black dots represent individual animals and the bars represent the 
mean for each group.  
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It has been reported that MBD2 binds to a differentially methylated CGI upstream of 
the Foxp3 locus and thus helps silence the gene in naïve CD4 cells when it is not 
needed (Lal et al., 2009). However, this CGI is located more than 5kb upstream of 
the Foxp3 gene and is associated with the 5’ end of another transcript. Subsequent 
studies have failed to repeat the differential methylation reported and found this CGI 
to be constitutively unmethylated (Josefowicz et al., 2009). However, a number of 
other differentially methylated regions have been identified in the Foxp3 locus one of 
which, an intronic CpG-rich region, has been reported to bind MeCP2 (Kim and 
Leonard, 2007). Unfortunately it is not possible to perform ChIP to test MBD2 
binding at this region for reasons discussed in section 4.7. Therefore it remains 
unclear how MBD2 contributes to gene regulation in Tregs and what the relationship 
is between the increased number of Tregs generated in response to TGF-β in vitro 
and the increased number of CD103+ Foxp3+ Tregs generated in vivo. TGF-β is 
involved in both in vitro Treg induction (Chen et al., 2003; Fantini et al., 2004) and 
in CD103 expression (El-Asady et al., 2005; Robinson et al., 2001) so it is possible 
that this provides a link between the two phenotypes. The variability of the in vitro 
Treg induction phenotype in Mbd2-/- mice also needs to be addressed. Nevertheless, 
these Treg phenotypes point to further involvement for MBD2 in the immune 
system.  
 
4.3.3 Mbd2-/- mice show increased susceptibility to oesophageal 
infection 
Histopathological examination of organs from wild-type and Mbd2-/- mice on a 
BALB/c background revealed hyperplasia and infiltration of eosinophils and 
lymphocytes specifically in the oesophagus of Mbd2-/- mice. Five out of six Mbd2-/- 
mice over 60 days of age were affected while younger Mbd2-/- mice and wild-type 





It was initially thought that this represented a spontaneous condition similar to the 
human condition eosinophilic oesophagitis which is characterised by upregulation of 
the chemokine eotaxin-3 and is associated with Th2 cytokine production (Blanchard 
et al., 2006). Since mice lack a homologue of the eotaxin-3 gene we examined 
expression of the gene encoding eotaxin-1 (Ccl11) which also acts as a eosinophil 
chemoattractant (Borchers, 2002) to investigate whether it might contribute to the 
oesophageal phenotype. Eotaxin-1 was upregulated in all six Mbd2-/- mice examined 
(aged 75-90 days) compared to wild-type mice (Figure 4.3.5A). In order to more 
thoroughly assess gene expression changes in the Mbd2-/- oesophagus, microarray 
analysis was performed (NimbleGen mm8_60mer_expression array) in triplicate on 
Figure 4.3.4 Mbd2-/- BALB/c mice show immune cell infiltration of the oesophagus 
H&E stained sections of oesophagus from A-C) Mbd2-/- and D-F) Wild-type mice. Lymphocytes (asterisk) 
and eosinophils (arrow) were observed in male and female Mbd2-/- mice over 60 days of age. 
[Histopathology by D. Brownstein]. 
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pools of male and female animals with an average age of 85 days. A total of 304 
transcripts were upregulated and 94 transcripts downregulated in Mbd2-/- 
oesophagus compared to wild-type, including many genes with immune system 



































































Gene Description Fold upregulation 
Sprr2e Small praline-rich protein 2E 162 
Uox Urate oxidase 145 
Defb3 Defensin beta 3 52 
Ear5 Eosinophil-associated ribonuclease 5 33 
IL-19 Interleukin 19 25 
Ccl8 Chemokine (C-C motif) ligand 8 11 
Cxcl2 Chemokine (C-X-C motif) ligand 2 9 
 
GO Biological process p-value 
Immune response 3.59E-22 
Inflammatory response 3.69E-08 
Antigen presentation 4.95E-05 
Immune cell chemotaxis 0.0419 
Figure 4.3.5 Gene expression in the Mbd2-/- oesophagus 
A) Eotaxin-1 expression in wild-type (wt) and Mbd2-/- (M2-/-) oesophagus. Expression is relative to Gapdh 
and error bars represent standard deviation from PCR replicates. B) A selection of genes upregulated in 
Mbd2-/- oesophagus compared to wild-type identified using NimbleGen expression arrays. C) GO terms 





This analysis of the Mbd2-/- oesophagus phenotype was carried out on mice just 
prior to a rederivationx of our transgenic mouse lines due to a pinworm infection in 
the animal unit. It was decided to re-examine the oesophagus phenotype in the re-
derived Mbd2-/- mice. Mbd2-/- mice on both a C57/BL6 and BALB/c background 
were examined. C57/BL6 mice are bred as heterozygotes which allowed wild-type 
littermates to be used for controls. As the Mbd2-/- BALB/c mice are maintained as a 
homozygous line, wild-type controls were co-housed with Mbd2-/- animals for two 
weeks prior to analysis to control for any environmental variation. All five of the 
Mbd2-/- BALB/c mice examined (aged 85-92 days) showed the oesophageal 
phenotype observed previously but, surprisingly, so did two out of five wild-type 
animals examined (aged 85 days). This suggests that this is not a spontaneous 
phenotype but rather reflects increased susceptibility of Mbd2-/- mice to an unknown 
oesophageal infection. None of the wild-type or Mbd2-/- C57/BL6 mice examined 
displayed the oesophagus phenotype indicating either that this genetic background is 
resistant to the infection or that the C57/BL6 mice were not exposed to the 
oesophageal pathogen. Background-specific immune responses have been observed 
previously between BALB/c and C57/BL6 mice (Reiner and Locksley, 1995). 
 
The increased susceptibility of Mbd2-/- mice to oesophageal infection is in keeping 
with the numerous immune system phenotypes observed in these mice including the 
compromised immune responses observed previously [(Hutchins et al., 2005) and P. 
Cook, unpublished]. However, it seems likely that the gene expression differences 
observed in Mbd2-/- oesophagus are not due to direct regulation of these genes by 
MBD2 but can be attributed to infiltrating immune system cells induced by the 
infection. 
 
                                                 
x The rederivation involved transfer of pre-implantation embryos into pseudopregnant females and 
was carried out to establish specific pathogen free mice. 
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4.4 Results: Gene expression changes in the absence of MBD2 
The immune system phenotypes observed in Mbd2-/- mice prompted us to use 
immune cells as a model in which to explore gene expression changes occurring in 
the absence of MBD2. 
 
4.4.1 Wild-type and Mbd2-/- immune cells show differences in 
gene expression 
Dendritic cells, B cells, naïve CD4, Th1 and Th2 cells were purified from Mbd2-/- 
C57/BL6 mice as described in section 3.2. RNA was extracted from these cells, 
labelled and hybridised to Illumina BeadChips (WTCRF) in parallel with the wild-
type samples used in chapter 3. Microarray analysis was carried out as described in 
section 3.4 and genes showing at least a 2-fold change in expression between wild-
type and Mbd2-/- cells were selected as differentially expressed. In general, modest 
numbers of gene expression differences were seen between wild-type and MBD2-
deficient cells although the number of differences varied between cell types. For 
example, quiescent naïve CD4 cells showed just 16 changes while activated Th1 
cells showed 93 changes between wild-type and Mbd2-/- cells. The greatest number 
of differences were seen between wild-type and Mbd2-/- dendritic cells (218 
differences) pointing to a prominent role for MBD2 in these cells. In most cases 
genes showing expression changes in the absence of MBD2 were upregulated, 
consistent with MBD2’s function as a transcriptional repressor (Figure 4.4.1 and 
Table 4.4.1). These data suggest that the removal of MBD2 does not have a global 
effect on gene expression but results in upregulation of a moderate number of genes. 
This could indicate that MBD2 does not have many target genes in the cell or that in 
the absence of MBD2 other silencing mechanisms can compensate, as has been 











































































































Cell type RefSeq genes changed in 
Mbd2-/- vs WT 
Upregulated genes 
DC 218 208 
B cell 32 32 
Naïve CD4 16 14 
Th1 93 71 
Th2 58 31 
 
In section 4.2, mis-expression of the key cytokine genes Ifng and Il4 was observed in 
the absence of MBD2, consistent with the reports of Hutchins and colleagues (2002). 
These genes were also found to be upregulated by the microarray study (Ifng was 
Figure 4.4.1 Comparison of gene expression in wild-type and Mbd2-/- immune cells 
Pair-wise comparison plots depicting gene expression in wild-type (WT) and Mbd2-/- dendritic cells (DC), B 
cells, naïve CD4, Th1 and Th2 cells. Each dot represents a unique probe on the array and probes located 
outside of the green lines show at least a 2-fold difference in expression. The scale is log2 of intensity 
values. 
Table 4.4.1 Gene expression differences between wild-type and Mbd2-/- cells 
For each cell type the number of RefSeq genes showing at least a 2-fold expression difference between 




upregulated 1.5-1.95-fold in Mbd2-/- Th2 cells and Il4 was upregulated 4-fold in 
Mbd2-/- Th1 cells). Consistent with a perturbed cell identity in these cells, Mbd2-/- 
Th1 cells mis-expressed a number of additional Th2-specific genes (8 genes; 
including Lat2, C3 and Il17f) while Mbd2-/- Th2 cells over-expressed some Th1-
specific genesxi (6 genes in total; including Ifitm1, Ctsw and Fh12). 
 
4.4.2 Validation of microarray results 
The array results for several genes were verified by qRT-PCR using Eef1A1 
expression as a reference (see section 3.4.3). Genes that changed expression in each 
of the immune cells types were tested and for each, qRT-PCR data confirmed 
microarray results. Verification was performed for 4 genes that change expression in 
Mbd2-/- naïve CD4 cells, 7 genes changed in both Th1 and Th2 cells, 5 genes 
changed in dendritic cells and 3 that change expression in Mbd2-/- B cells. A 
selection of these; Ppic, Il4i1, Il8ra and Ptpn14 is shown in Figure 4.4.2. 
                                                 
xi Th1-specific genes are those that are upregulated at least 2-fold in wild-type Th1 cells compared to 

















































































































































































































































































































































































































4.4.3 Absence of MBD2 affects different genes in different 
immune cell types 
We chose to focus on upregulated genes as these may be directly repressed by 
MBD2 and looked to see if the same genes are upregulated in the absence of MBD2 
in different cell types. Th1 and Th2 cells share the greatest number of MBD2 targets 
Figure 4.4.2 Validation of microarray results by qRT-PCR 
A) Ppic expression in wt and Mbd2-/- naïve CD4 cells B) Il4i1 in Th1 and Th2 cells C) Il8ra in dendritic cells 
D) Ptpn14 in B cells. For each, the top panel shows qRT-PCR relative to Eef1A1 (error bars = standard 
deviation from PCR replicates) and the bottom panel shows the absolute intensity value from the BeadChip 
arrays averaged across replicates. 
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with 16 genes upregulated in both Mbd2-/- Th1 and Th2 cells. This is consistent with 
the similar transcriptional profiles of Th1 and Th2 cells (see section 3.4). However, 
when more distant cell types were compared, very few of the same genes were 
changed in the absence of MBD2. For example, dendritic cells show 208 genes 
upregulated by at least 2-fold in the absence of MBD2 but only 7 of these are also 
upregulated in Mbd2-/- Th1 cells. Therefore, in general, removal of MBD results in 
different expression changes in different cell types.  
 
4.5 Results: ChIP for MBD2 was not successful 
In order to properly assess the number of MBD2 target genes and their relationship 
to DNA methylation it is necessary to determine where MBD2 binds in the genome 
not just which genes are mis-regulated in its absence. Once binding sites are known, 
one can assess whether MBD2 binds different targets in different cell types as the 
gene expression data suggest and if differential binding is directed by DNA 
methylation or involves other factors. 
 
4.5.1 Purification and testing of MBD2 antibodies 
ChIP involves cross-linking proteins to DNA followed by antibody-mediated 
isolation of a protein of interest and recovery of bound DNA sequences. In order to 
successfully carry out ChIP the antibody used must be specific for the protein of 
interest and be able to recognise its epitope after cross-linking. The α-MBD2 
antibody S923 was raised in sheep against an N-terminally truncated form of 
MBD2a-GST and has been shown to specifically immunoprecipitate MBD2a without 
cross-reacting with closely related MBD3 (Ng et al., 1999). In addition, it has been 
used previously in MBD2 ChIP studies (Barr et al., 2007; Berger et al., 2007; 
Hutchins et al., 2002). Western blot analysis using this antibody to probe cell extracts 
from mouse tail fibroblasts (MTFs) revealed a number of non-specific bands in 
addition to MBD2a (Figure 4.5.1). As one of the previously reported MBD2 ChIP 
experiments used affinity purified antibody (Berger et al., 2007) I decided to affinity 
purify S923 serum in order to remove antibody activity that was not specific for 
 
 181 
MBD2a. Initial attempts involved coupling GST-tagged recombinant human MBD2a 
(N-terminal fragment, amino acids 1-151) to an Affi-Gel matrix (Bio-Rad), binding 
the anti-serum and eluting antibody with specificity for MBD2a at low pH. However, 
coupling of recombinant MBD2 to Affi-Gel was inefficient (approximately 30% of 
recombinant MBD2 bound) and low yields of purified antibody were obtained 
(200µg of antibody was recovered from 2ml of serum). In addition, MBD2 signal by 
Western blot was weaker than when the unpurified serum was used and ChIP for 
MBD2 at known targets proved unsuccessful (data not shown). Further attempts to 
affinity purify S923 including using a different fragment of MBD2 (mouse MBD2 
amino acids 10-156) and coupling recombinant MBD2 to CNBr beads rather than 






Therefore, as an alternative to affinity purification, it was decided to purify IgG 
molecules from the serum in order to remove contaminating proteins and to 
concentrate the antibody activity. This was carried out using protein G which has 
specific affinity for the Fc domain of IgG molecules from many species including 
sheep. High yields of concentrated IgG were obtained from S923 serum using this 
method (concentration = 3.4mg/ml, 5mg IgG recovered from 2ml serum). I tested 
whether this antibody could immunoprecipitate MBD2a after cross-linking of MTF 
Figure 4.5.1 Western blot with S923 antibody gives non-specific bands in addition to 
MBD2 
Western blots in wild-type and Mbd2-/- MTFs using unpurified S923 serum shows that the antibody 
recognises MBD2 (arrow) but also recognises proteins that are not MBD2 as evidenced by the number of 
bands in the Mbd2-/- sample. 
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cell extracts using 1% formaldehyde. Mbd2-/- MTFs were used as a control to ensure 
that MBD2a specifically was being recognised. Immunoprecipitates were analysed 
by Western blot by probing with another MBD2 antibody R593 (Ng et al., 1999). 
Protein G-purified S923 pulled-down approximately 5-10% of MBD2a protein after 
cross-linking and, as expected, no band was seen for MBD2a in Mbd2-/- MTFs 
(Figure 4.5.2). This confirmed that S923 can immunoprecipitate MBD2. However, 
efficiency was low possibly due to the fact that some epitopes were obscured by 
cross-linking of MBD2 to other NuRD components. A similar percentage of MBD2 
was precipitated when cross-linked immunoprecipitation (IP) was carried out in 
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4.5.2 MBD2 ChIP was attempted at known targets 
I tried to repeat previously published MBD2 ChIP results using the purified S923 
antibody. MBD2 has been reported to bind the promoter of the TFF2 gene (which 
codes for a secretory protein expressed in the gastrointestinal mucosa) in the 
HCT116 human colon cancer cell line (Berger et al., 2007). I carried out ChIP for 
MBD2 over this region (Figure 4.5.3A) using MBD2-depleted cells (80% 
Figure 4.5.2 S923 can immunoprecipitate MBD2 after formaldehyde cross-linking 
Western blot for MBD2 (R593 antibody) on input from IP (inp, 5%), the fraction immunoprecipitated by 
purified S923 (IP, 25%) at various antibody concentrations (5, 10, 25µg) or S923 serum and the unbound 
fraction from the IP (5, 10, 25µg antibody, S = serum). MBD2a runs at 49kDa and no signal is seen for an IP 
in Mbd2-/- MTFs. Non-specific bands are indicated by the asterisk. 
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knockdown of MBD2 at the protein level) as a control for antibody-specificity. ChIP 
carried out in parallel using an antibody against histone H3 (Abcam) acted as a 
positive control while ChIP with pre-immune serum was used as a negative control. 
Surprisingly, the purified S923 antibody gave no enrichment for MBD2 over any of 
the three regions of the TFF2 promoter interrogated. ChIP signal in wild-type 
HCT116 cells was low (<0.01% of input DNA) and comparable to the signal seen 
when pre-immune serum was used for immunoprecipitation. In addition, signal did 
not decrease in the MBD2 knockdown cells (Figure 4.5.3B). Using crude S923 
serum gave similar results (data not shown). However, histone H3 was successfully 





















































Figure 4.5.3 ChIP for MBD2 at the TFF2 locus in HCT116 cells 
A) Regions of the TFF2 promoter interrogated by ChIP. Black lines indicate CpG residues. (Taken from 
Berger et al., 2007) B) ChIP using pre-immune serum (PI, negative control) and α-MBD2 (purified S923). C) 
ChIP for histone H3 (positive control). Wt = wild-type cells, shMBD2= cells where MBD2 was depleted by 
shRNA. Error bars = standard deviation from PCR replicates. 
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I concluded that the S923 antibody is unable to recognise MBD2 at the TFF2 locus. 
This could be due to the fact that the antibody pulls down only a small fraction of 
MBD2 present in the cell and thus is below the detection limit for ChIP. 
Alternatively, TFF2 may not actually be a direct target of MBD2.  
 
To assess whether I am simply looking at the wrong genomic location for MBD2 
binding I attempted to repeat ChIP for MBD2 at another published target, the Xist 
gene in male MTF cells (Barr et al., 2007). Two primer pairs spanning the Xist 
promoter (FR2 and FR3) were used to test DNA immunoprecipitated using purified 
S923. ChIP gave no enrichment for MBD2 at Xist in wild-type compared to Mbd2-/- 
cells with signal for MBD2 close to background levels (Figure 4.5.4A). Primers 
spanning a more extensive 9kb region of the Xist locus also failed to detect MBD2 
binding (data not shown). I then tested a range of other MBD2 antibodies by 
performing ChIP at the Xist promoter in MTFs. These included crude S923 serum, 
R593 antibody, ChIP grade α-MBD2 from Abcam (Phesse et al., 2008) and α-MBD2 
from Imgenex (Le Guezennec et al., 2006) (Figure 4.5.4B and C) as well as 
antibodies received from Paul Wade and Irina Stancheva (data not shown). None of 
the antibodies tested gave specific enrichment in wild-type compared to Mbd2-/- 
MTF cells and in general signal was similar to the levels seen for pre-immune serum 
and purified S923. Custom antibodies raised against peptides from the MBD2 protein 
were produced in conjunction with Cambridge Research Biosciences but these failed 

































































































































The lack of ChIP signal observed for MBD2 at Xist prompted us to examine 
additional genomic locations for MBD2 binding. MBD2 binding has been reported at 
two regions of the Il4 locus, conserved non-coding sequence 1 (CNS-1) and the 
Figure 4.5.4 ChIP for MBD2 at the Xist locus in MTFs  
A) Schematic of the Xist promoter. Grey bars indicate primer positions and the blue lines indicate CpG 
residues. B) ChIP for MBD2 at the Xist promoter (FR2 and FR3) carried out with pre-immune serum (PI) and 
purified S923 (S923) in wild-type and Mbd2-/- MTF cells. C) ChIP at Xist FR3 using pre-immune (PI), 
unpurified S923 (S923 serum), purified S923 (S923 pure) and Abcam α-MBD2 (Abcam). D) ChIP using pre-




intronic enhancer (2IE) in mouse Th1 cells (Hutchins et al., 2002). However, I failed 
to detect MBD2 binding at these regions (Figure 4.5.5A). Major satellite is highly 
methylated repetitive DNA which is organised into heterochromatic foci in mouse 
cells. Since, MBD2 has been shown to localise to these foci by immunofluorescence 
(Hendrich and Bird, 1998), we tested whether we could detect MBD2 binding by 
ChIP at the major satellite repeat. However, similar signal was seen in wild-type and 
Mbd2-/- MTF cells indicating no specific enrichment for MBD2 (Figure 4.5.5B).   
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There are a number of explanations for why MBD2 binding could not be detected at 
Xist or any of the other regions tested. One is that these regions, despite published 
ChIP data and expression differences in the absence of MBD2, are not actually 
bound by MBD2. Alternatively, the antibodies tested may not immunoprecipitate 
Figure 4.5.5 ChIP for MBD2 at Il4 and major satellite  
A) MBD2 ChIP at CNS-1 and the second intronic enhancer (2IE) of the Il4 gene carried out in wild-type and 
Mbd2-/- Th1 cells. B) ChIP at major satellite in MTFs. Cont = negative control (rabbit IgG) and S923 = 
purified S923. Error bars = standard deviation from PCR replicates 
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enough MBD2 to be detectable by ChIP or MBD2 may not be efficiently cross-
linked to DNA so that despite MBD2 pull-down bound DNA is not recovered. 
 
4.5.3 ChIP-chip for MBD2 did not identify convincing targets 
To test the first possibility I hybridised ChIP DNA (obtained using the purified S923 
antibody) from wild-type and Mbd2-/- CD4 T cells to NimbleGen CpG island plus 
promoter arrays to see if we could identify any MBD2 target genes. These arrays 
consist of tiled probes covering 1.3kb upstream and 500bp downstream of all RefSeq 
promoters and UCSC-annotated CpG islands. Microarray analysis was carried out by 
R. Illingworth and 7 regions were identified that showed enrichment for consecutive 
probes in wild-type compared to Mbd2-/- CD4 cells. Two of these regions were 
associated with methylated CGIs based on MAP-seq in CD4 cells (Table 4.5.1).  
 











0.02031 -0.1195 Inhbb 
 
yes  no 
chr1:172994070-
172996091 





0.1985 -0.05886 Rai1 
 
yes  yes 
chr13:37916607-
37919761 

















0.10250 -0.02093 Nkx6-2 
 
yes no 
PCR primers were designed against some of these regions and MBD2 binding tested 
by ChIP combined with qPCR in wild-type and Mbd2-/- T cells. None of the regions 
tested (Fcgr3, Ptch1, Eef2k, Nkx6-2 – two genomic regions for each) showed 
enrichment for MBD2 in wild-type compared to Mbd2-/- CD4 cells implying that the 
ChIP-chip results are artefacts. A selection of the ChIP-qPCR results are shown in 

































































Table 4.5.1 Potential MBD2 binding sites identified by ChIP-chip in CD4 cells 
Regions enriched for ChIP signal in wild-type compared to Mbd2-/- T cells. For each region, genomic 
location, median signal in wild-type and Mbd2-/- cells, associated gene, CGI association and methylation 
status as determined by MAP-seq in CD4 cells is shown. 
Figure 4.5.6 Testing MBD2 ChIP-chip results by ChIP-qPCR 
ChIP was carried out using a negative control (cont; rabbit IgG) and purified S923 and tested using primers 
located in A) Fcgr3 B) Eef2k and C) Nkx6-2. Error bars = standard deviation from PCR replicates 
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My inability to identify any bona fide MBD2 targets using this microarray-based 
approach suggests that the S923 antibody is not capable of immunoprecipitating 
enough MBD2 to give a specific signal in ChIP experiments or that cross-linking of 
MBD2 to DNA is inefficient. 
 
4.5.4 ChIP using FLAG-tagged MBD2 failed to identify specific 
binding sites 
To circumvent the issue of antibody efficiency in MBD2 ChIP (S923 only recovers 
5-10% of MBD2 in the cell) I made use of Mbd2-/- MTF cells where FLAG-tagged 
MBD2 has been introduced by retroviral infection (Barr et al., 2007). Cross-linked IP 
in these cells using α-FLAG-coupled beads (Sigma) pulled down the majority of 


















Since α-FLAG antibody was much more efficient at pulling down MBD2 than S923 
I tested whether it could detect MBD2 binding over the Xist promoter in these cells. 
ChIP over the Xist promoter using primers FR2 and FR3 gave a 2.5 to 3-fold 
enrichment of signal in the FLAG-MBD2 cells compared to the Mbd2-/- cells. 
Surprisingly a ChIP signal for MBD2 was also seen over the unmethylated CGI of 
the active gene ActB although the enrichment in FLAG-MBD2 cells compared to 
Figure 4.5.7 Cross-linked immunoprecipitation of FLAG-MBD2 
α-FLAG beads efficiently immunoprecipitate MBD2 in Mbd2-/- MTFs infected with FLAG-MBD2. Both 
MBD2a and MBD2b are recovered (IP, 25%) and are depleted in the unbound fraction (Un, 5%). 
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Mbd2-/- cells was less than at Xist (Figure 4.5.8A). This could indicate non-specific 
binding of FLAG-MBD2 which is expressed at approximately five times the 
endogenous level in these cells (data not shown). To test this possibility further I 
performed ChIP over a 9kb region encompassing the Xist CGI in FLAG-MBD2 and 
Mbd2-/- cells. The ChIP signal was higher in the FLAG-MBD2 cells compared to 
Mbd2-/- cells throughout most of the region with a slight increase over the 






















































Subsequent studies in the lab have shown that FLAG-MBD2 binding to the Xist CGI 
can be detected only when the protein is expressed at least five times the endogenous 
level (H. Owen, unpublished results). One explanation for this result is that, when 
over-expressed, a large proportion of MBD2 does not associate with the other NuRD 
Figure 4.5.8 FLAG ChIP across Xist 
ChIP using α-FLAG in FLAG-MBD2 and Mbd2-/- MTFs at A) Xist promoter (FR2 and FR3) and the ActB 
promoter B) Across a 9kb region of the Xist locus. Blue dashes underneath the ChIP profile indicate CpG 
density, the black box indicates exon 1 of Xist and the arrow indicates the direction of transcription. 
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complex components and therefore is easier to immunoprecipitate as it is not 
obscured by the rest of the complex. Indeed, gel filtration experiments show that in 
cells over-expressing FLAG-MBD2, the majority of MBD2 does not associate with 
the NuRD complex (H. Owen, unpublished). It is therefore unclear whether binding 
of over-expressed FLAG-MBD2 reflects binding of the endogenous protein or is 
associated with the NuRD complex. For this reason, as well as the fact that the 
increase in ChIP signal in FLAG-MBD2 cells compared to Mbd2-/- cells is relatively 
low, I decided to discontinue FLAG-MBD2 ChIP experiments. 
 
4.5.5 Formaldehyde cross-linking does not efficiently capture 
MBD2-DNA interactions 
Another explanation for my inability to recover DNA during MBD2 ChIP despite 
recovery of protein by cross-linked IP is that cross-linking of MBD2 to the DNA is 
inefficient. Studies using Fluorescence Recovery After Photobleaching (FRAP) have 
shown that the heterochromatic localisation of proteins with a recovery half-time of 
2.5 seconds or less is not captured by formaldehyde cross-linking (Schmiedeberg et 
al., 2009). Studies carried out in my lab have shown that in NIH3T3 fibroblast cells 
MBD2b-GFP has a FRAP half-time of 4.5 seconds (L. Schmiedeberg, unpublished). 
Schmiedeberg and colleagues found that proteins with half-times of this magnitude 
showed partial mis-localisation when formaldehyde-fixed cells were examined by 
immunofluorescence but proper localisation in live cells where fixation was not 
required to capture interactions (Schmiedeberg et al., 2009). Interestingly, this also 
translated into a reduced efficiency in ChIP experiments. To examine whether this 
could also be the case for MBD2, I transfected NIH3T3 cells with MBD2b-GFP and 
examined MBD2 localisation in fixed and live cells. When MBD2b-GFP localisation 
was examined in cells that had been fixed with formaldehyde approximately half of 
the cells showed preferential localisation of MBD2 to densely methylated 
heterochromatic foci (indicated by DAPI bright spots) but the rest of the cells 
showed diffuse nuclear localisation of MBD2 (Figure 4.5.9A). In contrast, when live 
cells were examined all of them showed correct heterochromatic localisation of 
MBD2b-GFP (Figure 4.5.9B). This suggests that formaldehyde may be inefficient at 
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capturing MBD2-chromatin interactions due to a relatively rapid exchange rate of 
MBD2 on DNA as indicated by its short recovery half-time in FRAP experiments.  












Inefficient cross-linking of MBD2 protein to DNA could partially explain my 
difficulty in performing ChIP for MBD2. To try and overcome this problem I 
included an additional cross-linker dimethyl 3,3´-dithiobispropionimidate (DTBP; 
Pierce) in my ChIP experiments which is reported to cross-link proteins at greater 
distances than formaldehyde (11.9 Å compared to 2Å for formaldehyde) although it 
is more efficient at capturing protein-protein interactions than protein-DNA 
interactions (Fujita and Wade, 2004). However, no difference was observed in ChIP 
Figure 4.5.9 Formaldehyde cross-linking fails to efficiently capture MBD2-DNA 
interactions 
A) Localisation of MBD2b-GFP in cells fixed with formaldehyde. Cells show either diffuse nuclear 
localisation of MBD2 or preferential localisation to heterochromatic foci.  B) In live cells MBD2b-GFP always 
preferentially associates with heterochromatin. GFP = MBD2b-GFP (green in merge), DAPI/Hoechst = DNA 
(blue in merge). 
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over Xist or major satellite using this cross-linker compared to formaldehyde alone 
(data not shown). 
 
4.6 Results: Analysis of histone H3 acetylation in Mbd2-/- Th1 cells 
Histone acetylation is a mark of gene activity and is enriched over the promoters of 
active genes (Wang et al., 2008). Deacetylation, on the other hand, is associated with 
gene repression and many of the MBD proteins recruit HDACs in order to facilitate 
transcriptional silencing (see section 1.3). As MBD2 is a component of the HDAC-
containing NuRD co-repressor complex it is expected that absence of MBD2 may 
lead to increases in histone acetylation due to a failure to recruit HDACs. Therefore, 
acetylation of histone H3 was examined in Mbd2-/- Th1 cells by Western Blot and 
ChIP-seq analysis. 
 
4.6.1 Global levels of histone H3 acetylation are not detectably 
changed in the absence of MBD2 
I used Western blot analysis to examine whether there was a change in the overall 
level of histone acetylation in Mbd2-/- Th1 cells compared to wild-type Th1 cells. 
Western blots were probed with an antibody with specificity for histone H3 when it 
is acetylated at the K9 and K14 residues (anti-histone H3 pan-acetyl; Millipore) and 
blots against unmodified histone H3 (Abcam) were carried out in parallel to act as a 
loading control. Signal was detected using chemiluminescence (Figure 4.6.1A) and 
blots were quantified using densitometry. The level of histone H3 acetylation (H3Ac) 
was expressed relative to total histone H3 (H3) (Figure 4.6.1B). Levels of H3Ac 
were found to be similar between wild-type and Mbd2-/- cells at least at the 
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4.6.2 Genome-wide profiling of H3Ac by ChIP shows differences 
between wild-type and Mbd2-/- Th1 cells 
In order to see if absence of MBD2 affected histone acetylation at particular genomic 
locations I profiled H3Ac in wild-type and Mbd2-/- Th1 cells using ChIP-seq. ChIP 
was carried out using the histone H3 pan-acetyl antibody and enrichment for H3Ac 
was verified by examining the active gene c-myc. At c-myc the level of H3Ac was 
comparable between wild-type and Mbd2-/- Th1 cells and consistent between 
experimental replicates (Figure 4.6.2). Illumina adaptors were attached to the 
remaining ChIP DNA and it was passed to the Wellcome Trust Sanger Centre for 
sequencing and mapping as previously described (section 3.3.3). Replicate lanes of 
sequencing were combined giving two lanes of sequencing for each sample. 
Figure 4.6.1 Western blot analysis of H3Ac levels in wt and Mbd2-/- Th1 cells 
A) Western blots for acetylated histone H3 (left) and total histone H3 (right). Increasing numbers of cells 
were loaded (50,000, 100,000, 250,000). B) Quantification of Western blots by densitometry. For each cell 






























































There was a 1.4-fold difference in sequencing coverage between the wild-type and 
Mbd2-/- samples (Table 4.6.1, upper panel). It is possible that this reflects a greater 
level of H3Ac in Mbd2-/- Th1 cells compared to wild-type Th1 cells although 
analysis of H3Ac levels by Western blot as well as ChIP analysis of the c-myc locus 
argue against this. Alternatively, the difference in read number may simply be 
reflective of better sequencing depth in the Mbd2-/- sample. ChIP-seq data were 
normalised to the average number of reads for the two samples in order to correct for 
this and analysis performed using the principles outlined in section 3.3 (Table 4.6.1, 
lower panel). 
 
Sample Number of reads generated 
(Maq ≥ 30) 
Number of bp mapped 
WT H3Ac 21,768,054 664,150,962 




Figure 4.6.2 Verification of H3Ac enrichment at c-myc in wt and Mbd2-/- Th1 cells 
Enrichment for H3Ac was tested over the c-myc locus prior to sequencing. Blue dashes underneath the 
profile indicate CpG density and a schematic of the gene is shown with the direction of transcription 
indicated by the arrow. 
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Analysis step Parameters 
Normalisation Scaled to 794 million reads 
Peak-finding H: 4   L: 150   G: 250 
Sliding window 100bp window, 20bp slide 
Identification of differences log2 difference > 1.7 in 9/13 contiguous windows  
Peak-finding followed by sliding window analysis identified 140 regions that showed 
increased H3Ac and 45 regions that showed decreased H3Ac in the absence of 
MBD2. I looked to see if any of the genes associated with these regions changed 
their expression in Mbd2-/- Th1 cells. Surprisingly only three genes; Fam83g, 
Slc15a3 and Plxnd1 showed increased expression and increased H3 acetylation in 
Mbd2-/- Th1 cells compared to wild-type (Figure 4.6.3). None of the genes 
downregulated in the absence of MBD2 showed a change in acetylation. Fam83g is a 
novel gene of unknown function, Slc15a3 codes for a peptide transporter while 
Plxnd1 encodes a transmembrane receptor reported to play a role in thymocyte 
maturation (Choi et al., 2008). None of these genes are master regulators in the 
immune system so it is unlikely that an increase in their acetylation and gene 
expression will affect a large number of other genes. The observation that many 
genes that change expression in Mbd2-/- Th1 cells do not show changes in H3Ac 
could indicate that absence of MBD2 has more subtle effects on histone acetylation, 
as my analysis parameters identify relatively large differences (3.25-fold). 
Conversely, many genes that show a change in histone acetylation in Mbd2-/- cells 
do not change their expression. This could suggest that there are multiple 
mechanisms repressing each gene and that an increase in acetylation due to removal 
of MBD2 alone is not always sufficient to induce expression. Alternatively it could 
suggest that the appropriate transcription factors are not present to activate 
expression of these genes in Th1 cells even if repression is compromised by the 
absence of MBD2. 
Table 4.6.1 Sequencing information and parameters for analysis of H3Ac ChIP-seq data 
Upper panel; number of 37bp sequencing reads generated for each cell type and the number of base pairs 
(bp) of mapped sequence obtained. Lower panel; parameters for each analysis step. H = height in number 









































































































































































Figure 4.6.3 Three genes have increased H3Ac and increased expression in Mbd2-/- 
Th1 cells compared to wild-type Th1 cells 
A) Fam83g (also known as 2310040C09Rik) B) Slc15a3 C) Plxnd1. For each example the upper panel 
shows read density profiles for by H3Ac ChIP-seq (green) and CGIs (blue). The lower panel shows the 
expression of each gene in wild-type (WT) and Mbd2-/- Th1 cells as determined by microarray analysis. 
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I then investigated if genes upregulated in the absence of Mbd2 showed a more 
subtle tendency to increase histone H3 acetylation. Using normalised data, I 
examined the average H3Ac profile for a region 3kb upstream and 3kb downstream 
of the transcription start site in wild-type and Mbd2-/- samples. This was carried out 
for all RefSeq genes in the mouse genome and the profile compared to that of genes 
upregulated in Mbd2-/- Th1 cells (analysis carried out with assistance from Shaun 
Webb). For the analysis, only genomic regions without overlapping genes were 
included to avoid complications due to intersection of multiple TSS regions. When 
the average profile of H3Ac across all TSSs was examined, as expected, acetylation 
was enriched 1kb either side of the TSS (Wang et al., 2008) and a dip in H3Ac signal 
was seen just before the TSS, indicative of the nucleosome free region characteristic 
of active promoters and promoters poised for transcription (Ozsolak et al., 2007). On 
average, a 2.25-fold increase in H3Ac was seen in Mbd2-/- Th1 cells compared to 
wild-type Th1 cells when all genes were examined (1kb up- and downstream of the 
TSS) (Figure 4.6.4A). This could indicate that absence of MBD2 affects histone 
acetylation at many gene promoters. Although the data were normalised prior to 
analysis, however, the possibility that this difference could be due to increased 
sequencing depth in the Mbd2-/- sample cannot be ruled out. H3 acetylation was then 
examined at the set of genes upregulated in Mbd2-/- Th1 cells compared to wild-type 
Th1 cells. At these genes, H3Ac was increased by an average of 2.5-fold over the 
region 1kb up- and downstream of the TSS in Mbd2-/- compared to wild-type Th1 
cells, similar to the increase seen at the TSS for all genes (Figure 4.6.4B). However, 
between 0-500bp downstream of the TSS the difference in acetylation was more 
pronounced for genes upregulated in the absence of MBD2 that for all genes (2.7-
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4.7 Results: The relationship between MBD2-regulated gene 
expression and DNA methylation 
I wanted to see whether genes that increased their expression in the absence of 
MBD2 were methylated and whether differential methylation could be responsible 
for directing MBD2 to cell type-specific targets. I also examined whether removal of 
MBD2, a methylation reader, could affect the methylation pattern itself. 
 
4.7.1 The majority of genes upregulated in Mbd2-/- cells are 
methylated 
A major question remaining about MBD2 function is whether methylation is 
responsible for directing MBD2/NuRD binding in vivo. To help address this question 
in the absence of ChIP data for MBD2 we examined whether genes that changed 
their expression in the absence of MBD2 were methylated. Gene expression data for 
Mbd2-/- dendritic cells and Th1 cells were compared to the methylation data 
generated for these cells using MAP-seq (chapter 3). These cell types were chosen as 
they show the greatest number of gene expression changes in the absence of MBD2. 
In total, 56% of genes upregulated in dendritic cells and 72% of genes upregulated in 
Th1 cells were associated with a peak of methylation determined by MAP-seq. A 
modest proportion of these upregulated genes associated with a methylated CGI 
Figure 4.6.4 The average H3Ac ChIP-seq profile at transcription start sites  
H3Ac ChIP-seq hits (calculated in 50bp window, 20bp slide, the median number of hits per window is 
plotted) for a region 3kb upstream and 3kb downstream of the TSS in wild-type (grey) and Mbd2-/- (black) 
Th1 cells in: A) all non-overlapping RefSeq genes (n=1700) B) non-overlapping genes upregulated in Mbd2-
/- compared to wt Th1 cells (n=66). 
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(17% in dendritic cells and 27% in Th1 cells) with the remainder of methylation 
occurring at non-CGI-associated regions. Some of the genes that associated with 
methylated CGIs were also associated with methylated non-CGI regions (Figure 
4.7.1). These methylated CGIs tended to be located in intragenic regions rather than 
at TSSs consistent with the fact that these CGIs are frequently methylated 
(Illingworth et al., 2010; Maunakea et al., 2010).  
 
A significant proportion of MBD2-regulated genes were not associated with 
methylation in the relevant cell type. However, this does not mean that these genes 
do not contain methylated CpG sites as MAP-seq can only detect methylation at 
relatively CpG-rich regions and most of the genome is CpG-deficient (see section 
3.3). This could be addressed by using a technique, such as bisulfite sequencing, that 




























4.7.2 MBD2-regulated genes are generally not associated with cell 
type-specific DNA methylation 
Another question regarding the relationship between MBD2 and the methylation 
pattern is whether cell type-specific DNA methylation directs MBD2 to different 
Figure 4.7.1 Association of genes upregulated in the absence of MBD2 with DNA 
methylation 
Genes upregulated in Mbd2-/- dendritic cells (DC) or Th1 cells (Th1) were examined for association with 
methylated peaks identified by MAP-seq in the relevant cell type. Genes were categorised as overlapping a 
CGI peak (meCGI), a non-CGI-associated peak (me nonCGI), both (meCGI&nonCGI) or as not overlapping 
methylation detected by MAP-seq (no MAP peak). 
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targets in different cell types. I examined whether genes that were upregulated in the 
absence of MBD2 only in specific immune cells also showed cell-type specific 
methylation patterns. I investigated 201 genes upregulated in Mbd2-/- dendritic cells 
that are not mis-expressed in Mbd2-/- Th1 cells (i.e. dendritic cell-specific targets). 
Of these, only four genes showed dendritic cell-specific methylation suggesting that 
differential methylation is not the major mechanism directing MBD2-mediated gene 
repression. This is in keeping with the observation that methylation patterns are 
relatively static between immune cell types and are therefore unlikely to be a major 
mechanism governing gene regulation (section 3.5). Of the genes that do show 
dendritic cell-specific methylation, the Socs3, Tnfaip2 and Scnn1a genes are 
methylated at intragenic CGIs while Hk3 is differentially methylated at a non-CGI-
associated region (MAP-seq and expression data for Socs3 and Tnfaip2 are shown in 
Figure 4.7.2A and B). Socs3 codes for suppressor of cytokine signalling 3 and 
regulates signalling during a number of immune system processes including T cell 
differentiation (Egwuagu et al., 2002; Kubo et al., 2003; Yu et al., 2003) while 
Tnfaip2 is a pro-inflammatory gene [see section 3.5.2 and (Mookherjee et al., 2006)]. 
It is hypothesised that these four genes are direct targets of MBD2 in dendritic cells 
but not in Th1 cells where they are hypomethylated. Mis-expression of these genes 
may have secondary effects on the expression of other genes which could account for 






































































































































































4.7.3 DNA methylation is not changed in the absence of MBD2 
Given that MBD2 is involved in reading the methylation pattern I investigated 
whether its absence affected DNA methylation itself. One hypothesis is that DNA 
methylation may not be efficiently maintained at MBD2 target genes in Mbd2-/- cells 
because methylation is not functional without MBD2 present to mediate its effect. 
Alternatively, if MBD2 can act as a DNA demethylase (Bhattacharya et al., 1999) 
DNA methylation would be expected to increase in Mbd2-/- cells compared to wild-
type cells. To address this issue, MAP-seq in wild-type and Mbd2-/- CD4 T cells was 
carried out. Two separate MAP-seq experiments were carried out for wild-type CD4 
cells. Each of these wild-type samples was compared to Mbd2-/- CD4 MAP-seq data 
separately and only differential methylation identified in both comparisons was taken 
as genuine. This compensated for variability between samples run at different times 
on different batches of MBD column. Differential methylation was identified as 
before (section 3.3) and sequencing information is outlined in Table 4.7.1. 
Figure 4.7.2 Genes upregulated in Mbd2-/- dendritic cells showing dendritic cell-specific 
DNA methylation  
A) Socs3 and B) Tnfaip2 which show increased methylation in dendritic cells compared to Th1 cells by 
MAP-seq and are upregulated in Mbd2-/- dendritic cells. For each the left hand panel shows the MAP-seq 
read density profile (red) and CGIs (blue) while the right hand panel shows expression of the genes (relative 




Sample Number of reads generated 
(Maq ≥ 30) 
Number of bp mapped 
WT CD4 1 25,005,336 427,865,743 
WT CD4 2 39,376,768 426,508,805 
Mbd2-/- CD4 35,855,841 394,428,880 
 
In general, DNA methylation detectable by MAP-seq did not change between wild-
type and Mbd2-/- CD4 cells. Six regions showed an increase in methylation in Mbd2-
/- cells compared to wild-type while just one region showed a decrease in 
methylation. Four of the regions are located within genes although none of these 
genes changed expression in the absence of MBD2 in any of the cell types tested. 
Two of the regions overlapped a methylated CGI. Details of methylation changes in 
Mbd2-/- compared to wild-type CD4 cells are summarised in Table 4.7.2 and 












Table 4.7.1 Sequencing information for MAP in wild-type and Mbd2-/- CD4 cells  














chr2: 33789520 - 33790020 gain no no no 
chr5: 28495080 - 28495680 gain En2 yes no 
chr5: 39458460 - 39458900 gain no no no 
chr7: 85291980 - 85292460 gain no no no 
chr16: 87901340 - 87901800 gain Grik1 no no 
chr17: 85012720 - 85013180 gain Plekhh2 no no 
chr14: 119321880 -119322300 loss Dzip1 yes no 

















Table 4.7.2 Regions showing a methylation difference in Mbd2-/- CD4 cells compared to 
wild-type CD4 cells  
Chromosomal location, whether the region shows gains or loss of methylation in Mbd2-/- cells, gene 
association and association with methylated CGIs are shown. None of the regions is associated with can 
expression change in Mbd2-/- cells. 
Figure 4.7.3 En2 and Dzip1 are two genes associated with a methylation difference in 
Mbd2-/- compared to wild-type CD4 cells  
MAP-seq profiles (red) are shown for A) En2 CGI that increases methylation in Mbd2-/- cells B) Dzip1 CGI 




As MBD2 has previously reported roles in the immune system (Hutchins et al., 2005; 
Hutchins et al., 2002; Kersh, 2006) this represented a good system in which to study 
MBD2’s role in gene expression and how this relates to DNA methylation. Reported 
defects in T helper cell differentiation in Mbd2-/- mice were confirmed by FACS 
staining for cytokine production and by analysis of gene expression using qRT-PCR. 
Additional immune system defects were observed in Mbd2-/- mice including 
impaired T cell proliferation, increased production of activated Treg cells in vivo and 
increased susceptibility to oesophageal infection. This prompted us to assess the 
extent to which gene expression is perturbed in immune system cells lacking MBD2. 
The idea that MBD2 is involved in regulating inducible processes such as the 
immune response is intriguing as this might explain the relatively mild phenotype of 
Mbd2-/- mice in the absence of immune challenge (Hendrich et al., 2001). 
 
4.8.1 MBD2 regulates gene expression in the immune system, 
perhaps in a redundant manner 
A modest number of gene expression changes were seen in Mbd2-/- immune cells 
compared to wild-type with the greatest number of differences occurring in dendritic 
cells. This suggests a prominent role for MBD2 in dendritic cells which is supported 
by collaborators who have observed that dendritic cells from Mbd2-/- mice seem to 
be defective in directing a Th2-type immune response (P. Cook, unpublished results). 
The majority of genes that change their expression in the absence of MBD2 were 
upregulated, consistent with MBD2’s role as a transcriptional repressor. The number 
of gene expression changes (between 16 and 218 genes depending on the cell type) 
occurring in the absence of MBD2 suggests that MBD2 is not a major regulator of 
gene expression or, at least, that it has a partially redundant function. As the NuRD 
complex can contain MBD3 instead of MBD2 (Le Guezennec et al., 2006) it is 
possible that MBD3/NuRD could compensate for a lack of MBD2 although in this 
case repression would not be directed by methylation as MBD3 does not 
preferentially bind methylated DNA (Hendrich and Bird, 1998). This possibility 
could be tested by knocking out MBD2 and MBD3 specifically in the immune 
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system which would circumvent the issue of embryonic lethality in the absence of 
MBD3 (Hendrich et al., 2001). Another possibility is that MBD2 is one of a number 
of redundant repressive mechanisms which are “stacked” at particular loci to ensure 
efficient gene silencing. This has been suggested to be the case at the Xist locus 
where absence of MBD2 leads to low level reactivation of Xist but renders Xist 
hypersensitive to the effects of impairing histone deacetylation and DNA 
methylation (Barr et al., 2007). A final and related explanation could be that Mbd2-/- 
mice have adapted to compensate for a lack of MBD2 during development. It would 
be intriguing to examine whether more gene expression changes would occur after 
sudden removal of MBD2 specifically in adult cells using a conditional knockout 
strategy. MBD2 stands out from the methyl-binding proteins MBD1 and MeCP2 as 
significant numbers of genes change expression in Mbd2-/- cells and most of these 
are upregulated consistent with a role as a transcriptional repressor. 
 
4.8.2 Absence of MBD2 results in different gene expression 
changes in different immune cell types 
I have shown that removal of MBD2 results in distinct expression changes in 
different cell types. It is possible that MBD2 binds the same sites in these cells but 
that genes are only upregulated in the absence of MBD2 when the appropriate cell-
specific transcription factors are present or when the chromatin environment is 
permissive to transcription. An alternative is that MBD2 binds to different sites in 
different cells, perhaps due to differential methylation in these cell types. I examined 
whether genes upregulated specifically in Mbd2-/- dendritic-cell were associated 
with dendritic cell-specific DNA methylation. This was not the case for the majority 
of genes, consistent with the relatively conserved patterns of methylation observed 
between immune system cell types (see chapter 3). However, the four genes, Socs3, 
Tnfaip2, Scnn1a and Hk3 that do show cell-specific methylation and regulation by 
MBD2 may be directly bound by MBD2 in a methylation-dependent manner. It is 
possible that upregulation of these genes in the absence of MBD2 may have 
secondary effects on other genes and be responsible for many of the gene expression 
changes observed in Mbd2-/- dendritic cells. Mapping MBD2 binding sites in 
different immune cell types will be necessary to ultimately determine the relationship 
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between the methylation pattern and MBD2 binding. However, as this is currently 
not possible (see section 4.7), the four genes showing MBD2-dependent repression 
and cell-specific methylation could be overexpressed and the effects on gene 
expression observed to see if any of the genes upregulated in Mbd2-/- dendritic cell 
are also upregulated in this context. 
 
4.8.3 MBD2 binding sites have not yet been determined 
To get to the heart of many of the aspects of MBD2 function discussed it is necessary 
to determine where MBD2 binds in vivo. Unfortunately, numerous attempts to carry 
out ChIP for MBD2 were unsuccessful. My lab’s custom made MBD2 antibody, 
S923, despite immunoprecipitating MBD2 protein, did not detect MBD2 at published 
targets. Furthermore, use of a microarray-based strategy to identify novel targets also 
proved unsuccessful. This could be due to the fact that only a small percentage of 
MBD2 is immunoprecipitated by S923 and this is not enough to give a signal above 
background level in ChIP experiments. Alternatively cross-linking of MBD2 to the 
DNA could be inefficient resulting in recovery of protein but compromised recovery 
of the associated DNA. This has shown to be the case for mutants of MeCP2 which 
show aberrant localisation in formaldehyde-fixed cells and reduced binding in ChIP 
experiments (Schmiedeberg et al., 2009). Also, since MBD2 is part of a large protein 
complex if there are instances where it is not directly bound to DNA it may be more 
difficult to capture interactions by cross-linking. Immunoprecipitation of FLAG-
tagged MBD2 using an α-FLAG antibody recovered the majority of MBD2 in the 
cell; however, specific association of MBD2 with known targets was not detected. 
Rather, FLAG-MBD2 cells showed a modest increase in ChIP signal to Mbd2-/- cells 
at all regions tested including the promoter of the active gene ActB. Therefore, it 
seems that MBD2 ChIP is either not efficient enough (using S923 in wild-type cells) 
or not specific enough (using α-FLAG in FLAG-MBD2 cells) to be used to 
determine genome-wide patterns of MBD2 binding in immune cells. This represents 
a major barrier to elucidating the extent and role of MBD2 in regulating gene 




4.8.4 Changes in H3Ac were observed in the absence of MBD2 
As MBD2 is part of a complex containing HDAC activity I examined whether 
removal of MBD2 was associated with an increase in acetylation of histone H3. 
Total levels of histone acetylation as assessed by Western blot were not affected in 
Mbd2-/- Th1 cells consistent with the abundance of MBD2 in the nucleus. Estimates 
suggest that there is approximately one molecule of MBD2 for every 36 nucleosomes 
in the cell (R. Ekiert, unpublished results). This is in contrast to MeCP2 which, in 
neurons, is nearly as abundant as the histone octamer and, as a consequence, its 
removal affects histone acetylation levels globally (Skene et al., 2010). However, 
ChIP-seq analysis of H3Ac distribution in wild-type and Mbd2-/- Th1 cells suggested 
that there may be a global increase in H3 acetylation over gene promoters in Mbd2-/- 
cells. This could be due to a failure to recruit the NuRD complex and associated 
HDACs to a large number of promoters although it is also possible that the observed 
difference might be due simply to a discrepancy in the number of sequencing reads 
between wild-type and Mbd2-/- samples which may have been more pronounced 
over promoters. To distinguish between these possibilities mapping of MBD2 
binding sites in Th1 cells would need to be carried out to investigate whether MBD2 
and other NuRD components bind a large number of gene promoters. In addition, 
Western blots using a more sensitive fluorescence detection method rather than 
chemiluminescence should be carried out to investigate whether a global difference 
in the level of histone acetylation in Mbd2-/- Th1 cells can be detected. It is possible 
that a 1.4-fold change in acetylation (which would be predicted over the whole 
genome from the difference in sequencing reads) might be too small to be detectable 
by Western blot or those changes in H3Ac level occurring specifically at promoters 
are diluted out by the rest of the H3Ac in the nucleus. This could explain the 
apparent discrepancy between the Western blot and ChIP-seq results.  
 
If MBD2 has a role in regulating acetylation at a large number of gene promoters, 
this is in conflict with the fact that only a modest number of genes change their 
expression in its absence. One explanation for this may be that, at many MBD2 
targets, redundant silencing mechanisms act together to prevent transcription. In 
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support of this, peak-finding analysis carried out on H3Ac ChIP-seq data identified 
many regions that showed a large increase in H3Ac in Mbd2-/- Th1 cells but were 
not associated with changes in gene expression.  
 
4.8.5 The methylation dependence of MBD2/NuRD binding needs 
to be established in vivo 
When genes upregulated in Mbd2-/- dendritic cells or Th1 cells were examined for 
association with DNA methylation in these cell types, although the majority (56% in 
dendritic cells and 71% in Th1 cells) were associated with DNA methylation, a 
sizeable proportion of genes did not associate with methylation detectable by MAP-
seq. One explanation for this may be that these regions are methylated but CpG-poor 
and cannot be interrogated by MAP-seq. Another possibility that can’t be excluded is 
that, although MBD2 preferentially binds to methylated CpGs in vitro and in reporter 
assays (Ng et al., 1999), other NuRD complex components or sequence-specific 
transcription factors (Miccio et al., 2010; Sridharan and Smale, 2007) can direct 
MBD2/NuRD to unmethylated targets. To assess the relationship between 
MBD2/NuRD binding and DNA methylation in vivo it would be necessary to 
identify MBD2 binding sites in the cell and assess their methylation status, ideally by 
a method such as bisulfite sequencing that can assess methylation at CpG-poor 
regions.  
 
4.8.6 MBD2 does not act as a DNA demethylase 
Assessment of DNA methylation by MAP-seq in wild-type and Mbd2-/- CD4 T cells 
revealed no global effect on methylation due to the absence of MBD2. This supports 
studies claiming that MBD2 does not function as a DNA demethylase (Hendrich et 
al., 2001; Ng et al., 1999; Santos et al., 2002) as previously reported (Bhattacharya et 
al., 1999). However, seven regions showed a difference in methylation between wild-
type and Mbd2-/- cells. One explanation for these differences is that wild-type and 
Mbd2-/- mice, while both being on a C57/BL6 background, were not from the same 
mouse line and there could be methylation differences between these lines. Bisulfite 
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sequencing of some of these regions will be necessary in order to determine if these 
changes are genuine.  
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Chapter 5 Discussion 
This thesis has examined cell type-specific CGI methylation and the role of the 
methyl-binding protein MBD2 using cells of the immune system as a model. 
Although somatic CGI methylation in normal cells has been well-documented in 
recent years (Eckhardt et al., 2006; Illingworth et al., 2008; Mohn et al., 2008; 
Schilling and Rehli, 2007; Weber et al., 2007) the extent and role of cell type-
specific methylation and, in particular its relationship to gene expression was still in 
need of further investigation. In addition, global gene expression changes in MBD2-
deficient primary single cell types had not yet been assessed. This is in spite of the 
fact that, unlike other MBD proteins, numerous examples of gene mis-regulation 
have been reported in Mbd2-/- mice (Barr et al., 2007; Berger et al., 2007; Hutchins 
et al., 2002). Immune cells are developmentally related, easily purified cell types that 
have documented instances of cell-specific DNA methylation and reported 
phenotypes in the absence of MBD2 making them particularly suitable for this kind 
of investigation. The main findings on cell-specific CGI methylation and the effect of 
removing MBD2 in immune system cells are discussed here along with possibilities 




5.1.1 The relationship between CGI methylation and gene 
expression 
CGIs represent a distinct fraction of the genome in terms of their CpG density, 
usually unmethylated state and association with a transcriptionally permissive 
chromatin environment. Methylation of CGIs has long been associated with gene 
repression (Csankovszki et al., 2001; Edwards and Ferguson-Smith, 2007). Many 
CGIs associate with gene promoters and the remainder have been suggested to 
represent novel transcription start sites (Illingworth et al., 2010; Maunakea et al., 
2010). Therefore, where cell-specific CGI methylation occurs and how this relates to 
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gene expression and histone modification is of particular interest. DNA methylation 
in a number of cell types from the hematopoietic lineage (dendritic cells, B cells, 
CD4 T cells, Th1 and Th2 cells) was assessed using MAP-seq with a particular focus 
on CGIs. To see if trends observed in these developmentally related cells applied to 
more distinct tissue types, methylation and expression data on immune cells were 
compared to those on distantly related brain. This showed that findings using an 
immune system model relate to tissue-specific CGI methylation in general.  
 
It is clear from my results that between highly related cell types, such as immune 
cells, the DNA methylation pattern is relatively static which is in stark contrast to the 
vast number of gene expression differences observed between these cells. Notably, 
during activation and differentiation of CD4 cells into Th1 or Th2 cells nearly 3,000 
genes change their expression by at least two-fold but only a handful of CGIs show a 
change in methylation. This argues that differential gene expression, especially in 
rapidly inducible systems such as T cell activation, is dependent on cell-specific 
transcription factors which can exert their effects more rapidly than epigenetic 
mechanisms. However, DNA methylation and other epigenetic changes may occur 
more gradually at key genes in order to facilitate continued expression or re-
expression of particular genes (for example upon re-exposure to the same immune 
stimulus). It seems no coincidence that the only CGI to show differential methylation 
between Th1 and Th2 cells is located in the gene encoding Gata3, the key Th2 cell 
transcription factor.  
 
A fundamental question regarding the relationship between CGI methylation and 
gene silencing is whether DNA methylation is a cause or consequence of gene 
activity. The fact that CGI methylation is often targeted to already silent genes, for 
example in X inactivation (Csankovszki et al., 2001) and ES cell differentiation 
(Mohn et al., 2008), suggests that it often follows initial silencing events to help 
maintain gene repression in a heritable manner. However, rapid methylation and 
demethylation events have been reported for individual CpG sites (Bruniquel and 
Schwartz, 2003; Jones and Chen, 2006). I observed specific demethylation of the 
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Gata3 intragenic CGI during Th2 cell differentiation. After 7 days of T cell culture 
this methylation change was relatively subtle despite a large increase in Gata3 
expression. However, after an 8 week Th2-inducing infection, the Gata3 CGI had 
become completely demethylated. This is consistent with a progressive loss of Gata3 
methylation occurring after initial gene activation rather than active demethylation 
driving gene expression. 
 
Evidence suggests a developmental origin for CGI methylation patterns. Small 
numbers of CGI and non-CGI methylation differences were observed between 
developmentally related immune cells with the fewest differences occurring between 
the most related cells (i.e. CD4, Th1 and Th2 cells). In contrast, a developmentally 
distinct tissue, brain, showed 2,000 CGI methylation differences compared to CD4 
cells and nearly 20,000 differences at non-CGI regions. Here, total methylation 
changes actually out-numbered gene expression changes suggesting that the DNA 
methylation pattern is more related to developmental history rather than it is to the 
gene expression program and is probably established early during lineage 
commitment.  
 
Intriguingly, most cell-specific methylation was found to occur at CGIs within gene 
bodies consistent with the findings of Maunakea et al. (2010). Despite not occurring 
at the annotated TSS, intragenic CGI methylation tended to associate with decreased 
gene expression. It is unclear how intragenic CGI methylation might affect 
expression of the associated gene. For a number of intragenic CGIs, for example 
those within the Kcnn4 and Gata3 genes, increased DNA methylation associated 
with a decrease in the “active” chromatin mark H3K4me3 and a decrease in gene 
expression. Such CGIs may represent alternative promoters for the associated gene 
as suggested by Maunakea and colleagues (2010) or a class of H3K4me3 positive 
enhancer. However, most differentially methylated intragenic CGIs were 
constitutively depleted for H3K4me3 in immune cells implying that they do not act 
as promoters in these cells. Given that many intragenic CGIs show evidence for 
promoter function (Illingworth et al., 2010; Maunakea et al., 2010) this implies that 
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these differentially methylated CGIs must act as promoters for novel genes in other 
tissues or at particular developmental stages as suggested by CAGE and Pol II 
binding data. Intragenic methylation might then affect expression of the associated 
annotated gene by an indirect mechanism such as impairment of Pol II elongation 
(Lorincz et al., 2004). Differential methylation may be stochastic or reflect the use of 
alternative silencing mechanisms such as polycomb which could be determined by 
the developmental origin of the cell type.  
 
It is clear from this work and the work of others that methylation of CGIs at 
annotated transcription start sites is a relatively rare phenomenon with just 2% of all 
TSS CGIs reported to be methylated (compared to 26-34% of intragenic CGIs) 
(Illingworth et al., 2010; Maunakea et al., 2010). For the approximately 60% of TSS 
CGIs that associate with housekeeping genes the reason for this is clear, these genes 
are ubiquitously expressed and therefore need to be maintained in an unmethylated 
state. However, many developmental and tissue-specific genes also possess CGI 
promoters (Illingworth et al., 2008; Larsen et al., 1992). In these cases perhaps DNA 
methylation is not a fast enough or dynamic enough mechanism to regulate gene 
expression. Perhaps the strong association of TSS CGIs with H3K4me3 helps keep 
them free of methylation and specific mechanisms are needed to disrupt this. It is 
conceivable that TSS CGI methylation is only employed when permanent, long-term 
silencing is required such as in the case of X inactivation, imprinting and in 
repression of some germline-specific and developmental genes in somatic cells 
(Csankovszki et al., 2001; Edwards and Ferguson-Smith, 2007; Illingworth et al., 
2008; Mohn et al., 2008). Intragenic CGI methylation, on the other hand, could be 
more common because these CGIs control expression of novel genes with very 
restricted expression patterns. 
 
5.1.2 Regulation of gene expression by MBD2  
I then examined the role of a methylation “reader”, the protein MBD2, in gene 
regulation in immune cells. Absence of MBD2 was found to result in a number of 
previously uncharacterised immune system phenotypes and a modest number of gene 
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expression changes. The abundance of MBD2 in the nucleus together with the 
number of genes upregulated in Mbd2-/- cells suggests a role for MBD2 in repressing 
a discrete number of target genes or at least in binding discrete genomic sites. This 
implies that MBD2 functions more like a classical transcriptional repressor than 
other MBD proteins. Mbd1-/- animals show a mild phenotype and very few gene 
expression changes (Zhao et al., 2003) while Mecp2y/- mice show a gross phenotype 
which mimics the symptoms of Rett syndrome (Guy et al., 2001) along with global 
changes in the chromatin state (Skene et al., 2010). My ChIP-seq results suggest that 
Mbd2-/- mice may show genome-wide changes in histone acetylation at gene 
promoters and as well as showing larger magnitude changes at a number of discrete 
genomic sites. The regions that increase their histone acetylation in Mbd2-/- Th1 
cells compared to wild-type Th1 cells do not always associate with upregulated 
genes. In these cases, gene mis-expression may be prevented by other repressive 
mechanisms which maintain repression in the absence of MBD2-dependent HDAC 
recruitment. This seems to be the case at the Xist locus where MBD2, DNA 
methylation and histone deacetylation all contribute to gene repression independently 
(Barr et al., 2007). This “stacking” of repressive tendencies may help to limit the 
number of gene expression changes occurring in Mbd2-/- mice and explain their 
relatively mild phenotype.  
 
In order to better understand the relationship between MBD2 and DNA methylation, 
I examined the association of genes upregulated in the absence of MBD2 with 
methylation detected by MAP-seq. Up to one-fifth of these associated with 
methylated intragenic CGIs (in Th1 cells). An intriguing possibility is that MBD2 
binding to methylated intragenic CGIs could lead to formation of a repressive 
chromatin environment and thus modulate transcriptional elongation as suggested by 
Lorincz and colleagues (2004). However, the fact that the majority of genes 
regulated by MBD2 do not associate with methylated CGIs suggests that MBD2 
often binds regions other than methylated CGIs. Indeed, a large proportion of 
MBD2-regulated genes associate with methylated non-CGI regions detected by 
MAP-seq. A related issue is whether MBD2 binds to different targets in different cell 
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types, as suggested by the gene expression data, and how these targets are 
recognised. I have observed little evidence that cell-specific DNA methylation 
directs MBD2 to particular target genes. The location of MBD2 binding sites will 
need to be determined in order to definitively address these questions, which, 
unfortunately, has so far proved unsuccessful. 
 
5.1.3 The contribution made by cell-specific CGI methylation and 
MBD2 to gene expression 
CGI methylation and MBD2 are part of the same system of gene repression. The fact 
that DNA methylation is essential for life (Li et al., 1992) but the phenotype of the 
Mbd2-/- mouse is relatively mild (Hendrich et al., 2001) suggests that DNA 
methylation exerts many of its effects independently of MBD2 and has a more 
significant role in development. Although I have focused on CGI methylation in this 
study, the majority of DNA methylation in the genome occurs outwith CGIs, and 
knockout of the Dnmts does not allow specific assessment of the contribution CGI 
methylation makes to development, gene regulation and cell survival. One 
hypothesis is that CGI methylation is necessary for developmental processes such as 
X inactivation and imprinting and for regulating a small number of key genes whose 
sustained repression is of paramount importance, but does not play a major role in 
gene regulation in general. A role in regulating a discrete number of target genes is 
also likely for MBD2 judging by the number of mis-regulated genes I have observed 
in Mbd2-/- immune cells. 
 
An important question given the focus of this work is the extent to which methylated 
CGIs tend to be bound by MBD proteins. Genes upregulated in the absence of 
MBD2 do not tend to associate with methylated TSS CGIs although a reasonable 
proportion contains intragenic CGIs. Although genes containing methylated TSS 
CGIs tend not to be upregulated in the absence of MBD2, this does not necessarily 
mean that MBD2 does not bind to these regions. It is possible that these genes are not 
mis-expressed when MBD2 is removed because methylated CGIs are inherently 
refractory to transcription, perhaps due to a failure to bind components of the 
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transcriptional machinery. MBD protein binding may simply add an additional layer 
of silencing to already silent methylated CGIs. Indeed, MBD2 has been reported to 
bind to the methylated Xist TSS CGI in male fibroblast cells but removal of MBD2 
only leads to Xist mis-expression in ~1% of cells implying that MBD2 is just one 
part of the silencing mechanism (Barr et al., 2007).  
 
5.2 Future work 
 
5.2.1 Elucidating the function of intragenic CGI methylation 
There are a number of experiments that could be done to further elucidate the role of 
cell type-specific intragenic CGI methylation in immune system cells. The first is to 
determine whether the intragenic CGIs with differential DNA methylation and 
H3K4me3 enrichment such as those located in Kcnn4 and Gata3 can act as 
alternative promoters for these genes and in what contexts these promoters are used. 
This could be determined by examining Pol II occupancy using ChIP (although 
initial attempts using an antibody against the hypophosphorylated form of Pol II 
were inconclusive) or by using 5’ RACE or CAGE to map transcription start sites in 
the relevant immune cell types. 
 
The second major task is to determine the role of the intragenic CGIs that are devoid 
of H3K4me3 and appear to be silenced in immune cells. Additional intragenic CGIs 
need to be examined for H3K27me3 association in the unmethylated context to 
determine whether the use of alternative silencing mechanisms is a common 
mechanism leading to cell-specific methylation. Since these CGIs don’t appear to act 
as promoters in immune cells it would be interesting to know if they act as promoters 
in other tissues. Overlap with published CAGE and Pol II data already suggests that 
this is the case for many of these. One place to look for expression is the germline as 
here CGIs are hypomethylated and a number of germline-specific genes have TSS 
CGI methylation in somatic tissues (Eckhardt et al., 2006; Weber et al., 2007). 
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Alternatively, it is possible that some of these intragenic CGIs regulate genes with a 
role earlier in the immune cell lineage, for example in HSCs.  
 
The remaining outstanding issue is to determine the reason for the association 
between intragenic CGI methylation and decreased gene expression. If the 
hypothesis that dense intragenic methylation impairs transcriptional elongation is 
correct, specifically disrupting methylation at these sites should lead to increased 
gene expression. Unfortunately targeted disruption of DNA methylation is not 
possible. A crude method of depleting DNA methylation is to treat cells with the 
chemical 5azaC which prevents the action of Dnmt1 (Creusot et al., 1982). This can 
have many secondary effects on the cell but has been used successfully to examine 
methylation-dependent regulation of alternative promoters (Maunakea et al., 2010). 
Addition of 5azaC to Th1 and Th2 cell cultures may allow the relationship between 
Gata3 intragenic methylation and gene expression to be examined. One could also 
attempt to transgenically delete a methylated intragenic CGI (provided it does not 
disrupt the coding potential of the gene) in ES cells to see how this affects gene 
expression. However, one side effect of this may be to delete the promoter for a 
novel gene which could have secondary effects on the cell. Although immune system 
cells have been a good primary cell type in which to examine the role of cell-specific 
methylation a more tractable and manipulatable system, such as ES cell 
differentiation, would be more suitable for more mechanistic investigations of some 
of these questions. 
 
5.2.2 Determining MBD2 binding sites 
To confirm many of the aspects of MBD2 function suggested by this work, 
identification of MBD2 binding sites in immune cells is necessary. Ideally their 
methylation status would be assessed by a high resolution method such as bisulfite 
sequencing which could interrogate CpG-poor sites although a lot of information 
could be gleaned by comparing binding data to the methylation maps of immune 
cells generated here by MAP-seq. Certainly the relationship between CGI 
methylation and MBD2 binding could be definitively assessed through genome-wide 
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mapping of MBD2 binding sites and comparison with MAP-seq data. It is unclear 
how precisely to overcome some of the difficulties with MBD2 ChIP reported here. 
One way may be to tag the endogenous MBD2 protein so that a more efficient 
antibody against the tag could be used for immunoprecipitation. Alternatively, ChIP 
for other NuRD components could be used as a substitute for MBD2 ChIP, a 
comparison of wild-type and Mbd2-/- cells would then allow specific MBD2/NuRD 
binding sites to be identified.  
 
5.3 Concluding remarks 
This work gives an insight into the role DNA methylation and its mediators play in 
gene regulation in the immune system. Notably it has identified that intragenic CGIs 
are particularly susceptible to cell type-specific DNA methylation and further 
confirmed a role for MBD2 in regulating immune cell gene expression. Additional 
experiments will be necessary in order to fully elucidate the function of intragenic 
CGI regions, why they are susceptible to cell-specific methylation and if the effects 




Agarwal, S., and Rao, A. (1998). Modulation of chromatin structure regulates 
cytokine gene expression during T cell differentiation. Immunity 9, 765-775. 
Agger, K., Christensen, J., Cloos, P.A., and Helin, K. (2008). The emerging 
functions of histone demethylases. Current opinion in genetics & development 18, 
159-168. 
Agger, K., Cloos, P.A., Christensen, J., Pasini, D., Rose, S., Rappsilber, J., Issaeva, 
I., Canaani, E., Salcini, A.E., and Helin, K. (2007). UTX and JMJD3 are histone 
H3K27 demethylases involved in HOX gene regulation and development. Nature 
449, 731-734. 
Allan, A.M., Liang, X., Luo, Y., Pak, C., Li, X., Szulwach, K.E., Chen, D., Jin, P., 
and Zhao, X. (2008). The loss of methyl-CpG binding protein 1 leads to autism-like 
behavioral deficits. Hum Mol Genet 17, 2047-2057. 
Amir, R.E., Van den Veyver, I.B., Wan, M., Tran, C.Q., Francke, U., and Zoghbi, 
H.Y. (1999). Rett syndrome is caused by mutations in X-linked MECP2, encoding 
methyl-CpG-binding protein 2. Nat Genet 23, 185-188. 
Antequera, F. (2003). Structure, function and evolution of CpG island promoters. 
Cell Mol Life Sci 60, 1647-1658. 
Auriol, E., Billard, L.M., Magdinier, F., and Dante, R. (2005). Specific binding of 
the methyl binding domain protein 2 at the BRCA1-NBR2 locus. Nucleic Acids Res 
33, 4243-4254. 
Avni, O., Lee, D., Macian, F., Szabo, S.J., Glimcher, L.H., and Rao, A. (2002). T(H) 
cell differentiation is accompanied by dynamic changes in histone acetylation of 
cytokine genes. Nature immunology 3, 643-651. 
Baguet, A., and Bix, M. (2004). Chromatin landscape dynamics of the Il4-Il13 locus 
during T helper 1 and 2 development. Proceedings of the National Academy of 
Sciences of the United States of America 101, 11410-11415. 
Bakker, J., Lin, X., and Nelson, W.G. (2002). Methyl-CpG binding domain protein 2 
represses transcription from hypermethylated pi-class glutathione S-transferase gene 
promoters in hepatocellular carcinoma cells. The Journal of biological chemistry 
277, 22573-22580. 
Ball, M.P., Li, J.B., Gao, Y., Lee, J.H., LeProust, E.M., Park, I.H., Xie, B., Daley, 
G.Q., and Church, G.M. (2009). Targeted and genome-scale strategies reveal gene-
body methylation signatures in human cells. Nature biotechnology 27, 361-368. 
Bannister, A.J., Zegerman, P., Partridge, J.F., Miska, E.A., Thomas, J.O., Allshire, 
R.C., and Kouzarides, T. (2001). Selective recognition of methylated lysine 9 on 
histone H3 by the HP1 chromo domain. Nature 410, 120-124. 
Baron, U., Floess, S., Wieczorek, G., Baumann, K., Grutzkau, A., Dong, J., Thiel, 
A., Boeld, T.J., Hoffmann, P., Edinger, M., et al. (2007). DNA demethylation in the 
human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) 
conventional T cells. European journal of immunology 37, 2378-2389. 
 
 221 
Barr, H., Hermann, A., Berger, J., Tsai, H.H., Adie, K., Prokhortchouk, A., 
Hendrich, B., and Bird, A. (2007). Mbd2 contributes to DNA methylation-directed 
repression of the Xist gene. Mol Cell Biol 27, 3750-3757. 
Barski, A., Cuddapah, S., Cui, K., Roh, T.Y., Schones, D.E., Wang, Z., Wei, G., 
Chepelev, I., and Zhao, K. (2007). High-resolution profiling of histone methylations 
in the human genome. Cell 129, 823-837. 
Barski, A., Jothi, R., Cuddapah, S., Cui, K., Roh, T.Y., Schones, D.E., and Zhao, K. 
(2009). Chromatin poises miRNA- and protein-coding genes for expression. Genome 
research 19, 1742-1751. 
Begenisich, T., Nakamoto, T., Ovitt, C.E., Nehrke, K., Brugnara, C., Alper, S.L., and 
Melvin, J.E. (2004). Physiological roles of the intermediate conductance, Ca2+-
activated potassium channel Kcnn4. The Journal of biological chemistry 279, 47681-
47687. 
Bell, A.C., and Felsenfeld, G. (2000). Methylation of a CTCF-dependent boundary 
controls imprinted expression of the Igf2 gene. Nature 405, 482-485. 
Bell, A.C., West, A.G., and Felsenfeld, G. (1999). The protein CTCF is required for 
the enhancer blocking activity of vertebrate insulators. Cell 98, 387-396. 
Berger, J., Sansom, O., Clarke, A., and Bird, A. (2007). MBD2 is required for correct 
spatial gene expression in the gut. Mol Cell Biol 27, 4049-4057. 
Bernstein, B.E., Kamal, M., Lindblad-Toh, K., Bekiranov, S., Bailey, D.K., Huebert, 
D.J., McMahon, S., Karlsson, E.K., Kulbokas, E.J., 3rd, Gingeras, T.R., et al. (2005). 
Genomic maps and comparative analysis of histone modifications in human and 
mouse. Cell 120, 169-181. 
Bernstein, B.E., Mikkelsen, T.S., Xie, X., Kamal, M., Huebert, D.J., Cuff, J., Fry, B., 
Meissner, A., Wernig, M., Plath, K., et al. (2006). A bivalent chromatin structure 
marks key developmental genes in embryonic stem cells. Cell 125, 315-326. 
Bhattacharya, S.K., Ramchandani, S., Cervoni, N., and Szyf, M. (1999). A 
mammalian protein with specific demethylase activity for mCpG DNA. Nature 397, 
579-583. 
Bhutani, N., Brady, J.J., Damian, M., Sacco, A., Corbel, S.Y., and Blau, H.M. 
(2009). Reprogramming towards pluripotency requires AID-dependent DNA 
demethylation. Nature 463, 1042-1047. 
Bird, A. (2002). DNA methylation patterns and epigenetic memory. Genes & 
development 16, 6-21. 
Bird, A., Taggart, M., Frommer, M., Miller, O.J., and Macleod, D. (1985). A fraction 
of the mouse genome that is derived from islands of nonmethylated, CpG-rich DNA. 
Cell 40, 91-99. 
Bird, A., and Tweedie, S. (1995). Transcriptional noise and the evolution of gene 
number. Philosophical transactions of the Royal Society of London 349, 249-253. 
Bird, A.P. (1980). DNA methylation and the frequency of CpG in animal DNA. 
Nucleic Acids Res 8, 1499-1504. 
 
 222 
Bird, A.P. (1995). Gene number, noise reduction and biological complexity. Trends 
Genet 11, 94-100. 
Bird, J.J., Brown, D.R., Mullen, A.C., Moskowitz, N.H., Mahowald, M.A., Sider, 
J.R., Gajewski, T.F., Wang, C.R., and Reiner, S.L. (1998). Helper T cell 
differentiation is controlled by the cell cycle. Immunity 9, 229-237. 
Birke, M., Schreiner, S., Garcia-Cuellar, M.P., Mahr, K., Titgemeyer, F., and Slany, 
R.K. (2002). The MT domain of the proto-oncoprotein MLL binds to CpG-
containing DNA and discriminates against methylation. Nucleic Acids Res 30, 958-
965. 
Blackledge, N.P., Zhou, J.C., Tolstorukov, M.Y., Farcas, A.M., Park, P.J., and Klose, 
R.J. (2010). CpG islands recruit a histone H3 lysine 36 demethylase. Molecular cell 
38, 179-190. 
Blanchard, C., Wang, N., Stringer, K.F., Mishra, A., Fulkerson, P.C., Abonia, J.P., 
Jameson, S.C., Kirby, C., Konikoff, M.R., Collins, M.H., et al. (2006). Eotaxin-3 and 
a uniquely conserved gene-expression profile in eosinophilic esophagitis. The 
Journal of clinical investigation 116, 536-547. 
Blankenberg, D., Taylor, J., Schenck, I., He, J., Zhang, Y., Ghent, M., 
Veeraraghavan, N., Albert, I., Miller, W., Makova, K.D., et al. (2007). A framework 
for collaborative analysis of ENCODE data: making large-scale analyses biologist-
friendly. Genome research 17, 960-964. 
Bock, C., Reither, S., Mikeska, T., Paulsen, M., Walter, J., and Lengauer, T. (2005). 
BiQ Analyzer: visualization and quality control for DNA methylation data from 
bisulfite sequencing. Bioinformatics (Oxford, England) 21, 4067-4068. 
Borchers, M., Ansay T, DeSalle R, Daugherty BL, Shen H, Metzger M, Lee NA, Lee 
JJ (2002). In vitro assessment of chemokine receptor-ligand interactions mediating 
mouse eosinophil migration. Journal of leukocyte biology 71, 1033-1041. 
Bowen, N.J., Fujita, N., Kajita, M., and Wade, P.A. (2004). Mi-2/NuRD: multiple 
complexes for many purposes. Biochimica et biophysica acta 1677, 52-57. 
Boyes, J., and Bird, A. (1991). DNA methylation inhibits transcription indirectly via 
a methyl-CpG binding protein. Cell 64, 1123-1134. 
Boyes, J., and Bird, A. (1992). Repression of genes by DNA methylation depends on 
CpG density and promoter strength: evidence for involvement of a methyl-CpG 
binding protein. The EMBO journal 11, 327-333. 
Brackertz, M., Gong, Z., Leers, J., and Renkawitz, R. (2006). p66alpha and p66beta 
of the Mi-2/NuRD complex mediate MBD2 and histone interaction. Nucleic Acids 
Res 34, 397-406. 
Brandeis, M., Frank, D., Keshet, I., Siegfried, Z., Mendelsohn, M., Nemes, A., 
Temper, V., Razin, A., and Cedar, H. (1994). Sp1 elements protect a CpG island 
from de novo methylation. Nature 371, 435-438. 
Brookes, E., and Pombo, A. (2009). Modifications of RNA polymerase II are pivotal 
in regulating gene expression states. EMBO reports 10, 1213-1219. 
 
 223 
Broske, A.M., Vockentanz, L., Kharazi, S., Huska, M.R., Mancini, E., Scheller, M., 
Kuhl, C., Enns, A., Prinz, M., Jaenisch, R., et al. (2009). DNA methylation protects 
hematopoietic stem cell multipotency from myeloerythroid restriction. Nat Genet 41, 
1207-1215. 
Bruniquel, D., and Schwartz, R.H. (2003). Selective, stable demethylation of the 
interleukin-2 gene enhances transcription by an active process. Nature immunology 
4, 235-240. 
Campanero, M.R., Armstrong, M.I., and Flemington, E.K. (2000). CpG methylation 
as a mechanism for the regulation of E2F activity. Proceedings of the National 
Academy of Sciences of the United States of America 97, 6481-6486. 
Cao, R., and Zhang, Y. (2004). The functions of E(Z)/EZH2-mediated methylation of 
lysine 27 in histone H3. Current opinion in genetics & development 14, 155-164. 
Carlone, D.L., Lee, J.H., Young, S.R., Dobrota, E., Butler, J.S., Ruiz, J., and Skalnik, 
D.G. (2005). Reduced genomic cytosine methylation and defective cellular 
differentiation in embryonic stem cells lacking CpG binding protein. Mol Cell Biol 
25, 4881-4891. 
Carlone, D.L., and Skalnik, D.G. (2001). CpG binding protein is crucial for early 
embryonic development. Mol Cell Biol 21, 7601-7606. 
Carninci, P., Sandelin, A., Lenhard, B., Katayama, S., Shimokawa, K., Ponjavic, J., 
Semple, C.A., Taylor, M.S., Engstrom, P.G., Frith, M.C., et al. (2006). Genome-wide 
analysis of mammalian promoter architecture and evolution. Nat Genet 38, 626-635. 
Chahrour, M., Jung, S.Y., Shaw, C., Zhou, X., Wong, S.T., Qin, J., and Zoghbi, H.Y. 
(2008). MeCP2, a key contributor to neurological disease, activates and represses 
transcription. Science 320, 1224-1229. 
Chang, S., Aune TM (2007). Dynamic changes in histone-methylation 'marks' across 
the locus encoding interferon-gamma during the differentiation of T helper type 2 
cells. Nature immunology 8, 723-731. 
Chappell, C., Beard, C., Altman, J., Jaenisch, R., and Jacob, J. (2006). DNA 
methylation by DNA methyltransferase 1 is critical for effector CD8 T cell 
expansion. J Immunol 176, 4562-4572. 
Chatagnon, A., Ballestar, E., Esteller, M., and Dante, R. (2010). A role for methyl-
CpG binding domain protein 2 in the modulation of the estrogen response of 
pS2/TFF1 gene. PLoS ONE 5, e9665. 
Chatagnon, A., Bougel, S., Perriaud, L., Lachuer, J., Benhattar, J., and Dante, R. 
(2009). Specific association between the methyl-CpG-binding domain protein 2 and 
the hypermethylated region of the human telomerase reverse transcriptase promoter 
in cancer cells. Carcinogenesis 30, 28-34. 
Chen, R.Z., Akbarian, S., Tudor, M., and Jaenisch, R. (2001). Deficiency of methyl-
CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat 
Genet 27, 327-331. 
Chen, W., Jin, W., Hardegen, N., Lei, K.J., Li, L., Marinos, N., McGrady, G., and 
Wahl, S.M. (2003). Conversion of peripheral CD4+CD25- naive T cells to 
 
 224 
CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. 
J Exp Med 198, 1875-1886. 
Cheng, P., Nefedova, Y., Miele, L., Osborne, B.A., and Gabrilovich, D. (2003). 
Notch signaling is necessary but not sufficient for differentiation of dendritic cells. 
Blood 102, 3980-3988. 
Choi, Y.I., Duke-Cohan, J.S., Ahmed, W.B., Handley, M.A., Mann, F., Epstein, J.A., 
Clayton, L.K., and Reinherz, E.L. (2008). PlexinD1 glycoprotein controls migration 
of positively selected thymocytes into the medulla. Immunity 29, 888-898. 
Cisse, B., Caton, M.L., Lehner, M., Maeda, T., Scheu, S., Locksley, R., Holmberg, 
D., Zweier, C., den Hollander, N.S., Kant, S.G., et al. (2008). Transcription factor 
E2-2 is an essential and specific regulator of plasmacytoid dendritic cell 
development. Cell 135, 37-48. 
Clouaire, T., de Las Heras, J.I., Merusi, C., and Stancheva, I. (2010). Recruitment of 
MBD1 to target genes requires sequence-specific interaction of the MBD domain 
with methylated DNA. Nucleic Acids Res. 
Coolen, M.W., Stirzaker, C., Song, J.Z., Statham, A.L., Kassir, Z., Moreno, C.S., 
Young, A.N., Varma, V., Speed, T.P., Cowley, M., et al. (2010). Consolidation of 
the cancer genome into domains of repressive chromatin by long-range epigenetic 
silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol 12, 235-246. 
Core, L.J., Waterfall, J.J., and Lis, J.T. (2008). Nascent RNA sequencing reveals 
widespread pausing and divergent initiation at human promoters. Science 322, 1845-
1848. 
Costello, J.F., Fruhwald, M.C., Smiraglia, D.J., Rush, L.J., Robertson, G.P., Gao, X., 
Wright, F.A., Feramisco, J.D., Peltomaki, P., Lang, J.C., et al. (2000). Aberrant 
CpG-island methylation has non-random and tumour-type-specific patterns. Nat 
Genet 24, 132-138. 
Creusot, F., Acs, G., and Christman, J.K. (1982). Inhibition of DNA 
methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-
azacytidine and 5-aza-2'-deoxycytidine. The Journal of biological chemistry 257, 
2041-2048. 
Cross, S.H., Charlton, J.A., Nan, X., and Bird, A.P. (1994). Purification of CpG 
islands using a methylated DNA binding column. Nat Genet 6, 236-244. 
Cross, S.H., Meehan, R.R., Nan, X., and Bird, A. (1997). A component of the 
transcriptional repressor MeCP1 shares a motif with DNA methyltransferase and 
HRX proteins. Nat Genet 16, 256-259. 
Cruikshank, W., and Little, F. (2008). lnterleukin-16: the ins and outs of regulating 
T-cell activation. Critical reviews in immunology 28, 467-483. 
Csankovszki, G., Nagy, A., and Jaenisch, R. (2001). Synergism of Xist RNA, DNA 
methylation, and histone hypoacetylation in maintaining X chromosome inactivation. 
The Journal of cell biology 153, 773-784. 
Daniels, R., Kinis, T., Serhal, P., and Monk, M. (1995). Expression of the myotonin 
protein kinase gene in preimplantation human embryos. Hum Mol Genet 4, 389-393. 
 
 225 
Daniels, R., Lowell, S., Bolton, V., and Monk, M. (1997). Transcription of tissue-
specific genes in human preimplantation embryos. Human reproduction (Oxford, 
England) 12, 2251-2256. 
de la Serna, I.L., Ohkawa, Y., and Imbalzano, A.N. (2006). Chromatin remodelling 
in mammalian differentiation: lessons from ATP-dependent remodellers. Nature 
reviews 7, 461-473. 
De Smet, C., Lurquin, C., Lethe, B., Martelange, V., and Boon, T. (1999). DNA 
methylation is the primary silencing mechanism for a set of germ line- and tumor-
specific genes with a CpG-rich promoter. Mol Cell Biol 19, 7327-7335. 
Delgado, S., Gomez, M., Bird, A., and Antequera, F. (1998). Initiation of DNA 
replication at CpG islands in mammalian chromosomes. The EMBO journal 17, 
2426-2435. 
Deng, J., Shoemaker, R., Xie, B., Gore, A., LeProust, E.M., Antosiewicz-Bourget, J., 
Egli, D., Maherali, N., Park, I.H., Yu, J., et al. (2009). Targeted bisulfite sequencing 
reveals changes in DNA methylation associated with nuclear reprogramming. Nature 
biotechnology 27, 353-360. 
Dennis, K., Fan, T., Geiman, T., Yan, Q., and Muegge, K. (2001). Lsh, a member of 
the SNF2 family, is required for genome-wide methylation. Genes & development 
15, 2940-2944. 
Djuretic, I.M., Levanon, D., Negreanu, V., Groner, Y., Rao, A., and Ansel, K.M. 
(2007). Transcription factors T-bet and Runx3 cooperate to activate Ifng and silence 
Il4 in T helper type 1 cells. Nature immunology 8, 145-153. 
Down, T.A., Rakyan, V.K., Turner, D.J., Flicek, P., Li, H., Kulesha, E., Graf, S., 
Johnson, N., Herrero, J., Tomazou, E.M., et al. (2008). A Bayesian deconvolution 
strategy for immunoprecipitation-based DNA methylome analysis. Nature 
biotechnology 26, 779-785. 
Dunning, M.J., Barbosa-Morais, N.L., Lynch, A.G., Tavare, S., and Ritchie, M.E. 
(2008). Statistical issues in the analysis of Illumina data. BMC bioinformatics 9, 85. 
Eckhardt, F., Lewin, J., Cortese, R., Rakyan, V.K., Attwood, J., Burger, M., Burton, 
J., Cox, T.V., Davies, R., Down, T.A., et al. (2006). DNA methylation profiling of 
human chromosomes 6, 20 and 22. Nat Genet 38, 1378-1385. 
Edwards, C.A., and Ferguson-Smith, A.C. (2007). Mechanisms regulating imprinted 
genes in clusters. Current opinion in cell biology 19, 281-289. 
Efroni, S., Duttagupta, R., Cheng, J., Dehghani, H., Hoeppner, D.J., Dash, C., Bazett-
Jones, D.P., Le Grice, S., McKay, R.D., Buetow, K.H., et al. (2008). Global 
transcription in pluripotent embryonic stem cells. Cell stem cell 2, 437-447. 
Egwuagu, C.E., Yu, C.R., Zhang, M., Mahdi, R.M., Kim, S.J., and Gery, I. (2002). 
Suppressors of cytokine signaling proteins are differentially expressed in Th1 and 
Th2 cells: implications for Th cell lineage commitment and maintenance. J Immunol 
168, 3181-3187. 
Ehrlich, M. (2003). The ICF syndrome, a DNA methyltransferase 3B deficiency and 
immunodeficiency disease. Clinical immunology (Orlando, Fla 109, 17-28. 
 
 226 
Ehrlich, M., Gama-Sosa, M.A., Huang, L.H., Midgett, R.M., Kuo, K.C., McCune, 
R.A., and Gehrke, C. (1982). Amount and distribution of 5-methylcytosine in human 
DNA from different types of tissues of cells. Nucleic Acids Res 10, 2709-2721. 
El-Asady, R., Yuan, R., Liu, K., Wang, D., Gress, R.E., Lucas, P.J., Drachenberg, 
C.B., and Hadley, G.A. (2005). TGF-{beta}-dependent CD103 expression by 
CD8(+) T cells promotes selective destruction of the host intestinal epithelium 
during graft-versus-host disease. J Exp Med 201, 1647-1657. 
Elgert, K.D. (2009). Immunology: Understanding the immune system. John Wiley 
and Sons 2nd edition. 
Epsztejn-Litman, S., Feldman, N., Abu-Remaileh, M., Shufaro, Y., Gerson, A., 
Ueda, J., Deplus, R., Fuks, F., Shinkai, Y., Cedar, H., et al. (2008). De novo DNA 
methylation promoted by G9a prevents reprogramming of embryonically silenced 
genes. Nature structural & molecular biology 15, 1176-1183. 
Esteve, P.O., Chin, H.G., Smallwood, A., Feehery, G.R., Gangisetty, O., Karpf, A.R., 
Carey, M.F., and Pradhan, S. (2006). Direct interaction between DNMT1 and G9a 
coordinates DNA and histone methylation during replication. Genes & development 
20, 3089-3103. 
Fantini, M.C., Becker, C., Monteleone, G., Pallone, F., Galle, P.R., and Neurath, 
M.F. (2004). Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- 
T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172, 
5149-5153. 
Faulkner, G.J., Kimura, Y., Daub, C.O., Wani, S., Plessy, C., Irvine, K.M., Schroder, 
K., Cloonan, N., Steptoe, A.L., Lassmann, T., et al. (2009). The regulated 
retrotransposon transcriptome of mammalian cells. Nat Genet 41, 563-571. 
Fazzari, M.J., and Greally, J.M. (2004). Epigenomics: beyond CpG islands. Nature 
reviews 5, 446-455. 
Felsenfeld, G., and Groudine, M. (2003). Controlling the double helix. Nature 421, 
448-453. 
Feng, Q., and Zhang, Y. (2001). The MeCP1 complex represses transcription through 
preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes 
& development 15, 827-832. 
Fields, P.E., Kim, S.T., and Flavell, R.A. (2002). Cutting edge: changes in histone 
acetylation at the IL-4 and IFN-gamma loci accompany Th1/Th2 differentiation. J 
Immunol 169, 647-650. 
Fields, P.E., Lee, G.R., Kim, S.T., Bartsevich, V.V., and Flavell, R.A. (2004). Th2-
specific chromatin remodeling and enhancer activity in the Th2 cytokine locus 
control region. Immunity 21, 865-876. 
Filion, G.J., Zhenilo, S., Salozhin, S., Yamada, D., Prokhortchouk, E., and Defossez, 
P.A. (2006). A family of human zinc finger proteins that bind methylated DNA and 
repress transcription. Mol Cell Biol 26, 169-181. 
 
 227 
Finney, C.A., Taylor, M.D., Wilson, M.S., and Maizels, R.M. (2007). Expansion and 
activation of CD4(+)CD25(+) regulatory T cells in Heligmosomoides polygyrus 
infection. European journal of immunology 37, 1874-1886. 
Fiorini, E., Merck, E., Wilson, A., Ferrero, I., Jiang, W., Koch, U., Auderset, F., 
Laurenti, E., Tacchini-Cottier, F., Pierres, M., et al. (2009). Dynamic regulation of 
notch 1 and notch 2 surface expression during T cell development and activation 
revealed by novel monoclonal antibodies. J Immunol 183, 7212-7222. 
Floess, S., Freyer, J., Siewert, C., Baron, U., Olek, S., Polansky, J., Schlawe, K., 
Chang, H.D., Bopp, T., Schmitt, E., et al. (2007). Epigenetic control of the foxp3 
locus in regulatory T cells. PLoS biology 5, e38. 
Fouse, S.D., Shen, Y., Pellegrini, M., Cole, S., Meissner, A., Van Neste, L., Jaenisch, 
R., and Fan, G. (2008). Promoter CpG methylation contributes to ES cell gene 
regulation in parallel with Oct4/Nanog, PcG complex, and histone H3 K4/K27 
trimethylation. Cell stem cell 2, 160-169. 
Fraga, M.F., Ballestar, E., Montoya, G., Taysavang, P., Wade, P.A., and Esteller, M. 
(2003). The affinity of different MBD proteins for a specific methylated locus 
depends on their intrinsic binding properties. Nucleic Acids Res 31, 1765-1774. 
Frommer, M., McDonald, L.E., Millar, D.S., Collis, C.M., Watt, F., Grigg, G.W., 
Molloy, P.L., and Paul, C.L. (1992). A genomic sequencing protocol that yields a 
positive display of 5-methylcytosine residues in individual DNA strands. 
Proceedings of the National Academy of Sciences of the United States of America 
89, 1827-1831. 
Fujita, N., Takebayashi, S., Okumura, K., Kudo, S., Chiba, T., Saya, H., and Nakao, 
M. (1999). Methylation-mediated transcriptional silencing in euchromatin by methyl-
CpG binding protein MBD1 isoforms. Mol Cell Biol 19, 6415-6426. 
Fujita, N., and Wade, P.A. (2004). Use of bifunctional cross-linking reagents in 
mapping genomic distribution of chromatin remodeling complexes. Methods (San 
Diego, Calif 33, 81-85. 
Fujita, N., Watanabe, S., Ichimura, T., Tsuruzoe, S., Shinkai, Y., Tachibana, M., 
Chiba, T., and Nakao, M. (2003). Methyl-CpG binding domain 1 (MBD1) interacts 
with the Suv39h1-HP1 heterochromatic complex for DNA methylation-based 
transcriptional repression. The Journal of biological chemistry 278, 24132-24138. 
Fuks, F., Burgers, W.A., Brehm, A., Hughes-Davies, L., and Kouzarides, T. (2000). 
DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat 
Genet 24, 88-91. 
Fuks, F., Hurd, P.J., Deplus, R., and Kouzarides, T. (2003). The DNA 
methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. 
Nucleic Acids Res 31, 2305-2312. 
Gamper, C.J., Agoston, A.T., Nelson, W.G., and Powell, J.D. (2009). Identification 
of DNA methyltransferase 3a as a T cell receptor-induced regulator of Th1 and Th2 
differentiation. J Immunol 183, 2267-2276. 
Gardiner-Garden, M., and Frommer, M. (1987). CpG islands in vertebrate genomes. 
Journal of molecular biology 196, 261-282. 
 
 228 
Gardiner-Garden, M., and Frommer, M. (1994). Transcripts and CpG islands 
associated with the pro-opiomelanocortin gene and other neurally expressed genes. 
Journal of molecular endocrinology 12, 365-382. 
Gaston, K., and Fried, M. (1995). CpG methylation has differential effects on the 
binding of YY1 and ETS proteins to the bi-directional promoter of the Surf-1 and 
Surf-2 genes. Nucleic Acids Res 23, 901-909. 
Gebhard, C., Schwarzfischer, L., Pham, T.H., Schilling, E., Klug, M., Andreesen, R., 
and Rehli, M. (2006). Genome-wide profiling of CpG methylation identifies novel 
targets of aberrant hypermethylation in myeloid leukemia. Cancer research 66, 6118-
6128. 
Geiman, T.M., Sankpal, U.T., Robertson, A.K., Zhao, Y., Zhao, Y., and Robertson, 
K.D. (2004). DNMT3B interacts with hSNF2H chromatin remodeling enzyme, 
HDACs 1 and 2, and components of the histone methylation system. Biochemical 
and biophysical research communications 318, 544-555. 
Goll, M.G., Kirpekar, F., Maggert, K.A., Yoder, J.A., Hsieh, C.L., Zhang, X., Golic, 
K.G., Jacobsen, S.E., and Bestor, T.H. (2006). Methylation of tRNAAsp by the DNA 
methyltransferase homolog Dnmt2. Science 311, 395-398. 
Gong, Z., Morales-Ruiz, T., Ariza, R.R., Roldan-Arjona, T., David, L., and Zhu, J.K. 
(2002). ROS1, a repressor of transcriptional gene silencing in Arabidopsis, encodes a 
DNA glycosylase/lyase. Cell 111, 803-814. 
Gonzalo, S., Jaco, I., Fraga, M.F., Chen, T., Li, E., Esteller, M., and Blasco, M.A. 
(2006). DNA methyltransferases control telomere length and telomere recombination 
in mammalian cells. Nat Cell Biol 8, 416-424. 
Gowher, H., and Jeltsch, A. (2002). Molecular enzymology of the catalytic domains 
of the Dnmt3a and Dnmt3b DNA methyltransferases. The Journal of biological 
chemistry 277, 20409-20414. 
Gowher, H., Liebert, K., Hermann, A., Xu, G., and Jeltsch, A. (2005). Mechanism of 
stimulation of catalytic activity of Dnmt3A and Dnmt3B DNA-(cytosine-C5)-
methyltransferases by Dnmt3L. The Journal of biological chemistry 280, 13341-
13348. 
Grogan, J.L., Wang, Z.E., Stanley, S., Harmon, B., Loots, G.G., Rubin, E.M., and 
Locksley, R.M. (2003). Basal chromatin modification at the IL-4 gene in helper T 
cells. J Immunol 171, 6672-6679. 
Gu, P., Le Menuet, D., Chung, A.C., and Cooney, A.J. (2006). Differential 
recruitment of methylated CpG binding domains by the orphan receptor GCNF 
initiates the repression and silencing of Oct4 expression. Mol Cell Biol 26, 9471-
9483. 
Guenther, M.G., Levine, S.S., Boyer, L.A., Jaenisch, R., and Young, R.A. (2007). A 
chromatin landmark and transcription initiation at most promoters in human cells. 
Cell 130, 77-88. 
Guy, J., Gan, J., Selfridge, J., Cobb, S., and Bird, A. (2007). Reversal of neurological 
defects in a mouse model of Rett syndrome. Science 315, 1143-1147. 
 
 229 
Guy, J., Hendrich, B., Holmes, M., Martin, J.E., and Bird, A. (2001). A mouse 
Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat 
Genet 27, 322-326. 
Haberland, M., Montgomery, R.L., and Olson, E.N. (2009). The many roles of 
histone deacetylases in development and physiology: implications for disease and 
therapy. Nature reviews 10, 32-42. 
Hamalainen, H.K., Tubman, J.C., Vikman, S., Kyrola, T., Ylikoski, E., Warrington, 
J.A., and Lahesmaa, R. (2001). Identification and validation of endogenous reference 
genes for expression profiling of T helper cell differentiation by quantitative real-
time RT-PCR. Analytical biochemistry 299, 63-70. 
Happel, N., and Doenecke, D. (2009). Histone H1 and its isoforms: contribution to 
chromatin structure and function. Gene 431, 1-12. 
Hardtke, S., Ohl, L., and Forster, R. (2005). Balanced expression of CXCR5 and 
CCR7 on follicular T helper cells determines their transient positioning to lymph 
node follicles and is essential for efficient B-cell help. Blood 106, 1924-1931. 
Harrington, M.A., Jones, P.A., Imagawa, M., and Karin, M. (1988). Cytosine 
methylation does not affect binding of transcription factor Sp1. Proceedings of the 
National Academy of Sciences of the United States of America 85, 2066-2070. 
Hegazy, A.N., Peine, M., Helmstetter, C., Panse, I., Frohlich, A., Bergthaler, A., 
Flatz, L., Pinschewer, D.D., Radbruch, A., and Lohning, M. (2010). Interferons 
direct Th2 cell reprogramming to generate a stable GATA-3(+)T-bet(+) cell subset 
with combined Th2 and Th1 cell functions. Immunity 32, 116-128. 
Heintzman, N.D., Stuart, R.K., Hon, G., Fu, Y., Ching, C.W., Hawkins, R.D., 
Barrera, L.O., Van Calcar, S., Qu, C., Ching, K.A., et al. (2007). Distinct and 
predictive chromatin signatures of transcriptional promoters and enhancers in the 
human genome. Nat Genet 39, 311-318. 
Hellman, A., and Chess, A. (2007). Gene body-specific methylation on the active X 
chromosome. Science 315, 1141-1143. 
Hendrich, B., Abbott, C., McQueen, H., Chambers, D., Cross, S., and Bird, A. 
(1999a). Genomic structure and chromosomal mapping of the murine and human 
Mbd1, Mbd2, Mbd3, and Mbd4 genes. Mamm Genome 10, 906-912. 
Hendrich, B., and Bird, A. (1998). Identification and characterization of a family of 
mammalian methyl-CpG binding proteins. Mol Cell Biol 18, 6538-6547. 
Hendrich, B., Guy, J., Ramsahoye, B., Wilson, V.A., and Bird, A. (2001). Closely 
related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse 
development. Genes & development 15, 710-723. 
Hendrich, B., Hardeland, U., Ng, H.H., Jiricny, J., and Bird, A. (1999b). The thymine 
glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. 
Nature 401, 301-304. 
Hermann, A., Gowher, H., and Jeltsch, A. (2004). Biochemistry and biology of 
mammalian DNA methyltransferases. Cell Mol Life Sci 61, 2571-2587. 
 
 230 
Ho, K.L., McNae, I.W., Schmiedeberg, L., Klose, R.J., Bird, A.P., and Walkinshaw, 
M.D. (2008). MeCP2 binding to DNA depends upon hydration at methyl-CpG. 
Molecular cell 29, 525-531. 
Ho, L., and Crabtree, G.R. (2010). Chromatin remodelling during development. 
Nature 463, 474-484. 
Hodgkin, J. (1994). Epigenetics and the maintenance of gene activity states in 
Caenorhabditis elegans. Developmental genetics 15, 471-477. 
Hong, L., Schroth, G.P., Matthews, H.R., Yau, P., and Bradbury, E.M. (1993). 
Studies of the DNA binding properties of histone H4 amino terminus. Thermal 
denaturation studies reveal that acetylation markedly reduces the binding constant of 
the H4 "tail" to DNA. The Journal of biological chemistry 268, 305-314. 
Hughes, T., Webb, R., Fei, Y., Wren, J.D., and Sawalha, A.H. (2010). DNA 
methylome in human CD4+ T cells identifies transcriptionally repressive and non-
repressive methylation peaks. Genes and immunity. 
Hutchins, A.S., Artis, D., Hendrich, B.D., Bird, A.P., Scott, P., and Reiner, S.L. 
(2005). Cutting edge: a critical role for gene silencing in preventing excessive type 1 
immunity. J Immunol 175, 5606-5610. 
Hutchins, A.S., Mullen, A.C., Lee, H.W., Sykes, K.J., High, F.A., Hendrich, B.D., 
Bird, A.P., and Reiner, S.L. (2002). Gene silencing quantitatively controls the 
function of a developmental trans-activator. Molecular cell 10, 81-91. 
Iguchi-Ariga, S.M., and Schaffner, W. (1989). CpG methylation of the cAMP-
responsive enhancer/promoter sequence TGACGTCA abolishes specific factor 
binding as well as transcriptional activation. Genes & development 3, 612-619. 
Illingworth, R., Gruenewald-Schneider, U., Webb, S., Kerr, A., James, K., Turner, 
D., Smith, C., Harrison, D., Andrews, R., and Bird, A. (2010). Orphan CpG islands 
identify numerous conserved promoters in the mammalian genome. PLoS genetics 
Accepted. 
Illingworth, R., Kerr, A., Desousa, D., Jorgensen, H., Ellis, P., Stalker, J., Jackson, 
D., Clee, C., Plumb, R., Rogers, J., et al. (2008). A novel CpG island set identifies 
tissue-specific methylation at developmental gene loci. PLoS biology 6, e22. 
Illingworth, R.S., and Bird, A.P. (2009). CpG islands--'a rough guide'. FEBS letters 
583, 1713-1720. 
Irizarry, R.A., Ladd-Acosta, C., Carvalho, B., Wu, H., Brandenburg, S.A., Jeddeloh, 
J.A., Wen, B., and Feinberg, A.P. (2008). Comprehensive high-throughput arrays for 
relative methylation (CHARM). Genome research 18, 780-790. 
Irizarry, R.A., Ladd-Acosta, C., Wen, B., Wu, Z., Montano, C., Onyango, P., Cui, H., 
Gabo, K., Rongione, M., Webster, M., et al. (2009). The human colon cancer 
methylome shows similar hypo- and hypermethylation at conserved tissue-specific 
CpG island shores. Nat Genet 41, 178-186. 
Ito, S., D'Alessio, A.C., Taranova, O.V., Hong, K., Sowers, L.C., and Zhang, Y. 
(2010). Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and 
inner cell mass specification. Nature. 
 
 231 
Ivascu, C., Wasserkort, R., Lesche, R., Dong, J., Stein, H., Thiel, A., and Eckhardt, 
F. (2007). DNA methylation profiling of transcription factor genes in normal 
lymphocyte development and lymphomas. The international journal of biochemistry 
& cell biology 39, 1523-1538. 
Jenuwein, T., and Allis, C.D. (2001). Translating the histone code. Science 293, 
1074-1080. 
Jones, B., and Chen, J. (2006). Inhibition of IFN-gamma transcription by site-
specific methylation during T helper cell development. The EMBO journal 25, 2443-
2452. 
Jones, P.A., and Baylin, S.B. (2002). The fundamental role of epigenetic events in 
cancer. Nature reviews 3, 415-428. 
Jones, P.A., and Baylin, S.B. (2007). The epigenomics of cancer. Cell 128, 683-692. 
Jones, P.A., Wolkowicz, M.J., Harrington, M.A., and Gonzales, F. (1990). 
Methylation and expression of the Myo D1 determination gene. Philosophical 
transactions of the Royal Society of London 326, 277-284. 
Jorgensen, H.F., Ben-Porath, I., and Bird, A.P. (2004). Mbd1 is recruited to both 
methylated and nonmethylated CpGs via distinct DNA binding domains. Mol Cell 
Biol 24, 3387-3395. 
Josefowicz, S.Z., Wilson, C.B., and Rudensky, A.Y. (2009). Cutting edge: TCR 
stimulation is sufficient for induction of Foxp3 expression in the absence of DNA 
methyltransferase 1. J Immunol 182, 6648-6652. 
Junt, T., Fink, K., Forster, R., Senn, B., Lipp, M., Muramatsu, M., Zinkernagel, 
R.M., Ludewig, B., and Hengartner, H. (2005). CXCR5-dependent seeding of 
follicular niches by B and Th cells augments antiviral B cell responses. J Immunol 
175, 7109-7116. 
Kaji, K., Caballero, I.M., MacLeod, R., Nichols, J., Wilson, V.A., and Hendrich, B. 
(2006). The NuRD component Mbd3 is required for pluripotency of embryonic stem 
cells. Nat Cell Biol 8, 285-292. 
Kaji, K., Nichols, J., and Hendrich, B. (2007). Mbd3, a component of the NuRD co-
repressor complex, is required for development of pluripotent cells. Development 
(Cambridge, England) 134, 1123-1132. 
Kaneda, M., Okano, M., Hata, K., Sado, T., Tsujimoto, N., Li, E., and Sasaki, H. 
(2004). Essential role for de novo DNA methyltransferase Dnmt3a in paternal and 
maternal imprinting. Nature 429, 900-903. 
Kersh, E.N. (2006). Impaired memory CD8 T cell development in the absence of 
methyl-CpG-binding domain protein 2. J Immunol 177, 3821-3826. 
Keshet, I., Schlesinger, Y., Farkash, S., Rand, E., Hecht, M., Segal, E., Pikarski, E., 
Young, R.A., Niveleau, A., Cedar, H., et al. (2006). Evidence for an instructive 
mechanism of de novo methylation in cancer cells. Nat Genet 38, 149-153. 
Khulan, B., Thompson, R.F., Ye, K., Fazzari, M.J., Suzuki, M., Stasiek, E., Figueroa, 
M.E., Glass, J.L., Chen, Q., Montagna, C., et al. (2006). Comparative isoschizomer 
profiling of cytosine methylation: the HELP assay. Genome research 16, 1046-1055. 
 
 232 
Kim, H.P., and Leonard, W.J. (2007). CREB/ATF-dependent T cell receptor-induced 
FoxP3 gene expression: a role for DNA methylation. J Exp Med 204, 1543-1551. 
Kim, J., Daniel, J., Espejo, A., Lake, A., Krishna, M., Xia, L., Zhang, Y., and 
Bedford, M.T. (2006). Tudor, MBT and chromo domains gauge the degree of lysine 
methylation. EMBO reports 7, 397-403. 
Kim, S.T., Fields, P.E., and Flavell, R.A. (2007). Demethylation of a specific 
hypersensitive site in the Th2 locus control region. Proceedings of the National 
Academy of Sciences of the United States of America 104, 17052-17057. 
Klose, R.J., and Bird, A.P. (2004). MeCP2 behaves as an elongated monomer that 
does not stably associate with the Sin3a chromatin remodeling complex. The Journal 
of biological chemistry 279, 46490-46496. 
Klose, R.J., Sarraf, S.A., Schmiedeberg, L., McDermott, S.M., Stancheva, I., and 
Bird, A.P. (2005). DNA binding selectivity of MeCP2 due to a requirement for A/T 
sequences adjacent to methyl-CpG. Molecular cell 19, 667-678. 
Klose, R.J., and Zhang, Y. (2007). Regulation of histone methylation by 
demethylimination and demethylation. Nat Rev Mol Cell Biol 8, 307-318. 
Kondo, Y., Shen, L., Cheng, A.S., Ahmed, S., Boumber, Y., Charo, C., Yamochi, T., 
Urano, T., Furukawa, K., Kwabi-Addo, B., et al. (2008). Gene silencing in cancer by 
histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat 
Genet 40, 741-750. 
Kriaucionis, S., and Heintz, N. (2009). The nuclear DNA base 5-
hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324, 
929-930. 
Kubo, M., Hanada, T., and Yoshimura, A. (2003). Suppressors of cytokine signaling 
and immunity. Nature immunology 4, 1169-1176. 
Kumanogoh, A., Shikina, T., Suzuki, K., Uematsu, S., Yukawa, K., Kashiwamura, 
S., Tsutsui, H., Yamamoto, M., Takamatsu, H., Ko-Mitamura, E.P., et al. (2005). 
Nonredundant roles of Sema4A in the immune system: defective T cell priming and 
Th1/Th2 regulation in Sema4A-deficient mice. Immunity 22, 305-316. 
Lachner, M., O'Carroll, D., Rea, S., Mechtler, K., and Jenuwein, T. (2001). 
Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 
410, 116-120. 
Lal, G., Zhang, N., van der Touw, W., Ding, Y., Ju, W., Bottinger, E.P., Reid, S.P., 
Levy, D.E., and Bromberg, J.S. (2009). Epigenetic regulation of Foxp3 expression in 
regulatory T cells by DNA methylation. J Immunol 182, 259-273. 
Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., 
Devon, K., Dewar, K., Doyle, M., FitzHugh, W., et al. (2001). Initial sequencing and 
analysis of the human genome. Nature 409, 860-921. 
Larsen, F., Gundersen, G., Lopez, R., and Prydz, H. (1992). CpG islands as gene 
markers in the human genome. Genomics 13, 1095-1107. 
 
 233 
Laurent, L., Wong, E., Li, G., Huynh, T., Tsirigos, A., Ong, C.T., Low, H.M., Kin 
Sung, K.W., Rigoutsos, I., Loring, J., et al. (2010). Dynamic changes in the human 
methylome during differentiation. Genome research 20, 320-331. 
Le Guezennec, X., Vermeulen, M., Brinkman, A.B., Hoeijmakers, W.A., Cohen, A., 
Lasonder, E., and Stunnenberg, H.G. (2006). MBD2/NuRD and MBD3/NuRD, two 
distinct complexes with different biochemical and functional properties. Mol Cell 
Biol 26, 843-851. 
Lee, D., Agarwal S, Rao A (2002). Th2 lineage commitment and efficient IL-4 
production involves extended demethylation of the IL-4 gene. Immunity 16, 649-
660. 
Lee, D.Y., Hayes, J.J., Pruss, D., and Wolffe, A.P. (1993). A positive role for histone 
acetylation in transcription factor access to nucleosomal DNA. Cell 72, 73-84. 
Lee, J.H., and Skalnik, D.G. (2005). CpG-binding protein (CXXC finger protein 1) is 
a component of the mammalian Set1 histone H3-Lys4 methyltransferase complex, 
the analogue of the yeast Set1/COMPASS complex. The Journal of biological 
chemistry 280, 41725-41731. 
Lee, P.P., Fitzpatrick, D.R., Beard, C., Jessup, H.K., Lehar, S., Makar, K.W., Perez-
Melgosa, M., Sweetser, M.T., Schlissel, M.S., Nguyen, S., et al. (2001). A critical 
role for Dnmt1 and DNA methylation in T cell development, function, and survival. 
Immunity 15, 763-774. 
Lehnertz, B., Ueda, Y., Derijck, A.A., Braunschweig, U., Perez-Burgos, L., Kubicek, 
S., Chen, T., Li, E., Jenuwein, T., and Peters, A.H. (2003). Suv39h-mediated histone 
H3 lysine 9 methylation directs DNA methylation to major satellite repeats at 
pericentric heterochromatin. Curr Biol 13, 1192-1200. 
Lembo, F., Pero, R., Angrisano, T., Vitiello, C., Iuliano, R., Bruni, C.B., and 
Chiariotti, L. (2003). MBDin, a novel MBD2-interacting protein, relieves MBD2 
repression potential and reactivates transcription from methylated promoters. Mol 
Cell Biol 23, 1656-1665. 
Lewis, J.D., Meehan, R.R., Henzel, W.J., Maurer-Fogy, I., Jeppesen, P., Klein, F., 
and Bird, A. (1992). Purification, sequence, and cellular localization of a novel 
chromosomal protein that binds to methylated DNA. Cell 69, 905-914. 
Li, B., Carey, M., and Workman, J.L. (2007). The role of chromatin during 
transcription. Cell 128, 707-719. 
Li, B., Jackson, J., Simon, M.D., Fleharty, B., Gogol, M., Seidel, C., Workman, J.L., 
and Shilatifard, A. (2009). Histone H3 lysine 36 dimethylation (H3K36me2) is 
sufficient to recruit the Rpd3s histone deacetylase complex and to repress spurious 
transcription. The Journal of biological chemistry 284, 7970-7976. 
Li, E., Beard, C., and Jaenisch, R. (1993). Role for DNA methylation in genomic 
imprinting. Nature 366, 362-365. 
Li, E., Bestor, T.H., and Jaenisch, R. (1992). Targeted mutation of the DNA 
methyltransferase gene results in embryonic lethality. Cell 69, 915-926. 
 
 234 
Li, H., Ilin, S., Wang, W., Duncan, E.M., Wysocka, J., Allis, C.D., and Patel, D.J. 
(2006). Molecular basis for site-specific read-out of histone H3K4me3 by the BPTF 
PHD finger of NURF. Nature 442, 91-95. 
Lin, X., and Nelson, W.G. (2003). Methyl-CpG-binding domain protein-2 mediates 
transcriptional repression associated with hypermethylated GSTP1 CpG islands in 
MCF-7 breast cancer cells. Cancer research 63, 498-504. 
Lister, R., Pelizzola, M., Dowen, R.H., Hawkins, R.D., Hon, G., Tonti-Filippini, J., 
Nery, J.R., Lee, L., Ye, Z., Ngo, Q.M., et al. (2009). Human DNA methylomes at 
base resolution show widespread epigenomic differences. Nature. 
Liu, W.H., and Lai, M.Z. (2005). Deltex regulates T-cell activation by targeted 
degradation of active MEKK1. Mol Cell Biol 25, 1367-1378. 
Liu, W.M., Maraia, R.J., Rubin, C.M., and Schmid, C.W. (1994). Alu transcripts: 
cytoplasmic localisation and regulation by DNA methylation. Nucleic Acids Res 22, 
1087-1095. 
Lorincz, M.C., Dickerson, D.R., Schmitt, M., and Groudine, M. (2004). Intragenic 
DNA methylation alters chromatin structure and elongation efficiency in mammalian 
cells. Nature structural & molecular biology 11, 1068-1075. 
Luger, K., Mader, A.W., Richmond, R.K., Sargent, D.F., and Richmond, T.J. (1997). 
Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389, 
251-260. 
Luo, S.W., Zhang, C., Zhang, B., Kim, C.H., Qiu, Y.Z., Du, Q.S., Mei, L., and 
Xiong, W.C. (2009). Regulation of heterochromatin remodelling and myogenin 
expression during muscle differentiation by FAK interaction with MBD2. The 
EMBO journal. 
Lyko, F., Ramsahoye, B.H., and Jaenisch, R. (2000). DNA methylation in 
Drosophila melanogaster. Nature 408, 538-540. 
Macleod, D., Ali, R.R., and Bird, A. (1998). An alternative promoter in the mouse 
major histocompatibility complex class II I-Abeta gene: implications for the origin of 
CpG islands. Mol Cell Biol 18, 4433-4443. 
Macleod, D., Charlton, J., Mullins, J., and Bird, A.P. (1994). Sp1 sites in the mouse 
aprt gene promoter are required to prevent methylation of the CpG island. Genes & 
development 8, 2282-2292. 
Makar, K.W., Perez-Melgosa, M., Shnyreva, M., Weaver, W.M., Fitzpatrick, D.R., 
and Wilson, C.B. (2003). Active recruitment of DNA methyltransferases regulates 
interleukin 4 in thymocytes and T cells. Nature immunology 4, 1183-1190. 
Makar, K.W., and Wilson, C.B. (2004). DNA methylation is a nonredundant 
repressor of the Th2 effector program. J Immunol 173, 4402-4406. 
Martin, V., Jorgensen, H.F., Chaubert, A.S., Berger, J., Barr, H., Shaw, P., Bird, A., 
and Chaubert, P. (2008). MBD2-mediated transcriptional repression of the p14ARF 
tumor suppressor gene in human colon cancer cells. Pathobiology 75, 281-287. 
Maunakea, A.K., Nagarajan, R.P., Bilenky, M., Ballinger, T.J., D'Souza, C., Fouse, 
S.D., Johnson, B.E., Hong, C., Nielsen, C., Zhao, Y., et al. (2010). Conserved role of 
 
 235 
intragenic DNA methylation in regulating alternative promoters. Nature 466, 253-
257. 
Mayer, W., Niveleau, A., Walter, J., Fundele, R., and Haaf, T. (2000). Demethylation 
of the zygotic paternal genome. Nature 403, 501-502. 
Meehan, R.R., Lewis, J.D., and Bird, A.P. (1992). Characterization of MeCP2, a 
vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids 
Res 20, 5085-5092. 
Meehan, R.R., Lewis, J.D., McKay, S., Kleiner, E.L., and Bird, A.P. (1989). 
Identification of a mammalian protein that binds specifically to DNA containing 
methylated CpGs. Cell 58, 499-507. 
Meissner, A., Mikkelsen, T.S., Gu, H., Wernig, M., Hanna, J., Sivachenko, A., 
Zhang, X., Bernstein, B.E., Nusbaum, C., Jaffe, D.B., et al. (2008). Genome-scale 
DNA methylation maps of pluripotent and differentiated cells. Nature 454, 766-770. 
Miccio, A., Wang, Y., Hong, W., Gregory, G.D., Wang, H., Yu, X., Choi, J.K., 
Shelat, S., Tong, W., Poncz, M., et al. (2010). NuRD mediates activating and 
repressive functions of GATA-1 and FOG-1 during blood development. The EMBO 
journal 29, 442-456. 
Mikkelsen, T.S., Ku, M., Jaffe, D.B., Issac, B., Lieberman, E., Giannoukos, G., 
Alvarez, P., Brockman, W., Kim, T.K., Koche, R.P., et al. (2007). Genome-wide 
maps of chromatin state in pluripotent and lineage-committed cells. Nature 448, 553-
560. 
Millar, C.B., Guy, J., Sansom, O.J., Selfridge, J., MacDougall, E., Hendrich, B., 
Keightley, P.D., Bishop, S.M., Clarke, A.R., and Bird, A. (2002). Enhanced CpG 
mutability and tumorigenesis in MBD4-deficient mice. Science 297, 403-405. 
Miller, T., Krogan, N.J., Dover, J., Erdjument-Bromage, H., Tempst, P., Johnston, 
M., Greenblatt, J.F., and Shilatifard, A. (2001). COMPASS: a complex of proteins 
associated with a trithorax-related SET domain protein. Proceedings of the National 
Academy of Sciences of the United States of America 98, 12902-12907. 
Mohn, F., Weber, M., Rebhan, M., Roloff, T.C., Richter, J., Stadler, M.B., Bibel, M., 
and Schubeler, D. (2008). Lineage-specific polycomb targets and de novo DNA 
methylation define restriction and potential of neuronal progenitors. Molecular cell 
30, 755-766. 
Mookherjee, N., Brown, K.L., Bowdish, D.M., Doria, S., Falsafi, R., Hokamp, K., 
Roche, F.M., Mu, R., Doho, G.H., Pistolic, J., et al. (2006). Modulation of the TLR-
mediated inflammatory response by the endogenous human host defense peptide LL-
37. J Immunol 176, 2455-2464. 
Morgan, H.D., Santos, F., Green, K., Dean, W., and Reik, W. (2005). Epigenetic 
reprogramming in mammals. Hum Mol Genet 14 Spec No 1, R47-58. 
Morinobu, A., Kanno, Y., and O'Shea, J.J. (2004). Discrete roles for histone 
acetylation in human T helper 1 cell-specific gene expression. The Journal of 
biological chemistry 279, 40640-40646. 
 
 236 
Murayama, A., Sakura, K., Nakama, M., Yasuzawa-Tanaka, K., Fujita, E., Tateishi, 
Y., Wang, Y., Ushijima, T., Baba, T., Shibuya, K., et al. (2006). A specific CpG site 
demethylation in the human interleukin 2 gene promoter is an epigenetic memory. 
The EMBO journal 25, 1081-1092. 
Myant, K., and Stancheva, I. (2008). LSH cooperates with DNA methyltransferases 
to repress transcription. Mol Cell Biol 28, 215-226. 
Nagano, T., Mitchell, J.A., Sanz, L.A., Pauler, F.M., Ferguson-Smith, A.C., Feil, R., 
and Fraser, P. (2008). The Air noncoding RNA epigenetically silences transcription 
by targeting G9a to chromatin. Science 322, 1717-1720. 
Nagar, M., Vernitsky, H., Cohen, Y., Dominissini, D., Berkun, Y., Rechavi, G., 
Amariglio, N., and Goldstein, I. (2008). Epigenetic inheritance of DNA methylation 
limits activation-induced expression of FOXP3 in conventional human CD25-CD4+ 
T cells. International immunology. 
Nan, X., Campoy, F.J., and Bird, A. (1997). MeCP2 is a transcriptional repressor 
with abundant binding sites in genomic chromatin. Cell 88, 471-481. 
Nan, X., Meehan, R.R., and Bird, A. (1993). Dissection of the methyl-CpG binding 
domain from the chromosomal protein MeCP2. Nucleic Acids Res 21, 4886-4892. 
Nan, X., Ng, H.H., Johnson, C.A., Laherty, C.D., Turner, B.M., Eisenman, R.N., and 
Bird, A. (1998). Transcriptional repression by the methyl-CpG-binding protein 
MeCP2 involves a histone deacetylase complex. Nature 393, 386-389. 
Nawijn, M.C., Dingjan, G.M., Ferreira, R., Lambrecht, B.N., Karis, A., Grosveld, F., 
Savelkoul, H., and Hendriks, R.W. (2001). Enforced expression of GATA-3 in 
transgenic mice inhibits Th1 differentiation and induces the formation of a T1/ST2-
expressing Th2-committed T cell compartment in vivo. J Immunol 167, 724-732. 
Ng, H.H., Jeppesen, P., and Bird, A. (2000). Active repression of methylated genes 
by the chromosomal protein MBD1. Mol Cell Biol 20, 1394-1406. 
Ng, H.H., Zhang, Y., Hendrich, B., Johnson, C.A., Turner, B.M., Erdjument-
Bromage, H., Tempst, P., Reinberg, D., and Bird, A. (1999). MBD2 is a 
transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat 
Genet 23, 58-61. 
Nicol, J.W., Helt, G.A., Blanchard, S.G., Jr., Raja, A., and Loraine, A.E. (2009). The 
Integrated Genome Browser: free software for distribution and exploration of 
genome-scale datasets. Bioinformatics (Oxford, England) 25, 2730-2731. 
Nuber, U.A., Kriaucionis, S., Roloff, T.C., Guy, J., Selfridge, J., Steinhoff, C., 
Schulz, R., Lipkowitz, B., Ropers, H.H., Holmes, M.C., et al. (2005). Up-regulation 
of glucocorticoid-regulated genes in a mouse model of Rett syndrome. Hum Mol 
Genet 14, 2247-2256. 
Oda, M., Yamagiwa, A., Yamamoto, S., Nakayama, T., Tsumura, A., Sasaki, H., 
Nakao, K., Li, E., and Okano, M. (2006). DNA methylation regulates long-range 
gene silencing of an X-linked homeobox gene cluster in a lineage-specific manner. 
Genes & development 20, 3382-3394. 
 
 237 
Ohm, J.E., McGarvey, K.M., Yu, X., Cheng, L., Schuebel, K.E., Cope, L., 
Mohammad, H.P., Chen, W., Daniel, V.C., Yu, W., et al. (2007). A stem cell-like 
chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation 
and heritable silencing. Nat Genet 39, 237-242. 
Okamoto, I., and Heard, E. (2009). Lessons from comparative analysis of X-
chromosome inactivation in mammals. Chromosome Res 17, 659-669. 
Okano, M., Bell, D.W., Haber, D.A., and Li, E. (1999). DNA methyltransferases 
Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian 
development. Cell 99, 247-257. 
Ooi, S.K., Qiu, C., Bernstein, E., Li, K., Jia, D., Yang, Z., Erdjument-Bromage, H., 
Tempst, P., Lin, S.P., Allis, C.D., et al. (2007). DNMT3L connects unmethylated 
lysine 4 of histone H3 to de novo methylation of DNA. Nature 448, 714-717. 
Oswald, J., Engemann, S., Lane, N., Mayer, W., Olek, A., Fundele, R., Dean, W., 
Reik, W., and Walter, J. (2000). Active demethylation of the paternal genome in the 
mouse zygote. Curr Biol 10, 475-478. 
Ozsolak, F., Song, J.S., Liu, X.S., and Fisher, D.E. (2007). High-throughput mapping 
of the chromatin structure of human promoters. Nature biotechnology 25, 244-248. 
Payer, B., and Lee, J.T. (2008). X chromosome dosage compensation: how mammals 
keep the balance. Annual review of genetics 42, 733-772. 
Penterman, J., Zilberman, D., Huh, J.H., Ballinger, T., Henikoff, S., and Fischer, 
R.L. (2007). DNA demethylation in the Arabidopsis genome. Proceedings of the 
National Academy of Sciences of the United States of America 104, 6752-6757. 
Phesse, T.J., Parry, L., Reed, K.R., Ewan, K.B., Dale, T.C., Sansom, O.J., and 
Clarke, A.R. (2008). Deficiency of Mbd2 Attenuates Wnt signalling. Mol Cell Biol. 
Pietersen, A.M., and van Lohuizen, M. (2008). Stem cell regulation by polycomb 
repressors: postponing commitment. Current opinion in cell biology 20, 201-207. 
Pils, M.C., Pisano, F., Fasnacht, N., Heinrich, J.M., Groebe, L., Schippers, A., 
Rozell, B., Jack, R.S., and Muller, W. (2010). Monocytes/macrophages and/or 
neutrophils are the target of IL-10 in the LPS endotoxemia model. European journal 
of immunology 40, 443-448. 
Polansky, J.K., Kretschmer, K., Freyer, J., Floess, S., Garbe, A., Baron, U., Olek, S., 
Hamann, A., von Boehmer, H., and Huehn, J. (2008). DNA methylation controls 
Foxp3 gene expression. European journal of immunology 38, 1654-1663. 
Ponger, L., Duret, L., and Mouchiroud, D. (2001). Determinants of CpG islands: 
expression in early embryo and isochore structure. Genome research 11, 1854-1860. 
Pradhan, M., Esteve, P.O., Chin, H.G., Samaranayke, M., Kim, G.D., and Pradhan, 
S. (2008). CXXC domain of human DNMT1 is essential for enzymatic activity. 
Biochemistry 47, 10000-10009. 
Prokhortchouk, A., Hendrich, B., Jorgensen, H., Ruzov, A., Wilm, M., Georgiev, G., 
Bird, A., and Prokhortchouk, E. (2001). The p120 catenin partner Kaiso is a DNA 




Pulukuri, S.M., and Rao, J.S. (2006). CpG island promoter methylation and silencing 
of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is 
associated with methyl-CpG-binding protein MBD2. Oncogene 25, 4559-4572. 
Rai, K., Huggins, I.J., James, S.R., Karpf, A.R., Jones, D.A., and Cairns, B.R. 
(2008). DNA demethylation in zebrafish involves the coupling of a deaminase, a 
glycosylase, and gadd45. Cell 135, 1201-1212. 
Ramirez-Carrozzi, V.R., Braas, D., Bhatt, D.M., Cheng, C.S., Hong, C., Doty, K.R., 
Black, J.C., Hoffmann, A., Carey, M., and Smale, S.T. (2009). A unifying model for 
the selective regulation of inducible transcription by CpG islands and nucleosome 
remodeling. Cell 138, 114-128. 
Ramsahoye, B.H., Biniszkiewicz, D., Lyko, F., Clark, V., Bird, A.P., and Jaenisch, 
R. (2000). Non-CpG methylation is prevalent in embryonic stem cells and may be 
mediated by DNA methyltransferase 3a. Proceedings of the National Academy of 
Sciences of the United States of America 97, 5237-5242. 
Rauch, T.A., Wu, X., Zhong, X., Riggs, A.D., and Pfeifer, G.P. (2009). A human B 
cell methylome at 100-base pair resolution. Proceedings of the National Academy of 
Sciences of the United States of America 106, 671-678. 
Reiner, S.L. (2007). Development in motion: helper T cells at work. Cell 129, 33-36. 
Reiner, S.L., and Locksley, R.M. (1995). The regulation of immunity to Leishmania 
major. Annu Rev Immunol 13, 151-177. 
Reynolds, P.A., Sigaroudinia, M., Zardo, G., Wilson, M.B., Benton, G.M., Miller, 
C.J., Hong, C., Fridlyand, J., Costello, J.F., and Tlsty, T.D. (2006). Tumor suppressor 
p16INK4A regulates polycomb-mediated DNA hypermethylation in human 
mammary epithelial cells. The Journal of biological chemistry 281, 24790-24802. 
Rinn, J.L., Kertesz, M., Wang, J.K., Squazzo, S.L., Xu, X., Brugmann, S.A., 
Goodnough, L.H., Helms, J.A., Farnham, P.J., Segal, E., et al. (2007). Functional 
demarcation of active and silent chromatin domains in human HOX loci by 
noncoding RNAs. Cell 129, 1311-1323. 
Robertson, A.K., Geiman, T.M., Sankpal, U.T., Hager, G.L., and Robertson, K.D. 
(2004). Effects of chromatin structure on the enzymatic and DNA binding functions 
of DNA methyltransferases DNMT1 and Dnmt3a in vitro. Biochemical and 
biophysical research communications 322, 110-118. 
Robertson, K.D., Ait-Si-Ali, S., Yokochi, T., Wade, P.A., Jones, P.L., and Wolffe, 
A.P. (2000). DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses 
transcription from E2F-responsive promoters. Nat Genet 25, 338-342. 
Robinson, P.W., Green, S.J., Carter, C., Coadwell, J., and Kilshaw, P.J. (2001). 
Studies on transcriptional regulation of the mucosal T-cell integrin alphaEbeta7 
(CD103). Immunology 103, 146-154. 
Roh, T.Y., Cuddapah, S., Cui, K., and Zhao, K. (2006). The genomic landscape of 
histone modifications in human T cells. Proceedings of the National Academy of 
Sciences of the United States of America 103, 15782-15787. 
 
 239 
Roh, T.Y., Cuddapah, S., and Zhao, K. (2005). Active chromatin domains are 
defined by acetylation islands revealed by genome-wide mapping. Genes & 
development 19, 542-552. 
Romagnani, S. (2006). Regulation of the T cell response. Clin Exp Allergy 36, 1357-
1366. 
Rountree, M.R., Bachman, K.E., and Baylin, S.B. (2000). DNMT1 binds HDAC2 
and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 
25, 269-277. 
Ruike, Y., Imanaka, Y., Sato, F., Shimizu, K., and Tsujimoto, G. (2010). Genome-
wide analysis of aberrant methylation in human breast cancer cells using methyl-
DNA immunoprecipitation combined with high-throughput sequencing. BMC 
genomics 11, 137. 
Russo, V.E.A., Martienssen, R.A., and Riggs, A.D. (1996). Epigenetics mechanisms 
of gene regulation. Cold Spring Harbour Laboratory Press. 
Ruthenburg, A.J., Allis, C.D., and Wysocka, J. (2007). Methylation of lysine 4 on 
histone H3: intricacy of writing and reading a single epigenetic mark. Molecular cell 
25, 15-30. 
Sado, T., Fenner, M.H., Tan, S.S., Tam, P., Shioda, T., and Li, E. (2000). X 
inactivation in the mouse embryo deficient for Dnmt1: distinct effect of 
hypomethylation on imprinted and random X inactivation. Developmental biology 
225, 294-303. 
Saito, M., and Ishikawa, F. (2002). The mCpG-binding domain of human MBD3 
does not bind to mCpG but interacts with NuRD/Mi2 components HDAC1 and 
MTA2. The Journal of biological chemistry 277, 35434-35439. 
Sambrook, J., and Russell, D., W. (2001). Molecular Cloning: A laboratory manual. 
Cold Spring Harbour Laboratory Press 3rd edition. 
Sansom, O.J., Berger, J., Bishop, S.M., Hendrich, B., Bird, A., and Clarke, A.R. 
(2003). Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nat Genet 34, 145-
147. 
Santangelo, S., Cousins, D.J., Winkelmann, N.E., and Staynov, D.Z. (2002). DNA 
methylation changes at human Th2 cytokine genes coincide with DNase I 
hypersensitive site formation during CD4(+) T cell differentiation. J Immunol 169, 
1893-1903. 
Santos, F., Hendrich, B., Reik, W., and Dean, W. (2002). Dynamic reprogramming 
of DNA methylation in the early mouse embryo. Developmental biology 241, 172-
182. 
Sarraf, S.A., and Stancheva, I. (2004). Methyl-CpG binding protein MBD1 couples 
histone H3 methylation at lysine 9 by SETDB1 to DNA replication and chromatin 
assembly. Molecular cell 15, 595-605. 
Schilling, E., and Rehli, M. (2007). Global, comparative analysis of tissue-specific 
promoter CpG methylation. Genomics 90, 314-323. 
 
 240 
Schlesinger, Y., Straussman, R., Keshet, I., Farkash, S., Hecht, M., Zimmerman, J., 
Eden, E., Yakhini, Z., Ben-Shushan, E., Reubinoff, B.E., et al. (2007). Polycomb-
mediated methylation on Lys27 of histone H3 pre-marks genes for de novo 
methylation in cancer. Nat Genet 39, 232-236. 
Schmidl, C., Klug, M., Boeld, T.J., Andreesen, R., Hoffmann, P., Edinger, M., and 
Rehli, M. (2009). Lineage-specific DNA methylation in T cells correlates with 
histone methylation and enhancer activity. Genome research 19, 1165-1174. 
Schmiedeberg, L., Skene, P., Deaton, A., and Bird, A. (2009). A temporal threshold 
for formaldehyde crosslinking and fixation. PLoS ONE 4, e4636. 
Schoenborn, J.R., Dorschner, M.O., Sekimata, M., Santer, D.M., Shnyreva, M., 
Fitzpatrick, D.R., Stamatoyannopoulos, J.A., and Wilson, C.B. (2007). 
Comprehensive epigenetic profiling identifies multiple distal regulatory elements 
directing transcription of the gene encoding interferon-gamma. Nature immunology 
8, 732-742. 
Schuettengruber, B., Chourrout, D., Vervoort, M., Leblanc, B., and Cavalli, G. 
(2007). Genome regulation by polycomb and trithorax proteins. Cell 128, 735-745. 
Schwartz, Y.B., and Pirrotta, V. (2007). Polycomb silencing mechanisms and the 
management of genomic programmes. Nature reviews 8, 9-22. 
Sekimata, M., Takahashi, A., Murakami-Sekimata, A., and Homma, Y. (2001). 
Involvement of a novel zinc finger protein, MIZF, in transcriptional repression by 
interacting with a methyl-CpG-binding protein, MBD2. The Journal of biological 
chemistry 276, 42632-42638. 
Sequeira-Mendes, J., Diaz-Uriarte, R., Apedaile, A., Huntley, D., Brockdorff, N., and 
Gomez, M. (2009). Transcription initiation activity sets replication origin efficiency 
in mammalian cells. PLoS genetics 5, e1000446. 
Serre, D., Lee, B.H., and Ting, A.H. (2009). MBD-isolated Genome Sequencing 
provides a high-throughput and comprehensive survey of DNA methylation in the 
human genome. Nucleic Acids Res. 
Shen, L., Kondo, Y., Guo, Y., Zhang, J., Zhang, L., Ahmed, S., Shu, J., Chen, X., 
Waterland, R.A., and Issa, J.P. (2007). Genome-wide profiling of DNA methylation 
reveals a class of normally methylated CpG island promoters. PLoS genetics 3, 
2023-2036. 
Siegfried, Z., Eden, S., Mendelsohn, M., Feng, X., Tsuberi, B.Z., and Cedar, H. 
(1999). DNA methylation represses transcription in vivo. Nat Genet 22, 203-206. 
Simon, J.A., and Kingston, R.E. (2009). Mechanisms of polycomb gene silencing: 
knowns and unknowns. Nat Rev Mol Cell Biol 10, 697-708. 
Skene, P.J., Illingworth, R.S., Webb, S., Kerr, A.R., James, K.D., Turner, D.J., 
Andrews, R., and Bird, A.P. (2010). Neuronal MeCP2 is expressed at near histone-
octamer levels and globally alters the chromatin state. Molecular cell 37, 457-468. 
Sleutels, F., Zwart, R., and Barlow, D.P. (2002). The non-coding Air RNA is 
required for silencing autosomal imprinted genes. Nature 415, 810-813. 
 
 241 
Smiraglia, D.J., Rush, L.J., Fruhwald, M.C., Dai, Z., Held, W.A., Costello, J.F., 
Lang, J.C., Eng, C., Li, B., Wright, F.A., et al. (2001). Excessive CpG island 
hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol 
Genet 10, 1413-1419. 
Smith, A.E., Chronis, C., Christodoulakis, M., Orr, S.J., Lea, N.C., Twine, N.A., 
Bhinge, A., Mufti, G.J., and Thomas, N.S. (2009). Epigenetics of human T cells 
during the G0-->G1 transition. Genome research 19, 1325-1337. 
Song, F., Smith, J.F., Kimura, M.T., Morrow, A.D., Matsuyama, T., Nagase, H., and 
Held, W.A. (2005). Association of tissue-specific differentially methylated regions 
(TDMs) with differential gene expression. Proceedings of the National Academy of 
Sciences of the United States of America 102, 3336-3341. 
Sridharan, R., and Smale, S.T. (2007). Predominant interaction of both Ikaros and 
Helios with the NuRD complex in immature thymocytes. The Journal of biological 
chemistry 282, 30227-30238. 
Stein, R., Razin, A., and Cedar, H. (1982). In vitro methylation of the hamster 
adenine phosphoribosyltransferase gene inhibits its expression in mouse L cells. 
Proceedings of the National Academy of Sciences of the United States of America 
79, 3418-3422. 
Steinert, S., Shay, J.W., and Wright, W.E. (2004). Modification of subtelomeric 
DNA. Mol Cell Biol 24, 4571-4580. 
Strahl, B.D., and Allis, C.D. (2000). The language of covalent histone modifications. 
Nature 403, 41-45. 
Strahl, B.D., Grant, P.A., Briggs, S.D., Sun, Z.W., Bone, J.R., Caldwell, J.A., 
Mollah, S., Cook, R.G., Shabanowitz, J., Hunt, D.F., et al. (2002). Set2 is a 
nucleosomal histone H3-selective methyltransferase that mediates transcriptional 
repression. Mol Cell Biol 22, 1298-1306. 
Suetake, I., Shinozaki, F., Miyagawa, J., Takeshima, H., and Tajima, S. (2004). 
DNMT3L stimulates the DNA methylation activity of Dnmt3a and Dnmt3b through 
a direct interaction. The Journal of biological chemistry 279, 27816-27823. 
Suzuki, M.M., and Bird, A. (2008). DNA methylation landscapes: provocative 
insights from epigenomics. Nature reviews 9, 465-476. 
Suzuki, M.M., Kerr, A.R., De Sousa, D., and Bird, A. (2007). CpG methylation is 
targeted to transcription units in an invertebrate genome. Genome research 17, 625-
631. 
Swain, S.L., Bradley, L.M., Croft, M., Tonkonogy, S., Atkins, G., Weinberg, A.D., 
Duncan, D.D., Hedrick, S.M., Dutton, R.W., and Huston, G. (1991). Helper T-cell 
subsets: phenotype, function and the role of lymphokines in regulating their 
development. Immunological reviews 123, 115-144. 
Tahiliani, M., Koh, K.P., Shen, Y., Pastor, W.A., Bandukwala, H., Brudno, Y., 
Agarwal, S., Iyer, L.M., Liu, D.R., Aravind, L., et al. (2009). Conversion of 5-
methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner 
TET1. Science 324, 930-935. 
 
 242 
Takai, D., and Jones, P.A. (2002). Comprehensive analysis of CpG islands in human 
chromosomes 21 and 22. Proceedings of the National Academy of Sciences of the 
United States of America 99, 3740-3745. 
Takemoto, N., Kamogawa, Y., Jun Lee, H., Kurata, H., Arai, K.I., O'Garra, A., Arai, 
N., and Miyatake, S. (2000). Cutting edge: chromatin remodeling at the IL-4/IL-13 
intergenic regulatory region for Th2-specific cytokine gene cluster. J Immunol 165, 
6687-6691. 
Tan, C.P., and Nakielny, S. (2006). Control of the DNA methylation system 
component MBD2 by protein arginine methylation. Mol Cell Biol 26, 7224-7235. 
Tang, Q., and Bluestone, J.A. (2008). The Foxp3+ regulatory T cell: a jack of all 
trades, master of regulation. Nature immunology 9, 239-244. 
Taylor, J., Schenck, I., Blankenberg, D., and Nekrutenko, A. (2007). Using galaxy to 
perform large-scale interactive data analyses. Current protocols in bioinformatics 
Chapter 10, Unit 10 15. 
Tazi, J., and Bird, A. (1990). Alternative chromatin structure at CpG islands. Cell 60, 
909-920. 
Thomson, J.P., Skene, P.J., Selfridge, J., Clouaire, T., Guy, J., Webb, S., Kerr, A.R., 
Deaton, A., Andrews, R., James, K.D., et al. (2010). CpG islands influence 
chromatin structure via the CpG-binding protein Cfp1. Nature 464, 1082-1086. 
Toy, D., Kugler, D., Wolfson, M., Vanden Bos, T., Gurgel, J., Derry, J., Tocker, J., 
and Peschon, J. (2006). Cutting edge: interleukin 17 signals through a heteromeric 
receptor complex. J Immunol 177, 36-39. 
Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J.G., Baylin, S.B., and Issa, J.P. 
(1999). CpG island methylator phenotype in colorectal cancer. Proceedings of the 
National Academy of Sciences of the United States of America 96, 8681-8686. 
Tremethick, D.J. (2007). Higher-order structures of chromatin: the elusive 30 nm 
fiber. Cell 128, 651-654. 
Tsukada, Y., Fang, J., Erdjument-Bromage, H., Warren, M.E., Borchers, C.H., 
Tempst, P., and Zhang, Y. (2006). Histone demethylation by a family of JmjC 
domain-containing proteins. Nature 439, 811-816. 
Tudor, M., Akbarian, S., Chen, R.Z., and Jaenisch, R. (2002). Transcriptional 
profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes 
in the brain. Proceedings of the National Academy of Sciences of the United States 
of America 99, 15536-15541. 
Tweedie, S., Charlton, J., Clark, V., and Bird, A. (1997). Methylation of genomes 
and genes at the invertebrate-vertebrate boundary. Mol Cell Biol 17, 1469-1475. 
Vardimon, L., Kressmann, A., Cedar, H., Maechler, M., and Doerfler, W. (1982). 
Expression of a cloned adenovirus gene is inhibited by in vitro methylation. 
Proceedings of the National Academy of Sciences of the United States of America 
79, 1073-1077. 
Vermeulen, M., Mulder, K.W., Denissov, S., Pijnappel, W.W., van Schaik, F.M., 
Varier, R.A., Baltissen, M.P., Stunnenberg, H.G., Mann, M., and Timmers, H.T. 
 
 243 
(2007). Selective anchoring of TFIID to nucleosomes by trimethylation of histone 
H3 lysine 4. Cell 131, 58-69. 
Vire, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., 
Van Eynde, A., Bernard, D., Vanderwinden, J.M., et al. (2006). The Polycomb group 
protein EZH2 directly controls DNA methylation. Nature 439, 871-874. 
Voo, K.S., Carlone, D.L., Jacobsen, B.M., Flodin, A., and Skalnik, D.G. (2000). 
Cloning of a mammalian transcriptional activator that binds unmethylated CpG 
motifs and shares a CXXC domain with DNA methyltransferase, human trithorax, 
and methyl-CpG binding domain protein 1. Mol Cell Biol 20, 2108-2121. 
Wakabayashi, Y., Watanabe, H., Inoue, J., Takeda, N., Sakata, J., Mishima, Y., 
Hitomi, J., Yamamoto, T., Utsuyama, M., Niwa, O., et al. (2003). Bcl11b is required 
for differentiation and survival of alphabeta T lymphocytes. Nature immunology 4, 
533-539. 
Walsh, C.P., Chaillet, J.R., and Bestor, T.H. (1998). Transcription of IAP 
endogenous retroviruses is constrained by cytosine methylation. Nat Genet 20, 116-
117. 
Walter, K., Bonifer, C., and Tagoh, H. (2008). Stem cell-specific epigenetic priming 
and B cell-specific transcriptional activation at the mouse Cd19 locus. Blood 112, 
1673-1682. 
Wang, Y., Zhang, H., Chen, Y., Sun, Y., Yang, F., Yu, W., Liang, J., Sun, L., Yang, 
X., Shi, L., et al. (2009). LSD1 is a subunit of the NuRD complex and targets the 
metastasis programs in breast cancer. Cell 138, 660-672. 
Wang, Z., Zang, C., Rosenfeld, J.A., Schones, D.E., Barski, A., Cuddapah, S., Cui, 
K., Roh, T.Y., Peng, W., Zhang, M.Q., et al. (2008). Combinatorial patterns of 
histone acetylations and methylations in the human genome. Nat Genet 40, 897-903. 
Waterston, R.H., Lindblad-Toh, K., Birney, E., Rogers, J., Abril, J.F., Agarwal, P., 
Agarwala, R., Ainscough, R., Alexandersson, M., An, P., et al. (2002). Initial 
sequencing and comparative analysis of the mouse genome. Nature 420, 520-562. 
Watt, F., and Molloy, P.L. (1988). Cytosine methylation prevents binding to DNA of 
a HeLa cell transcription factor required for optimal expression of the adenovirus 
major late promoter. Genes & development 2, 1136-1143. 
Weber, M., Davies, J.J., Wittig, D., Oakeley, E.J., Haase, M., Lam, W.L., and 
Schubeler, D. (2005). Chromosome-wide and promoter-specific analyses identify 
sites of differential DNA methylation in normal and transformed human cells. Nat 
Genet 37, 853-862. 
Weber, M., Hellmann, I., Stadler, M.B., Ramos, L., Paabo, S., Rebhan, M., and 
Schubeler, D. (2007). Distribution, silencing potential and evolutionary impact of 
promoter DNA methylation in the human genome. Nat Genet 39, 457-466. 
Webster, K.E., O'Bryan, M.K., Fletcher, S., Crewther, P.E., Aapola, U., Craig, J., 
Harrison, D.K., Aung, H., Phutikanit, N., Lyle, R., et al. (2005). Meiotic and 
epigenetic defects in Dnmt3L-knockout mouse spermatogenesis. Proceedings of the 
National Academy of Sciences of the United States of America 102, 4068-4073. 
 
 244 
Wei, G., Wei, L., Zhu, J., Zang, C., Hu-Li, J., Yao, Z., Cui, K., Kanno, Y., Roh, 
T.Y., Watford, W.T., et al. (2009). Global mapping of H3K4me3 and H3K27me3 
reveals specificity and plasticity in lineage fate determination of differentiating 
CD4+ T cells. Immunity 30, 155-167. 
Widschwendter, M., Fiegl, H., Egle, D., Mueller-Holzner, E., Spizzo, G., Marth, C., 
Weisenberger, D.J., Campan, M., Young, J., Jacobs, I., et al. (2007). Epigenetic stem 
cell signature in cancer. Nat Genet 39, 157-158. 
Wiebauer, K., and Jiricny, J. (1990). Mismatch-specific thymine DNA glycosylase 
and DNA polymerase beta mediate the correction of G.T mispairs in nuclear extracts 
from human cells. Proceedings of the National Academy of Sciences of the United 
States of America 87, 5842-5845. 
Wikstrom, I., Forssell, J., Goncalves, M., Colucci, F., and Holmberg, D. (2006). E2-2 
regulates the expansion of pro-B cells and follicular versus marginal zone decisions. 
J Immunol 177, 6723-6729. 
Wikstrom, I., Forssell, J., Penha-Goncalves, M.N., Bergqvist, I., and Holmberg, D. 
(2008). A role for E2-2 at the DN3 stage of early thymopoiesis. Molecular 
immunology 45, 3302-3311. 
Wilson, A.S., Power, B.E., and Molloy, P.L. (2007). DNA hypomethylation and 
human diseases. Biochimica et biophysica acta 1775, 138-162. 
Winders, B.R., Schwartz, R.H., and Bruniquel, D. (2004). A distinct region of the 
murine IFN-gamma promoter is hypomethylated from early T cell development 
through mature naive and Th1 cell differentiation, but is hypermethylated in Th2 
cells. J Immunol 173, 7377-7384. 
Woodcock, D.M., Lawler, C.B., Linsenmeyer, M.E., Doherty, J.P., and Warren, 
W.D. (1997). Asymmetric methylation in the hypermethylated CpG promoter region 
of the human L1 retrotransposon. The Journal of biological chemistry 272, 7810-
7816. 
Worbs, T., and Forster, R. (2007). A key role for CCR7 in establishing central and 
peripheral tolerance. Trends in immunology 28, 274-280. 
Wu, H.A., and Bernstein, E. (2008). Partners in imprinting: noncoding RNA and 
polycomb group proteins. Developmental cell 15, 637-638. 
Wu, J., and Lingrel, J.B. (2005). Kruppel-like factor 2, a novel immediate-early 
transcriptional factor, regulates IL-2 expression in T lymphocyte activation. J 
Immunol 175, 3060-3066. 
Wysocka, J., Swigut, T., Xiao, H., Milne, T.A., Kwon, S.Y., Landry, J., Kauer, M., 
Tackett, A.J., Chait, B.T., Badenhorst, P., et al. (2006). A PHD finger of NURF 
couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature 442, 
86-90. 
Xue, Y., Wong, J., Moreno, G.T., Young, M.K., Cote, J., and Wang, W. (1998). 
NURD, a novel complex with both ATP-dependent chromatin-remodeling and 
histone deacetylase activities. Molecular cell 2, 851-861. 
 
 245 
Yano, S., Ghosh, P., Kusaba, H., Buchholz, M., and Longo, D.L. (2003). Effect of 
promoter methylation on the regulation of IFN-gamma gene during in vitro 
differentiation of human peripheral blood T cells into a Th2 population. J Immunol 
171, 2510-2516. 
Yoder, J.A., Walsh, C.P., and Bestor, T.H. (1997). Cytosine methylation and the 
ecology of intragenomic parasites. Trends Genet 13, 335-340. 
Youdell, M.L., Kizer, K.O., Kisseleva-Romanova, E., Fuchs, S.M., Duro, E., Strahl, 
B.D., and Mellor, J. (2008). Roles for Ctk1 and Spt6 in regulating the different 
methylation states of histone H3 lysine 36. Mol Cell Biol 28, 4915-4926. 
Young, J.I., Hong, E.P., Castle, J.C., Crespo-Barreto, J., Bowman, A.B., Rose, M.F., 
Kang, D., Richman, R., Johnson, J.M., Berget, S., et al. (2005). Regulation of RNA 
splicing by the methylation-dependent transcriptional repressor methyl-CpG binding 
protein 2. Proceedings of the National Academy of Sciences of the United States of 
America 102, 17551-17558. 
Yu, C.R., Mahdi, R.M., Ebong, S., Vistica, B.P., Gery, I., and Egwuagu, C.E. (2003). 
Suppressor of cytokine signaling 3 regulates proliferation and activation of T-helper 
cells. The Journal of biological chemistry 278, 29752-29759. 
Yu, Q., Thieu, V.T., and Kaplan, M.H. (2007). Stat4 limits DNA methyltransferase 
recruitment and DNA methylation of the IL-18Ralpha gene during Th1 
differentiation. The EMBO journal 26, 2052-2060. 
Zhang, H., Meng, F., Chu, C.L., Takai, T., and Lowell, C.A. (2005). The Src family 
kinases Hck and Fgr negatively regulate neutrophil and dendritic cell chemokine 
signaling via PIR-B. Immunity 22, 235-246. 
Zhang, X., Yazaki, J., Sundaresan, A., Cokus, S., Chan, S.W., Chen, H., Henderson, 
I.R., Shinn, P., Pellegrini, M., Jacobsen, S.E., et al. (2006). Genome-wide high-
resolution mapping and functional analysis of DNA methylation in arabidopsis. Cell 
126, 1189-1201. 
Zhang, Y., Jurkowska, R., Soeroes, S., Rajavelu, A., Dhayalan, A., Bock, I., Rathert, 
P., Brandt, O., Reinhardt, R., Fischle, W., et al. (2010). Chromatin methylation 
activity of Dnmt3a and Dnmt3a/3L is guided by interaction of the ADD domain with 
the histone H3 tail. Nucleic Acids Res. 
Zhang, Y., LeRoy, G., Seelig, H.P., Lane, W.S., and Reinberg, D. (1998). The 
dermatomyositis-specific autoantigen Mi2 is a component of a complex containing 
histone deacetylase and nucleosome remodeling activities. Cell 95, 279-289. 
Zhang, Y., Ng, H.H., Erdjument-Bromage, H., Tempst, P., Bird, A., and Reinberg, 
D. (1999). Analysis of the NuRD subunits reveals a histone deacetylase core 
complex and a connection with DNA methylation. Genes & development 13, 1924-
1935. 
Zhao, J., Sun, B.K., Erwin, J.A., Song, J.J., and Lee, J.T. (2008). Polycomb proteins 
targeted by a short repeat RNA to the mouse X chromosome. Science 322, 750-756. 
Zhao, X., Ueba, T., Christie, B.R., Barkho, B., McConnell, M.J., Nakashima, K., 
Lein, E.S., Eadie, B.D., Willhoite, A.R., Muotri, A.R., et al. (2003). Mice lacking 
methyl-CpG binding protein 1 have deficits in adult neurogenesis and hippocampal 
 
 246 
function. Proceedings of the National Academy of Sciences of the United States of 
America 100, 6777-6782. 
Zilberman, D., Gehring, M., Tran, R.K., Ballinger, T., and Henikoff, S. (2007). 
Genome-wide analysis of Arabidopsis thaliana DNA methylation uncovers an 







1. CpG islands influence chromatin structure via the CpG-binding protein Cfp1 
2. A temporal threshold for formaldehyde crosslinking and fixation 
 
